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ABSTRACT 
 
The thiazole/oxazole-modified microcins (TOMMs) are a recently grouped class of ribosomally 
synthesized and posttranslationally modified peptides. Encoded by many bacteria and archaea, 
these natural products occupy a large chemical and functional space and are linked by the 
presence of the eponymous azole moieties. Previous work has demonstrated that an 
evolutionarily conserved, heterotrimeric enzyme complex (TOMM synthetase) is responsible for 
azole biogenesis. The TOMM synthetase transforms select serine, threonine and cysteine 
residues in the core peptide into azole heterocycles via a two-step cyclodehydration-
dehydrogenation reaction. The installation of the azol(in)e heterocycles endows the peptide with 
rigidity and, in all characterized TOMM natural products, is required for biological activity. 
Despite being reconstituted nearly two decades ago, many questions remain regarding the role of 
each protein in the TOMM synthetase and the mechanism of cyclodehydration. Previous 
attempts to elucidate the molecular details of azole formation were impeded by the poor 
stability/solubility of reconstituted TOMM synthetases. In this thesis I report the characterization 
of the biosynthetic machinery from two novel TOMM cluster from Bacillus sp. Al Hakam that 
do not suffer from these issues. Using these robust synthetase complexes, I demonstrate that the 
cyclodehydration reaction proceeds via a phosphorylated hemi-orthoamide intermediate (chapter 
2) and provide definitive roles from each of the proteins in the cyclodehydratase complex 
(chapter 4 and 5). My findings identify an unprecedented role for ATP and provide the first 
function to the previously uncharacterized YcaO superfamily of proteins. Furthermore, in order 
to complete my mechanistic investigations of the TOMM synthetase, I developed a novel 
strategy for generating peptides with site-specific carbonyl oxygen isotope labels (chapter 3). I 
also demonstrate that this strategy can be expanded to the site-specific installation of thioamides.  
	  	   iii	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Ar scáth a chéile a mhaireann na daoine. 
 
	  	   iv	  
 
ACKNOWLEDGEMENTS 
I would like to begin by thanking my advisor, Professor Doug Mitchell. You gave me the right 
amount of guidance to keep me on track but enough free reign to go after the questions that truly 
excited me. Your enthusiasm for research is contagious. It has been a pleasure working along 
side you these last 5 years. I am grateful for my excellent collaborators, Satish Nair, Vinayak 
Agarwal, and Jonathan Chekan for their patience and persistence. I would also like to thank the 
Professors that have served on my committee over the course of my graduate career: Professor 
Wilfred van der Donk, Professor Satish Nair, Professor John Gerlt, Professor Eric Oldfield, 
Professor Yi Lu, and Professor Huimin Zhao.  
During my time at UIUC I have been fortunate to work with fantastic colleagues. I would 
like to thank every member of the Mitchell lab for contributing to what has become a fantastic 
work environment. More specifically I would like to extend my gratitude to Joel Melby, Tucker 
Maxson, Spencer Peck and Tyler “Jones” Takeshita. I will never forget my lost dancing pants, 
the impassable fence, and all of the good times and rambunctious nights. I would never have 
survived graduate school were it not for your friendship. 
Finally, I would like to thank my mother, my sister Stephanie, my entire extended family, 
and my “significant other” Evelyn. I cannot express how much your love and support has meant 
to me. Suffice it to say that none of this would have been possible without you. Thank you... 
	  	   v	  
TABLE OF CONTENTS 
LIST OF TABLES AND FIGURES  .........................................................................................  x 
CHAPTER 1: INTRODUCTION  .............................................................................................  1 
1.1 Ribosomally synthesized posttranslationally modified peptides (RiPPs)  ..................  1 
1.2 Thiazole-Oxazole Modified Microcins (TOMMs)  ....................................................  5 
1.3 Biosynthesis of TOMMs  ............................................................................................  7 
1.3.1 Azole Biosynthesis  ......................................................................................  8 
1.3.2 Macrocyclization of TOMM Natural Products  ...........................................  9 
1.3.3 Radical-Mediated Transformations in TOMM Biogenesis  ......................  13 
1.3.4 Prenylation in Cyanobactin Biosynthesis  .................................................  18 
1.3.5 C-terminal Amidation in Thiopeptides  .....................................................  21 
1.3.6 N-terminal Dimethylation in Plantazolicin Biosynthesis  ..........................  23 
1.4 Summary and Outlook  .............................................................................................  24 
1.5 References  ................................................................................................................  25 
 
CHAPTER 2: TOMM CYCLODEHYDRATASES UTILIZE ATP FOR CARBONYL 
OXYGEN ACTIVATION  .......................................................................................................  31 
            2.1 Introduction  ..............................................................................................................  31 
2.2 Minimal Requirements for Balh Cyclodehydratase Activity  ...................................  34 
            2.3 A Cyclizable Residue Stimulates Rapid ATP Hydrolysis  .......................................  37 
            2.4 ATP Hydrolysis is Tightly Coupled to Azoline Formation  .....................................  39 
            2.5 ATP is Hydrolyzed by a Non-Solvent Oxygen Nucleophile  ...................................  41 
            2.6 TOMM Cyclodehydrations Occur via an Activated Carbonyl Intermediate ............  43 
            2.7 Summary and Outlook  .............................................................................................  46 
            2.8 Experimental  ............................................................................................................  51 
2.8.1 Substitution of BcerB for BalhB  ................................................................ 51 
2.8.2 Protein overexpression and purification  ...................................................  51 
2.8.3 Purine nucleotide phosphorylase-based phosphate detection assay  .........  52 
2.8.4 Subtractive activity studies  .......................................................................  53 
2.8.5 Substrate analog assays  .............................................................................  53 
2.8.6 Stoichiometry of ATP utilization  ..............................................................  54 
	  	   vi	  
2.8.7 31P-NMR analysis of phosphate isotope incorporation of 18O-water  
reactions  .............................................................................................................  54 
2.8.8  31P-NMR analysis of phosphate isotope incorporation in [18O5]-BalhA1  
reactions  .............................................................................................................  55 
2.8.9  LCMS detection of ring formation  ..........................................................  56 
2.8.10 Malachite green phosphate detection assay  ............................................  57 
2.8.11 LCMS detection of [16O]-ADP from 18O-water reactions  ......................  57 
2.8.12 ADP isotope composition from [18O5]-BalhA1 reactions  .......................  57 
2.8.13 Bioinformatics  .........................................................................................  58 
2.9 References  ................................................................................................................  58 
 
CHAPTER 3: AZOLINE-MEDIATED PEPTIDE BACKBONE LABELING AS A TOOL 
FOR STUDYING TOMM BIOSYNTHESIS  ........................................................................  62 
3.1 Introduction  ..............................................................................................................  63 
3.2 Oxygen Isotope Incorporation into Peptide Backbones Through Azoline  
Hydrolysis  ......................................................................................................................  67 
3.3 Thiolysis of Oxazoline Heterocycles Allows for Site-Selective Thioamide    
Incorporation  ..................................................................................................................  70 
3.4 Leader Peptide-Independent Peptide Backbone Labeling  .......................................  74 
3.5 Engineering of Dehydrogenase-Dependent Synthetases for Backbone Labeling  ...  80 
3.6 Azoline Localization Provides Insights into Cyclodehydratase Substrate  
Processing  ......................................................................................................................  83 
3.7 Azoline Stoichiometry of Natural Products Obtained via Backbone Labeling  .......  89 
3.8 Summary and Outlook  .............................................................................................  93 
3.9 Experimental  ............................................................................................................  94 
3.9.1 General methods  .......................................................................................  94 
3.9.2 Protein overexpression and purification  ...................................................  94 
3.9.3 Overexpression and purification of Trx-BalhA1  ......................................  94 
3.9.4 BalhA1 18O-labeling studies  ......................................................................  95 
3.9.5 FT-MS/MS localization of 18O labels  .......................................................  96 
3.9.6 Processing of leader peptide-free substrates  .............................................  97 
	  	   vii	  
3.9.7 Rate of BalhA1core processing  ...................................................................  97 
3.9.8 Mcb synthetase reactions  ..........................................................................  98 
3.9.9 Thiolysis of azoline heterocycles  ..............................................................  98 
3.9.10 BalhX synthesis  ......................................................................................  99 
3.9.11 Dehydrogenase alignments  .....................................................................  99 
3.9.12 McbC mutagenesis  ..................................................................................  99 
3.9.13 18O labeling of BalhA2 and McbC-K201A/Y202A reactions  ................  99 
3.9.14 MS/MS localization thioamides and azol(in)e heterocycles  .................  100 
3.9.15 Iodoacetamide labeling of McbA in McbC-K201A and -Y202A  
reactions  ............................................................................................................ 100 
3.9.16 18O-labeling of TOMM natural products  ..............................................  101 
3.9.17 BalhA1 core cloning  .............................................................................  101 
3.10 References  ............................................................................................................  101 
 
CHAPTER 4: BIOCHEMICAL AND STRUCTURAL CHARACTERIZATION OF THE 
YCAO SUPERFAMILY  .......................................................................................................  105 
4.1 Introduction  ............................................................................................................  106 
4.2 The TOMM D Protein Alone is Sufficient for Azoline Formation  .......................  110 
4.3 TOMM YcaOs Utilize ATP for Amide Backbone Activation  ..............................  115 
4.4 Non-TOMM YcaO Proteins Also Utilize ATP  .....................................................  117 
4.5 Structural Characterization of ATP-binding in Ec-YcaO  ......................................  119 
4.6 The Ec-YcaO ATP-Binding Site is Conserved in TOMM YcaOs  ........................  124 
4.7 The Ec-YcaO ATP-Binding Site is Vital for BalhD Cyclodehydratase  
Activity  ........................................................................................................................  130 
4.8 The Proline-Rich C-terminus of TOMM YcaOs Affects C Protein Binding and           
Catalysis  ......................................................................................................................   138 
4.9 Summary and Outlook  ...........................................................................................  151 
4.10 Experimental  ........................................................................................................  153 
4.10.1 General methods  ...................................................................................  153 
4.10.2 Single-turnover activity studies  ............................................................  154 
4.10.3 Iodoacetamide labeling  .........................................................................  154 
	  	   viii	  
4.10.4 Heterocycle localization via FT-MS/MS  ..............................................  154 
4.10.5 BalhD-only ATP/ring stoichiometry  .....................................................  155 
4.10.6 Malachite green phosphate detection assay  ..........................................  155 
4.10.7 31P-NMR analysis of phosphate isotope incorporation of 18O-water  
reactions  ...........................................................................................................  156 
4.10.8 Cloning of MBP-YcaO  .........................................................................  156 
4.10.9 Preparation of BalhD PxPxP mutants  ...................................................  157 
4.10.10 Site-directed mutagenesis  ...................................................................  157 
4.10.11 Overexpression and purification of MBP-tagged proteins  .................  157 
4.10.12 Multiple sequence alignments  .............................................................  157 
4.10.13 Cytoscape sequence similarity network  ..............................................  157 
4.10.14 Maximum likelihood phylogenetic analysis  .......................................  157 
4.10.15 ATP-binding site conservation  ...........................................................  158 
4.10.16 Proline-rich C-terminus analysis  .........................................................  158 
4.10.17 Ec-YcaO crystallization and structural solution  .................................  158 
4.10.18 Endpoint heterocycle formation assays  ..............................................  159 
4.10.19 BalhD mutant kinetic studies  ..............................................................  159 
4.10.20 Size-Exclusion chromatography  .........................................................  159 
4.10.21 Mutant BalhD IC50 determination  .......................................................  160 
4.10.22 BalhC “KM” for active BalhD mutants  ...............................................  160 
4.11 References  ............................................................................................................  161 
 
CHAPTER 5: THE ROLE OF TOMM E1-HOMOLOGS IN AZOLINE  
BIOSYNTHESIS  ....................................................................................................................  165 
5.1 Introduction   ...........................................................................................................  165 
5.2 TOMM C Proteins Direct YcaO Cyclodehydratase Activity  ................................  168 
5.3 TOMM C Proteins are Responsible for Leader Peptide Recognition  ....................  170 
5.4 TOMM C Proteins Potentiate YcaO Cyclodehydratase Activity  ..........................  171 
5.5 The Role of Auxiliary E1-Homologs in Azoline Biogenesis  ................................  173 
5.6 Summary and Outlook  ...........................................................................................  179 
5.7 Experimental  ..........................................................................................................  182 
	  	   ix	  
5.7.1 General methods  .....................................................................................  182 
5.7.2 Balh cluster 2 cloning  .............................................................................  182 
5.7.3 Protein overexpression and purification  .................................................  182 
5.7.4 18O labeling of BalhD-treated BalhA1 reactions  ....................................  182 
5.7.5 BalhC leader peptide recognition  ............................................................  183 
5.7.6 BalhD-A4LEH6 activity  ..........................................................................  183 
5.7.7 Balh cluster 2 overnight heterocyclization assays  ..................................  184 
5.7.8 Size-exclusion chromatography  ..............................................................  184 
5.8 References  ..............................................................................................................  184 
 
APPENDIX A: LIST OF PRIMERS  ...................................................................................  187 
 
APPENDIX B: ADDITIONAL BALH CYCLODEHYDRATASE MUTANTS  .............  192 
B.1 Unpublished BalhC Mutants .................................................................................   192 
B.2 Unpublished BalhD Mutants .................................................................................   193 
 
APPENDIX C: YCAO PROTEINS FOR CRYSTALLOGRAPHY SCREEN  ...............  195 
C.1 YcaO proteins screened at UIUC  ..........................................................................  195 
C.2 YcaO proteins screened by Steve Almo (Albert Einstein College of Medicine) ...  196 
	  	   x	  
LIST OF FIGURES AND TABLES 
 
Figure 1.1: RiPP natural product biosynthesis and diversity  ......................................................  4 
Figure 1.2: TOMM Natural Product Diversity  ...........................................................................  6 
Figure 1.3: TOMM Azole Biogenesis  ........................................................................................  8 
Figure 1.4: [4+2] cycloaddition in thiopeptide biosynthesis  ....................................................  12 
Figure 1.5: The mechanism of MIA formation in nosiheptide biosynthesis  ............................  17 
Figure 1.6: Cyanobactin prenylation  ........................................................................................  20 
Figure 1.7: C-terminal amidation of thiopeptides  .....................................................................  22 
Figure 2.1: TOMM biosynthetic gene clusters and possible mechanisms of ATP utilization 
during azole formation  ...............................................................................................................  33 
Table 2.1: Substrate kinetic parameters for Balh synthetase  ....................................................  35 
Figure 2.2: Minimal requirement for cyclodehydratase activity and ATP hydrolysis product  
of the Balh synthetase  ................................................................................................................  36 
Figure 2.3: BalhA1-NC inhibition and BalhNC-C40 processing  .............................................  38 
Figure 2.4: ATP/azole stoichiometry for substrate processing  .................................................  40 
Figure 2.5: ATP is utilized to directly activate the amide backbone of the substrate  ..............  42 
Figure 2.6: Isotope composition of ADP produced in [18O]-water  ...........................................  42 
Figure 2.7: 31P-NMR of 18O5-BalhA1 reactions  .......................................................................  45 
Figure 2.8: TOMM azoline installation is reminiscent of intein-mediated protein splicing  ....  48 
Figure 2.9: The proposed enzymatic mechanism of PurM and ThiI  ........................................  49 
Figure 2.10: Alternative mechanism of azoline formation  .......................................................  49 
Figure 2.11: Strategies for azole biosynthesis outside of TOMMs  ..........................................  50 
Figure 3.1: Azolines in natural products and AMPL overview  ................................................  66 
Figure 3.2: Peptide substrate sequences  ...................................................................................  68 
Figure 3.3: Site-specific incorporation of 18O labels into BalhA1  ...........................................  68 
Figure 3.4: 18O labeling of BalhA1 is dependent on azoline heterocycles  ...............................  69 
Figure 3.5: Thiolysis is specific for oxazoline heterocycles  .....................................................  72 
Figure 3.6: Potassium hydrosulfide (KHS) treatment of unmodified BalhNC-A40T  ..............  73 
Figure 3.7: BalhX thiolysis reaction and localization  ...............................................................  73 
	  	   xi	  
Figure 3.8: BalhA1core processing  .............................................................................................  77 
Figure 3.9: Azol(in)e localization on BCD-treated BalhA1core  .................................................  78 
Figure 3.10: McbA and SagX processing by a non-cognate BCD complex  ............................  78 
Figure 3.11: Leader peptide-free processing follows previously established rules  ..................  79 
Figure 3.12: TOMM dehydrogenase alignments  ......................................................................  81 
Figure 3.13: Stability and FMN loading of McbC-K201A and -Y202A  ..................................  82 
Figure 3.14: Azoline formation by the microcin B17 synthetase  .............................................  82 
Figure 3.15: Azoline localization on BalhA2 via 18O labeling  .................................................  85 
Figure 3.16: Iodoacetamide labeling of McbA following treatment with McbC variants  .......  86 
Figure 3.17: Azoline localization on McbA following treatment with McbC-K201A  ............  87 
Figure 3.18: Azoline localization on McbA following treatment with McbC-Y201A  ............  88 
Figure 3.19: 18O-labeling of plantazolicin  ................................................................................  90 
Figure 3.20: 18O-labeling of ulithiacyclamide  ..........................................................................  91 
Figure 3.21: 18O-labeling of lissoclinamide 4  ...........................................................................  92 
Figure 4.1: YcaO gene clusters and sequence of precursor peptides used in this study  .........  108 
Figure 4.2: The biosynthetic gene clusters for trifolitoxin and bottromycin do not contain a 
recognizable TOMM C protein  ................................................................................................  109 
Figure 4.3: BalhD is an ATP-dependent cyclodehydratase  ....................................................  111 
Figure 4.4: MS/MS localization of the BalhD installed dehydration product  ........................  112 
Figure 4.5: BalhC potentiates the BalhD ATPase activity  .....................................................  113 
Figure 4.6: BalhD ATP/ring stoichiometry is dysregulated in the absence of BalhC  ............  114 
Figure 4.7: TOMM YcaOs activate carbonyl oxygens with ATP  ..........................................  116 
Figure 4.8: Ec-YcaO hydrolyzes ATP to AMP and pyrophosphate  .......................................  118 
Figure 4.9: Structural homology between Ec-YcaO and TruD and structure of AMP-bound  
Ec-YcaO  ...................................................................................................................................  121 
Figure 4.10: Structure of AMP-bound Ec-YcaO  ....................................................................  122 
Figure 4.11: ATP coordination in Ec-YcaO  ...........................................................................  123 
Figure 4.12: Cytoscape sequence similarity network for the YcaO superfamily  ...................  126 
Figure 4.13: Conservation of the Ec-YcaO ATP-binding residues in the superfamily  ..........  127 
Figure 4.14: The canonical E1 domain ATP-binding site is not conserved in TOMM C  
proteins  .....................................................................................................................................  128 
	  	   xii	  
Figure 4.15: The ATP-binding pocket is conserved in characterized TOMM YcaOs  ...........  129 
Table 4.1: Mutations to the ATP-binding pocket of BalhD decrease cyclodehydratase  
activity ......................................................................................................................................   132 
Figure 4.16: Mapping ATP-binding residues from Ec-YcaO to BalhD  .................................  133 
Figure 4.17: Mutations to the BalhD ATP-binding site affect heterocycle formation  ...........  134 
Figure 4.18: Mutations to the ATP-binding site that decrease cyclodehydratase activity also 
affect BalhD-only activity  ........................................................................................................  135 
Figure 4.19: The KM for ATP does not depend on the concentration of BalhA1  ...................  136 
Figure 4.20: Mutations of the Mg2+-binding residues prevent ATPase potentiation by  
BalhC  .......................................................................................................................................  136 
Figure 4.21: Effect of the ATP-binding site mutations on BalhC binding  .............................  137 
Table 4.2: Mutations to the C-terminus of BalhD disrupt catalysis  ........................................  140 
Figure 4.22: The C-terminal PxPxP motif conserved in TOMM YcaOs is near the ATP- 
binding site in TruD  .................................................................................................................  141 
Figure 4.23: The PxPxP motif of BalhD is critical for cyclodehydratase activity  .................  142 
Figure 4.24: Mutations that relocate the C-terminus of BalhD prevent ATPase potentiation  
by BalhC  ..................................................................................................................................  143 
Figure 4.25: C-terminal truncations of BalhD affect BalhC binding  .....................................  144 
Figure 4.26: Removal of the C-terminal residue of BalhD dysregulates the order of azole 
formation  ..................................................................................................................................  145 
Figure 4.27: Mutagenesis of the C-terminus of BalhD affects cyclodehydratase activity  .....  146 
Figure 4.28: The sequence of the C-terminus of BalhD is important for binding BalhC  .......  147 
Figure 4.29: BalhD P429G displays an altered order of heterocycle formation  .....................  148 
Figure 4.30: Mutations to the C-terminus of BalhD also affect BalhC-independent  
catalysis  ....................................................................................................................................  149 
Figure 4.31: The conserved TOMM YcaO C-terminus is critical for activity in the microcin B17 
cyclodehydratase  ......................................................................................................................  150 
Figure 5.1: Azoline localization on BalhD-treated BalhA1 via 18O-labeling  .........................  169 
Figure 5.2: BalhC is responsible for leader peptide recognition  ............................................  170 
Figure 5.3: A C-terminal His6 tag on BalhD abolishes cyclodehydratase activity  .................  172 
Figure 5.4: BalhC modulates ATP binding and hydrolysis by BalhD  ....................................  172 
	  	   xiii	  
Figure 5.5: Overview of the Balh TOMM biosynthetic clusters  ............................................  175 
Figure 5.6: Heterocycle formation on Balh2A is Balh2F and Balh2CD dependent  ...............  176 
Figure 5.7: The cyclized Balh2A product contains 13 thiazolines  .........................................  177 
Figure 5.8: Balh2F is responsible for leader peptide recognition in Balh cluster 2  ...............  178 
Figure 5.9: An updated model for azoline formation by TOMM cyclodehydratases  .............  181 
Table A.1: Primers for chapter 3 constructs  ...........................................................................  187 
Table A.2: Primers for chapter 4 constructs  ...........................................................................  187 
Table A.3: Primers for YcaO constructs cloned for crystallography screens  .........................  188 
Table A.4: Primers for chapter 5 constructs  ...........................................................................  189 
Table A.5: Primers for unpublished cyclodehydratase mutants  .............................................  190 
Table B.1: Mutant BalhC activity  ...........................................................................................  192 
Table B.2: Mutant BalhD activity  ...........................................................................................  193 
Table B.3: Mutant BalhD BalhA1 and ATP kinetics  ..............................................................  194 
Table C.1: YcaOs used for crystallography screens  ...............................................................  195 
Table C.2: YcaOs screened by Steve Almo  ............................................................................  196	  
	  	   1	  
CHAPTER 1: INTRODUCTION 
This chapter was taken in part from Dunbar & Mitchell1 and Dunbar Chekan et al.2 All material 
is reproduced with permission from the American Chemical Society and Nature Publishing 
Group, respectively. 
 
I am grateful to Courtney Cox for generating the YcaO Cytoscape network. 
 
 
1.1 Ribosomally Synthesized Post-Translationally Modified Peptides (RiPPs) 
How does one measure the impact that natural products have had on human health and science as 
a whole? Natural products, or the derivatives thereof, encompass the lion’s share of drugs in 
therapeutic use.3-5 The exquisite complexity of these compounds has served as a source of 
inspiration for organic chemists for over a century, leading to the development of reaction 
methodologies too numerous to list.5,6 Synthetic organic chemistry as we know it today would 
likely not exist had the study of natural products been neglected. While the impact on human 
therapeutics and synthesis has been immense, natural products research also enabled the study of 
fundamental biological processes. For example, research into the mode of action of antibiotics 
continues to provide insight into bacterial biochemistry and physiology,7-9 while compounds 
such as phalloidin (filamentous actin stabilizer), rapamycin (mTOR inhibitor), and tunicamycin 
(N-glycosylation inhibitor) have become invaluable tools for probing eukaryotic cell biology.10-12 
Furthermore, the study of natural products and their biosynthesis has revolutionized the way we 
think about the chemistry of biological systems. With the vast majority of Nature’s biosynthetic 
potential remaining to be discovered,13,14 the study of natural products will likely continue to 
inspire future generations of scientists. 
A class of natural products receiving significant recent attention is the ribosomally 
synthesized posttranslationally modified peptides (RiPPs).15,16 Comprised of the lanthipeptides, 
microcins and the thiazole/oxazole-modified microcins (TOMMs) among others, RiPPs occupy a 
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large chemical, genetic, and functional space, but remain linked by a common mechanism of 
biosynthesis. In all cases, a ribosomally synthesized precursor peptide undergoes modification by 
a set of tailoring enzymes usually found in the local genomic region (i.e. within the biosynthetic 
gene cluster, Figure 1.1). These modifications include, but are not limited to, varied cyclizations, 
dehydrations, and rearrangements, all of which are responsible for endowing the peptide with a 
rigidified structure, biological activity, and improved protease stability. The tailoring enzymes 
encoded in the biosynthetic gene cluster govern the posttranslational modifications received and, 
in some cases, the structure of the final product can be accurately predicted.17-19 In most cases, 
modification is followed by the proteolytic removal of an N-terminal leader peptide (or, less 
frequently, a C-terminal follow peptide) required for recognition by the tailoring enzymes, and 
the mature compound is exported.20 Using this simple strategy, a varied compound library can be 
constructed from a minimal amount of genetic space. In fact, the investigation of RiPPs has 
overturned the longstanding paradigm that large genomes are required for an organism to 
produce architecturally complex natural products.21,22  
Adding to the allure of this class of natural products is the gene-encoded nature of the 
precursor peptide coupled with the often high level of promiscuity of the biosynthetic enzymes, 
allowing for the facile generation of unnatural compound derivatives.15,19,23-25 This approach has 
garnered a great deal of excitement due to the potential to develop therapeutically relevant 
derivatives of this underutilized compound class.26,27 Although the basis for the high level of 
promiscuity is not fully understood, the use of an N-terminal leader peptide is thought to play a 
role. By spatially separating peptide recognition from the residues that will be modified the 
enzymes have the ability to process a substrate multiple times at diverse positions using a single 
recognition strategy.20  
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The profound interest in these natural products has fueled extensive studies into 
biosynthetic mechanisms. Recent successes in the study of RiPP biosynthetic enzymes have 
greatly expanded our view of Nature’s synthetic organic potential. In addition to the discovery of 
novel biological chemistry, these studies provide a window through which the evolutionary 
adaptation of enzymes can be observed. However, there are many tailoring enzymes that have 
yet to be characterized and many posttranslational modifications whose biosynthesis remains 
enigmatic. For additional information regarding the advances in the field of non-TOMM, RiPP 
biosynthesis I direct the reader towards recent reviews.16,28 
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Figure 1.1 | RiPP natural product biosynthesis and diversity. The general strategy for RiPP 
biosynthesis is illustrated in the generic gene cluster and schematic below. The functional 
assignment for each of the open reading frames is displayed. An array of ribosomal natural 
products generated from this strategy is displayed along with their RiPP subclass and 
characterized bioactivity or molecular target, when known. Post-translational modifications are 
colored red. This figure was adapted with permission from Dunbar & Mitchell.1 
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1.2 Thiazole-Oxazole Modified Microcins (TOMMs) 
Thiostrepton was the first azole/azoline containing RiPP natural product to be structurally 
characterized.29 Although the structures of other thiazol(in)e and oxazol(in)e-containing natural 
products were solved over the following 25 years, it was not until the mid-1990s that the first 
insights into azole biosynthesis were revealed with the study of microcin B17.30 Following this 
discovery, just two additional biosynthetic gene clusters of this type were identified over the next 
decade (streptolysin S31 and patellamide A/C32), and the unification of the TOMM family as a 
whole was only recently realized.22  
 TOMMs are comprised of the thiopeptides, azole-containing cyanobactins, linear azole-
containing peptides (LAPs), trifolitoxins, and bottromycins (Fig. 1.1 and 1.2).16 As implied by 
the name, all members of the TOMM subclass of RiPPs contain Cys-, Ser-, or Thr-derived 
azol(in)e heterocycles. The installation of these heterocycles onto a precursor peptide endows the 
molecule with conformational rigidity and, in all cases examined to date, is absolutely required 
for biological activity.16,23 Consistent with the structural diversity observed in characterized 
family members, TOMMs display diverse biological functions including, but not limited to, 
acting as antibacterial and antiviral compounds, antitumor agents, and cytolytic virulence 
factors.16,33  
Currently well over 400 TOMMs have been structurally and/or functionally 
characterized;16 however, there are still approximately 700 bioinformatically identifiable gene 
clusters in GenBank with no discernable structure or function (Fig. 1.2).2 These uncharacterized 
clusters are found in both Archaea and Bacteria and the characterization of such clusters will 
undoubtedly expand the structural and functional diversity of this important class of natural 
products.  
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Figure 1.2 | TOMM Natural Product Diversity. A Cytoscape sequence similarity network of 
the TOMM D protein (discussed below) is displayed. Each node represents a unique TOMM D 
protein, and lines are drawn between nodes if the proteins share at least BLAST e-value of at 
least e-80. Nodes are colored if the structure or function of the natural product is known or can be 
inferred from bioinformatics. Select structures of characterized TOMM natural products are 
displayed. The biological activity is shown in parenthesis followed by the associated molecular 
target, if the mechanism of action is known. All post-translational modifications are shown in 
red, while the blue serine in the microcin B17 structure marks the site of the 9th azole that is 
found as a minor product during biosynthesis.  Ab, denotes antibacterial activity. This figure was 
adapted with permission from Dunbar & Chekan et al.2 
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1.3 Biosynthesis of TOMMs 
The first genetic evidence that TOMM natural products were of ribosomal origin was provided 
with the characterization of the trifolitoxin and microcin B17 biosynthetic clusters in 1993 and 
1994, respectively.34,35 Shortly after these initial reports, the enzymes responsible for azole 
formation during microcin B17 biosynthesis were purified and characterized.30 The extraordinary 
studies performed on the microcin B17 synthetase provided the framework for all subsequent 
work on TOMM biosynthesis. Following these seminal studies, the TOMM biosynthetic clusters 
for natural products that contain auxiliary post-translational modifications have been 
discovered.23 Recently, many of auxiliary tailoring enzymes responsible for the maturation of 
diverse TOMMs have been reconstituted and studied.1 Although all TOMM tailoring enzymes 
were originally hypothesized to require an N-terminal leader or C-terminal follower peptide for 
substrate recognition,1,16,36-39 exceptions to this strategy for peptide substrate binding have 
emerged.40-43 The following sections will describe our current understanding of the biosynthesis 
of TOMM natural products. While the modifications discussed below provide a flavor of the 
diversity of biological chemistry involved in TOMM biogenesis, there are many tailoring events 
that are completely uncharacterized. As such, TOMM biosynthesis is likely to remain a fruitful 
area of research for years to come. 
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1.3.1 Azole Biosynthesis 
A heterotrimeric protein complex, referred to as the TOMM synthetase, is required to install the 
characteristic azole heterocycles on a precursor peptide.30,32,44 Studies performed on the TOMM 
enzymatic machinery involved in microcin B17 and azol(in)e-containing cyanobactin 
biosynthesis have demonstrated that azole heterocycles are installed through two steps: a 
cyclodehydration to generate an azoline heterocycle and a subsequent flavin mononucleotide 
(FMN)-dependent dehydrogenation to afford the aromatic azole (Fig. 1.3).30,44,45 While the 
enzymatic complex responsible for these transformations has been partially characterized, the 
dehydrogenase (B-protein) is the only enzyme with a definitive function.46 Dissection of the 
biochemical functions of the C and D proteins has been stymied by the inability to obtain 
individual activities for either protein; however, cyclodehydratase activity has been demonstrated 
for a complex of the two proteins32,45 and has been shown to require ATP hydrolysis.47,48 
Underscoring this linked function, roughly half of known TOMM clusters express C and D as a 
single polypeptide (CD fusion).23,32 Although significant progress has been made towards 
understanding the rules that govern substrate promiscuity, the mechanism of azoline formation 
and the role of ATP in the reaction is not currently understood.23  
 
 
 
Figure 1.3 | TOMM Azole Biogenesis. Azole heterocycles in TOMM natural products are 
installed by the successive action of a cyclodehydratase (C and D proteins) and a flavin 
mononucleotide (FMN)-dependent dehydrogenase (B protein). The cumulative mass change for 
each step is shown below the modification.  
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1.3.2 Macrocyclization of TOMM Natural Products 
Multiple subclasses of TOMM natural products are macrocyclized (Fig. 1.1 and Fig. 1.2).  
Although the mechanisms for macrolactam and macroamidine formation in bottromycin and 
YM-216391 remain uncharacterized,49-53 the mechanism of macrocyclization in cyanobactin and 
thiopeptide biosynthesis has been partially elucidated. 
Cyanobactin biosynthesis begins with the installation of azole(in)e heterocycles by PatD, 
a TOMM synthetase.48 Next, a subtilisin-like protease, PatA, removes the leader peptide and 
separates the heterocyclized patellamide A/C peptides (patellamide precursor peptides often 
contain multiple core peptides separated by protease cleavage sites), each bearing an AYDG 
sequence at their C-termini.54 This tetrapeptide motif serves as a recognition sequence for 
another subtilisin-like protease, PatG. In vitro studies demonstrated that PatG removes the C-
terminal AYDG tag and facilitates cyanobactin N-to-C macrocyclization.54 Given the homology 
to subtilisin, a mechanism was proposed where the acyl-enzyme intermediate was resolved with 
the N-terminus, rather than water, to generate the macrolactam. 
 Recently, the crystal structure of the central PatG macrocyclase domain, PatGmac, was 
solved.55 As expected, PatGmac adopts the subtilisin-like fold. However, PatG contains an 
additional loop positioned over the active site. The PatG-type protease/macrocyclase proteins all 
contain a 30–50 amino acid insertion between two of the three residues involved in subtilisin 
catalytic triad, providing a bioinformatic handle for identifying cyanobactin macrocylases.54 An 
analysis of PatGmac co-crystallized with a peptide substrate demonstrated that this insertion was 
responsible for shielding the active site from water and also binding of the AYDG sequence.55 
Using both site-directed mutagenesis and selective truncations of this insertion sequence, it was 
determined that any disruption of AYDG recognition or water shielding resulted in a loss of 
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macrocyclase, but not protease, activity. Combined with the observation that the acyl-enzyme 
intermediate is remarkably long lived, a mechanism was proposed in which the insertion loop 
prevents AYDG peptide dissociation after cleavage until the N-terminus displaces it and resolves 
the covalent intermediate. 
 The PatG-catalyzed transformation is extraordinary for three reasons: (1) unlike the 
thioesterase domains in polyketide and non-ribosomal peptide synthetases, PatG 
macrocyclization occurs on an unactivated substrate without an external energy source, (2) the 
prime side specificity (recognition is C-terminal to the scissile bond) of PatG facilitates the 
processing of hypervariable substrates with a minimal sequence tag is in stark contrast to other 
subtilisin-like proteases and (3) the strong sequence similarity to subtilisin proteases suggests 
that these proteins have been naturally evolved to catalyze a variety of chemical 
transformations.54  
While cyanobactins are head-to-tail macrolactams, the central macrocycle found in all 
thiopeptides is formed through a cycloaddition processes that forms two carbon-carbon 
linkages.56 This macrocyclization forms the ubiquitous thiopeptide (dehydro)pyridine ring, 
which is critical for target recognition.57 Recent investigations into thiocillin biosynthesis have 
demonstrated that the pyridine ring is assembled via the TclM-catalyzed trans-annular 
heteroannulation of two dehydroalanine residues (Fig. 1.4).58,59 This formal [4+2] cycloaddition 
has received a great deal of attention, as it has been postulated to proceed through an aza-Diels-
Alder mechanism. Although the Diels-Alder is one of the most widely employed reactions in 
organic synthesis, no naturally occurring catalyst has been definitively proven to carry out a 
concerted [4+2] cycloaddition.60 Theoretically, 13C primary kinetic isotope effects (KIEs) could 
be used to determine if the TclM-catalyzed cycloaddition occurs via a stepwise or concerted 
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mechanism.61 To perform this experiment, the two differentially (dual) labeled substrates shown 
in Figure 1.4 would be required. If the mechanism were concerted, a primary 13C KIE would be 
observed with both substrates; however, if cycloaddition occurred via a stepwise mechanism, a 
KIE would only be observed for one of the dual-labeled substrates. While this experiment may 
seem relatively straightforward, in practice it will be difficult. TclM has never been reconstituted 
in vitro, the heterocyclized and dehydrated substrate is not readily accessible, and the expected 
primary 13C KIEs require a highly sensitive kinetic assay to measure. A more tractable 
alternative for the discovery of a bona fide Diels-Alderase may be to examine the enzyme 
responsible for the [4+2] cycloaddition in spinosin A biosynthesis.62 While SpnF is not 
responsible for producing a RiPP, it has been reconstituted in vitro, the reaction allows for the 
use of 2H secondary KIEs (which are typically 30% larger than 13C primary KIEs),61 and the 
substrate is more amenable to chemical synthesis.  
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Figure 1.4 | [4+2] cycloaddition in thiopeptide biosynthesis. Two potential mechanisms for 
installing the pyridine moiety of thiocillin I (red) are displayed. Starting from the tautomer form, 
the orange arrows demonstrate a concerted Diels-Alder mechanism, while the purple arrows 
follow a stepwise, polar mechanism. The shared step of each mechanism is displayed as a dashed 
black arrow. After the [4+2] cycloaddition is complete, the elimination of water and the leader 
sequence (LP) affords the central pyridine ring. The colored circles on the tautomer form of the 
uncyclized intermediate indicate positions where dual 13C-labeling could distinguish between 
stepwise and concerted cyclization mechanisms. 
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1.3.3 Radical-Mediated Transformations in TOMM Biogenesis 
While the presence of the core macrocycle is seen in all thiopeptides, select family members also 
contain a second macrocycle.56 This ring is not formed from the gene-encoded peptide sequence 
but rather occurs through the posttranslational attachment of a modified tryptophan.63-67 
Currently, two types of this auxiliary macrocycle have been identified. In thiostrepton, the 
macrocycle is comprised of a L-tryptophan-derived quinaldic acid moiety, whose biosynthesis 
occurs via a complex and poorly understood pathway and thus will not be discussed 
further.63,65,68 In contrast, nosiheptide contains an indolic acid derivative, which is assembled via 
the action of two rSAM enzymes, NosL and NosN (Fig. 1.5A).64 Through genetic studies, it was 
discovered that deletion of nosL abolished nosiheptide production, but that supplementation of 3-
methyl-2-indolic acid (MIA) rescued product formation. Moreover, a nosN deletion formed a 
nosiheptide derivative with MIA attached via a single thioester linkage rather than the expected 
3,4-dimethyl indolic acid derivative. These results were used to putatively assign NosL and 
NosN as the enzymes involved in the rearrangement of L-tryptophan to MIA and the methylation 
of the unactivated C4 position, respectively.64  
 To better understand the transformation of L-tryptophan to MIA, NosL was recently 
heterologously expressed and investigated in vitro.69 Support for assigning NosL as the sole 
protein responsible for MIA formation came initially from the detection of MIA in NosL-
expressing E. coli. Further characterization demonstrated that NosL reductively cleaved SAM 
and used the 5’-Ado radical to form MIA. Reactions conducted with [1-13C]- and [3-13C]-labeled 
L-tryptophan showed that both carbons were retained during the transformation, while reactions 
conducted with [2H8]-L-tryptophan established that initial hydrogen abstraction does not occur 
from any of the C-H bonds in tryptophan. Fortuitously, a detailed analysis of the NosL product 
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profile identified four side products: 3-methylindole, glyoxate, glycine and formaldehyde. This 
led to the mechanistic proposal presented in Figure 1.5B. Based on the [2H8]-L-tryptophan 
experiment, the 5’-Ado radical is proposed to abstract the N-H hydrogen to generate a stabilized 
indole radical. This radical then fragments to form 3-methylene indole and a glycine radical, 
derivatives of which were identified as shunt products. Subsequent radical attack on the C2 
position of the indole ring, and decomposition of the glycine subunit to form formaldehyde and 
ammonium, affords MIA. A subsequent report on NocL, a NosL homolog in nocathiacin MIA 
biogenesis, directly detected the glycine radical by EPR, strongly supporting this mechanism.70  
Prior to the study of NosL, no member of the rSAM superfamily had been shown to 
catalyze both the fragmentation and rearrangement of a substrate.71 While this chemistry is 
noteworthy, glutamate mutase, a cobalamin-dependent enzyme, catalyzes a similar 
fragmentation-rearrangement reaction.72 Glutamate mutase uses a cobalamin-generated 5’-Ado 
radical to perform C-H abstraction. Akin to the NosL mechanism, the resulting radical 
decomposes into a glycine radical and acrylate. In a final step, these recombine to afford 2-
methylaspartate. However, unlike glutamate mutase, NosL catalyzes a fragmentation-
recombination reaction with elimination of a portion of the molecule during the transformation.  
In addition to the radical-based rearrangements that form the side-rings of thiopeptides, 
various positions within members of this TOMM subclass are methylated, despite being 
unactivated and non-nucleophilic.64,73 Recent efforts have identified similar modifications in 
other RiPP biosynthetic clusters, including the bottromycins and polytheonamides.50-53,74 In 
certain cases, labeling studies indicated that SAM was the source of these methyl groups;75,76 
however, the unactivated nature of the modified position suggested that a radical mechanism 
would be necessary. Accordingly, recent studies conducted on two rRNA methyltransferases, 
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RlmN and Cfr, provided the first definitive evidence that rSAM enzymes can perform 
methylation reactions.77,78 These proteins have become the founding members of the radical 
SAM methyltransferase (RSMT) protein family, of which there are three bioinformatically-
identifiable classes.73 Class A is solely comprised of RlmN and Cfr, contains only a rSAM 
domain, and is the best characterized class to date. However, as these enzymes are involved in 
ribonucleotide methylation and not RiPP biosynthesis, they will not be discussed further. Rather, 
focus will be placed on class B and class C RSMTs because analyses of several RiPP 
biosynthetic clusters demonstrate that in all cases where the natural product is methylated at an 
unactivated position, a RSMT of one of these classes is present. 
In addition to the canonical rSAM domain, class B RSMTs contain an N-terminal 
cobalamin-binding domain. Recently, the first class B RSMT to be characterized, TsrM which is 
involved in thiostrepton biosynthesis, was recently reconstituted in vitro and exhibited a novel 
strategy for methylation.79 TsrM catalyzed the SAM and cobalamin-dependent methylation of 
the C2 position of tryptophan, which has been predicted to be the precursor for the quinaldic acid 
moiety.65 Unlike all other rSAM homologs, TsrM did not carry out the reductive cleavage of 
SAM despite containing a CxxxCxxC ligated Fe-S cluster.79 Instead, SAM was used as a methyl 
source for the in situ formation of a methylcobalamin cofactor, which then serves as the methyl 
source for tryptophan methylation. Although the mechanism of methyltransfer from the 
methylcobalamin cofactor to tryptophan remains enigmatic, preliminary data suggests that the 
Fe-S cluster may play a pivotal role as a redox cofactor in the transformation. While this initial 
study of TsrM is interesting from a mechanistic point of view, it also has larger implications for 
the classification of the rSAM superfamily. The protein contains the conserved Fe-S cluster 
ligation motif and is SAM dependent, but does not catalyze the reductive cleavage of the 
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sulfonium moiety, a previously ubiquitous feature of the enzyme family. This prompts the 
question as to whether TsrM is a true member of the rSAM superfamily. Moreover, the 
characterization of additional class B RSMTs will be required to determine if this unusual 
utilization of SAM by a rSAM domain is a conserved strategy for methylation of unactivated 
positions.   
 To date, no member of the class C RSMTs has been reconstituted. These proteins share 
significant similarity to the rSAM protein coproporphyrinogen III oxidase (HemN), which is 
responsible for the oxidative decarboxylation of coproporphyrinogen III to form 
protoporphyrinogen IX in heme biogenesis.80 Although Class C RSMTs contain both a HemN-
like rSAM domain and a domain similar to the C-terminus of HemN, they lack the N-terminal 
“trip-wire” domain of HemN.73 Studies on HemN have demonstrated that the rSAM TIM barrel 
core binds two molecules of SAM81 and a comparison to class C RSMTs hints that these 
enzymes may also simultaneously bind two SAM molecules.73  
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Figure 1.5 | The mechanism of MIA formation in nosiheptide biosynthesis. (a) The structure 
of nosiheptide is displayed with the indolic acid ring highlighted in red. The uncharacterized 
radical SAM methyltransferase, NosA, and an as of yet unidentified protein methylate and 
oxidize MIA to afford the second attachment point (blue moiety). (b) The proposed mechanism 
of indolic acid formation by the radical SAM protein NosL is shown. The structures of the 
intermediates/products enclosed in the dotted circles were detected in reaction mixtures. The 
colored asterisks denote 13C-labeled positions that were used to demonstrate the fate of the 
carbon backbone during the rearrangement. 
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1.3.4 Prenylation in Cyanobactin Biosynthesis 
Amongst other modifications, select cyanobactins are further decorated by O-prenylation. 
Deriving from dimethylallyl pyrophosphate (DMAPP), this modification is observed at Ser, Thr 
and Tyr residues. Ser and Thr prenylation occurs through the C3 position of DMAPP (reverse 
prenylation; Fig. 1.6A). Conversely Tyr prenylation appears to occur exclusively through the C1 
position (forward prenylation; Fig. 1.6A).82 This modification is notable, as the only known O-
prenylated RiPPs are cyanobactins. Based on comparative genomics, TruF and its homologs 
were tentatively assigned as O-prenyltransferases.17 However, this assignment was complicated 
by the fact that TruF-like proteins are not homologous to known prenyltransferases and are 
essential in the biosynthesis of non-prenylated cyanobactins as well.17,19  
 In 2011, the first insights into cyanobactin prenylation emerged with the in vitro 
reconstitution of a prenyltransferase from Lyngbya aestuarii, LynF.41 While the product of the 
Lyn cluster remains uncharacterized, initial activity screens with various peptides substrates 
confirmed that LynF was a tryrosine prenyltransferase. Unexpectedly, LynF displayed a strong 
selectivity for macrocyclized substrates over linear peptides. Moreover, LynF was not able to 
prenylate substrates with leader peptides regardless of whether they contained azol(in)e 
heterocycles. Considering that heterocyclization occurs prior to macrocyclization, this suggested 
that prenylation is the final step in cyanobactin biosynthesis. Further analysis of LynF’s substrate 
promiscuity demonstrated that the protein displayed relaxed sequence specificity, but a definitive 
set of modification rules could not be established. This prompts the question as to how substrate 
recognition is achieved in vivo given that LynF does not utilize the standard leader peptide 
recognition strategy used by most RiPP tailoring enzymes. Reaction products were analyzed by 
2D-NMR to definitively establish the site of Tyr prenylation. Surprisingly, the spectra showed 
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that LynF catalyzed forward C-prenylation ortho to the phenolic oxygen, rather than O-
prenylation. Similar transformations have been characterized in other biosynthetic pathways, and 
are proposed to proceed via an electrophilic aromatic substitution mechanism.83 To evaluate the 
mechanism of LynF prenylation, reaction products were analyzed with multiple spectroscopic 
methods over a reaction time course. The results demonstrated that the substrate initially 
undergoes reverse O-prenylation, but slowly converts to the forward C-prenylated phenol, most 
likely through a Claisen rearrangement (Fig. 1.6B). 
 Although highly similar reaction schemes have been synthetically employed,84,85 LynF 
represents the first instance of enzymatic C-prenylation via a reverse O-prenylation/Claisen 
rearrangement route. Additional experiments concluded that this rearrangement occurs at a slow 
but measurable rate (0.23 h-1) in the absence of enzyme, demonstrating that reverse O-prenylated 
phenols are prone to spontaneous rearrangement.41 This result provides a possible explanation as 
to why reverse O-prenylated phenol rings are not seen in natural products while reverse O-
prenylated hydroxyl moieties are common. It remains uncertain whether the rearrangement is 
truly uncatalyzed in vivo or if the product of the Lyn cluster is actually C-prenylated. Regardless, 
LynF remains the only RiPP prenyltransferase characterized to date and demonstrates that C-
prenylation in natural product biosynthesis can be achieved via a Claisen rearrangement, as was 
predicted over 40 years ago.86  
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Figure 1.6 | Cyanobactin prenylation. a) The two forms of O-prenylation are displayed along 
with examples of natural products containing each modification. b) The LynF prenylation 
mechanism. After reverse O-prenylation of tyrosine, the intermediate undergoes a Claisen 
rearrangement to afford the C-prenylated product. As the product of the Lyn cluster has not been 
identified, the predicted product is displayed without stereochemistry. The DMAPP derived 
prenyl groups are shown in red. 
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1.3.5 C-terminal Amidation in Thiopeptides 
The C-termini of many thiopeptides are amidated. This modification, while easy to overlook 
when considering the structural complexity of these heavily modified RiPPs, has an important 
role in biological activity.42 Recently, the tailoring machinery responsible for C-terminal 
amidation moiety has been characterized in thiostrepton and nosiheptide biosynthesis.42,43 These 
studies demonstrated that two divergent strategies have been utilized by Nature to perform the 
amidation in a leader peptide-independent fashion. In nosiheptide biosynthesis, genetic deletions 
and in vitro reactions were used to identify nosA as the gene responsible for C-terminal 
amidation.43 The ΔnosA strain produced a nosiheptide analog with an additional C-terminal 
dehydroalanine moiety, which is derived from the dehydration of the terminal serine of the 
precursor peptide. Reactions with purified NosA validated this assignment and revealed that 
pyruvate was a reaction byproduct. Based on the pH dependence of the reaction and the cofactor 
independent activity of NosA, this reaction is predicted to proceed via the enamide de-alkylation 
mechanism displayed in Figure 1.7A. Thiostrepton, on the other hand, requires at least three 
enzymes to perform the same modification.42,63,65 An unidentified methyltransferase is 
hypothesized to generate the C-terminal methylester on the precursor peptide to facilitate the 
dehydration of the terminal Ser. Subsequently, TsrB (also called TsrU65) catalyzes the 
saponification of the methylated thiostrepton intermediate. Finally, the carboxylate is modified 
by an asparagine synthetase-like amidotransferase, TsrC (also called TsrT65), which the forms 
the amide linkage, presumably though an adenylated intermediate.42 The proposed mechanism of 
this modification is displayed in Figure 1.7B; however, additional studies are necessary to 
identify the methyltransferase and to establish the mechanism of TsrC. 
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Figure 1.7 | C-terminal amidation of thiopeptides. The putative mechanism for C-terminal 
amide formation is displayed for (a) nosiheptide and (b) thiostrepton. The proposed 
transformation catalyzed by TsrC is boxed. Tables listing the other thiopeptides that utilize each 
mechanism, along with the responsible enzyme, are shown on the right. 
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1.3.6 N-terminal Dimethylation in Plantazolicin Biosynthesis 
Plantazolicin (Pzn) is a linear TOMM natural product produced by Bacillus amyloliquefaciens 
(for structure see Fig. 1.2) with narrow-spectrum bactericidal activity against Bacillus anthracis 
and, more recently, nematicidal activity.87-89 Deletion mutagenesis studies have demonstrated 
that the dimethylation of the N-terminus is critical for antimicrobial activity.87,88 N-terminal 
methylation in RiPPs is very rare. Apart from Pzn, the linaridin antibiotics are the only 
characterized RiPPs that are N-terminally methylated.90,91 Akin to the C-terminal amidation of 
thiopeptides and the prenylation of cyanobactins, N-terminal methylation is a leader peptide 
independent process. Reconstitution of the SAM-dependent Pzn methyltransferase, BamL, 
demonstrated that the enzyme is highly specific for the heterocyclized Pzn precursor peptide.40 
An X-ray crystal structure of BamL and a homolog from Bacillus pumilus (BpumL) 
demonstrated that this remarkable selectivity is due to the presence of a very narrow substrate-
binding channel.40 At the tightest point, the channel is too narrow to accommodate a peptide 
bearing carbonyl oxygens. Heterocyclization of the Cys, Ser, and Thr side chains, results in the 
elimination of the carbonyl oxygen and decreases the width of the molecule enough to facilitate 
binding.40 Although the channel is deep enough to accommodate the first 4-5 residues of the Pzn 
core peptide, studies performed with synthetic substrate analogs have demonstrated that the 
recognition occurs at the N-terminal Arg and the first thiazole heterocycle.92,93 Based on the 
crystal structure, the Arg is thought to be coordinated by a conserved Asp in the active site, while 
the thiazole is believed to be required to allow the peptide to pass through the narrowest part of 
the channel.40 As all Pzn core peptides begin with an Arg and Cys,87 this strategy for substrate 
recognition by the methyltransferase is likely invariant within this subfamily of TOMMs. 
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1.4 Summary and Outlook 
Recent successes in the study of TOMM, and more generally RiPP, biosynthetic enzymes have 
greatly expanded our view of Nature’s synthetic organic potential. In addition to the discovery of 
novel biological chemistry, these studies provide a window through which the evolutionary 
adaptation of enzymes can be observed. Although marked progress has been made in the last two 
decades towards understanding the complex post-translational modifications that occur during 
TOMM biogenesis, there are many aspects of TOMM biosynthesis that remain uncharacterized 
and many posttranslational modifications whose biosynthesis remains enigmatic. As such, the 
post-translational modifications discussed above only represent a subset of the characterized 
TOMM chemical space.  
Perhaps the most pronounced gap in our knowledge of TOMM biosynthesis can be found 
in the mechanism of azoline formation, which is the focus of this thesis. Studies carried out on 
diverse TOMM biosynthetic pathways have demonstrated that heterocycle formation occurs 
early in precursor peptide maturation and can be important for downstream processing by 
auxiliary tailoring enzymes.16 Despite the central role that azole formation plays in TOMM 
biogenesis, the finer details of azole formation remain uncharacterized. While the role of the 
dehydrogenase is established, the activities of the C and D proteins remain contentious. 
Furthermore, the mechanism of azoline formation, in particular the role that ATP plays during 
cyclodehydration, is not understood. Although other laboratories have attempted to address these 
outstanding questions in TOMM biosynthesis, the poor stability and solubility of previously 
characterized TOMM synthetases stymied progress. Using two novel TOMM synthetases from 
Bacillus sp. Al Hakam, I provide answers to these longstanding questions in TOMM biogenesis.  
	  	   25	  
1.5 References 
 (1) Dunbar, K. L.; Mitchell, D. A. ACS Chem. Biol. 2013, 8, 473. 
 (2) Dunbar, K. L.; Chekan, J. R.; Cox, C. L.; Burkhart, B. J.; Nair, S. K.; Mitchell, D. A. Nat. 
Chem. Biol. 2014, Accepted. 
 (3) Harvey, A. L. Drug Discovery Today 2008, 13, 894. 
 (4) Newman, D. J.; Cragg, G. M. J. Nat. Prod. 2012, 75, 311. 
 (5) Wilson, R. M.; Danishefsky, S. J. J. Org. Chem. 2006, 71, 8329. 
 (6) Razzak, M.; De Brabander, J. K. Nat. Chem. Biol. 2011, 7, 865. 
 (7) Falconer, S. B.; Czarny, T. L.; Brown, E. D. Nat. Chem. Biol. 2011, 7, 415. 
 (8) Romero, D.; Traxler, M. F.; Lopez, D.; Kolter, R. Chem. Rev. 2011, 111, 5492. 
 (9) Kocaoglu, O.; Calvo, R. A.; Sham, L. T.; Cozy, L. M.; Lanning, B. R.; Francis, S.; Winkler, 
M. E.; Kearns, D. B.; Carlson, E. E. ACS Chem. Biol. 2012. 
 (10) Heitman, J.; Movva, N. R.; Hall, M. N. Science 1991, 253, 905. 
 (11) Yajima, J.; Alonso, M. C.; Cross, R. A.; Toyoshima, Y. Y. Curr. Biol. 2002, 12, 301. 
 (12) Varki A.; Cummings R. D.; Esko J. D.; Freeze H. H.; Stanley P.; Bertozzi C. R.; Hart G. 
W.; E., E. M. In Essentials of Glycobiology; 2nd ed.; Cold Spring Harbor Laboratory Press: Cold 
Spring Harbor, New York, 2009, p 705. 
 (13) Baltz, R. H. J. Ind. Microbiol. Biotechnol. 2006, 33, 507. 
 (14) Bentley, S. D.; Chater, K. F.; Cerdeno-Tarraga, A. M.; Challis, G. L.; Thomson, N. R.; 
James, K. D.; Harris, D. E.; Quail, M. A.; Kieser, H.; Harper, D.; Bateman, A.; Brown, S.; 
Chandra, G.; Chen, C. W.; Collins, M.; Cronin, A.; Fraser, A.; Goble, A.; Hidalgo, J.; Hornsby, 
T.; Howarth, S.; Huang, C. H.; Kieser, T.; Larke, L.; Murphy, L.; Oliver, K.; O'Neil, S.; 
Rabbinowitsch, E.; Rajandream, M. A.; Rutherford, K.; Rutter, S.; Seeger, K.; Saunders, D.; 
Sharp, S.; Squares, R.; Squares, S.; Taylor, K.; Warren, T.; Wietzorrek, A.; Woodward, J.; 
Barrell, B. G.; Parkhill, J.; Hopwood, D. A. Nature 2002, 417, 141. 
 (15) Velasquez, J. E.; van der Donk, W. A. Curr. Opin. Chem. Biol. 2011, 15, 11. 
	  	   26	  
 (16) Arnison, P. G.; Bibb, M. J.; Bierbaum, G.; Bowers, A. A.; Bugni, T. S.; Bulaj, G.; 
Camarero, J. A.; Campopiano, D. J.; Challis, G. L.; Clardy, J.; Cotter, P. D.; Craik, D. J.; 
Dawson, M.; Dittmann, E.; Donadio, S.; Dorrestein, P. C.; Entian, K. D.; Fischbach, M. A.; 
Garavelli, J. S.; Goransson, U.; Gruber, C. W.; Haft, D. H.; Hemscheidt, T. K.; Hertweck, C.; 
Hill, C.; Horswill, A. R.; Jaspars, M.; Kelly, W. L.; Klinman, J. P.; Kuipers, O. P.; Link, A. J.; 
Liu, W.; Marahiel, M. A.; Mitchell, D. A.; Moll, G. N.; Moore, B. S.; Muller, R.; Nair, S. K.; 
Nes, I. F.; Norris, G. E.; Olivera, B. M.; Onaka, H.; Patchett, M. L.; Piel, J.; Reaney, M. J. T.; 
Rebuffat, S.; Ross, R. P.; Sahl, H. G.; Schmidt, E. W.; Selsted, M. E.; Severinov, K.; Shen, B.; 
Sivonen, K.; Smith, L.; Stein, T.; Sussmuth, R. D.; Tagg, J. R.; Tang, G. L.; Truman, A. W.; 
Vederas, J. C.; Walsh, C. T.; Walton, J. D.; Wenzel, S. C.; Willey, J. M.; van der Donk, W. A. 
Nat. Prod. Rep. 2013, 30, 108. 
 (17) Donia, M. S.; Schmidt, E. W. Chem. Biol. 2011, 18, 508. 
 (18) Donia, M. S.; Ravel, J.; Schmidt, E. W. Nat. Chem. Biol. 2008, 4, 341. 
 (19) Donia, M. S.; Hathaway, B. J.; Sudek, S.; Haygood, M. G.; Rosovitz, M. J.; Ravel, J.; 
Schmidt, E. W. Nat. Chem. Biol. 2006, 2, 729. 
 (20) Oman, T. J.; van der Donk, W. A. Nat. Chem. Biol. 2010, 6, 9. 
 (21) Li, B.; Sher, D.; Kelly, L.; Shi, Y.; Huang, K.; Knerr, P. J.; Joewono, I.; Rusch, D.; 
Chisholm, S. W.; van der Donk, W. A. Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 10430. 
 (22) Haft, D. H.; Basu, M. K.; Mitchell, D. A. BMC Biol. 2010, 8, 70. 
 (23) Melby, J. O.; Nard, N. J.; Mitchell, D. A. Curr. Opin. Chem. Biol. 2011, 15, 369. 
 (24) Tianero, M. D.; Donia, M. S.; Young, T. S.; Schultz, P. G.; Schmidt, E. W. J. Am. Chem. 
Soc. 2012, 134, 418. 
 (25) Melby, J. O.; Dunbar, K. L.; Trinh, N. Q.; Mitchell, D. A. J. Am. Chem. Soc. 2012, 134, 
5309. 
 (26) Field, D.; Hill, C.; Cotter, P. D.; Ross, R. P. Mol. Microbiol. 2010, 78, 1077. 
 (27) Bowers, A. A. MedChemComm 2012, 3, 905. 
 (28) McIntosh, J. A.; Donia, M. S.; Schmidt, E. W. Nat. Prod. Rep. 2009, 26, 537. 
 (29) Anderson, B.; Hodgkin, D. C.; Viswamitra, M. A. Nature 1970, 225, 233. 
	  	   27	  
 (30) Li, Y. M.; Milne, J. C.; Madison, L. L.; Kolter, R.; Walsh, C. T. Science 1996, 274, 1188. 
 (31) Nizet, V.; Beall, B.; Bast, D. J.; Datta, V.; Kilburn, L.; Low, D. E.; De Azavedo, J. C. 
Infect. Immun. 2000, 68, 4245. 
 (32) Schmidt, E. W.; Nelson, J. T.; Rasko, D. A.; Sudek, S.; Eisen, J. A.; Haygood, M. G.; 
Ravel, J. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 7315. 
 (33) Molloy, E. M.; Cotter, P. D.; Hill, C.; Mitchell, D. A.; Ross, R. P. Nat. Rev. Microbiol. 
2011, 9, 670. 
 (34) Breil, B. T.; Ludden, P. W.; Triplett, E. W. J. Bacteriol. 1993, 175, 3693. 
 (35) Yorgey, P.; Davagnino, J.; Kolter, R. Mol. Microbiol. 1993, 9, 897. 
 (36) Mitchell, D. A.; Lee, S. W.; Pence, M. A.; Markley, A. L.; Limm, J. D.; Nizet, V.; Dixon, J. 
E. J. Biol. Chem. 2009, 284, 13004. 
 (37) Koehnke, J.; Bent, A. F.; Zollman, D.; Smith, K.; Houssen, W. E.; Zhu, X.; Mann, G.; Lebl, 
T.; Scharff, R.; Shirran, S.; Botting, C. H.; Jaspars, M.; Schwarz-Linek, U.; Naismith, J. H. 
Angew. Chem. Int. Ed. Engl. 2013, 52, 13991. 
 (38) Sardar, D.; Pierce, E.; McIntosh, J. A.; Schmidt, E. W. ACS Synth. Biol. 2014. 
 (39) Madison, L. L.; Vivas, E. I.; Li, Y. M.; Walsh, C. T.; Kolter, R. Mol. Microbiol. 1997, 23, 
161. 
 (40) Lee, J.; Hao, Y.; Blair, P. M.; Melby, J. O.; Agarwal, V.; Burkhart, B. J.; Nair, S. K.; 
Mitchell, D. A. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 12954. 
 (41) McIntosh, J. A.; Donia, M. S.; Nair, S. K.; Schmidt, E. W. J. Am. Chem. Soc. 2011, 133, 
13698. 
 (42) Liao, R.; Liu, W. J. Am. Chem. Soc. 2011, 133, 2852. 
 (43) Yu, Y.; Guo, H.; Zhang, Q.; Duan, L.; Ding, Y.; Liao, R.; Lei, C.; Shen, B.; Liu, W. J. Am. 
Chem. Soc. 2010, 132, 16324. 
 (44) Lee, S. W.; Mitchell, D. A.; Markley, A. L.; Hensler, M. E.; Gonzalez, D.; Wohlrab, A.; 
Dorrestein, P. C.; Nizet, V.; Dixon, J. E. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 5879. 
 (45) McIntosh, J. A.; Donia, M. S.; Schmidt, E. W. J. Am. Chem. Soc. 2010, 132, 4089. 
	  	   28	  
 (46) Milne, J. C.; Roy, R. S.; Eliot, A. C.; Kelleher, N. L.; Wokhlu, A.; Nickels, B.; Walsh, C. 
T. Biochemistry 1999, 38, 4768. 
 (47) Milne, J. C.; Eliot, A. C.; Kelleher, N. L.; Walsh, C. T. Biochemistry 1998, 37, 13250. 
 (48) McIntosh, J. A.; Schmidt, E. W. Chembiochem 2010, 11, 1413. 
 (49) Jian, X. H.; Pan, H. X.; Ning, T. T.; Shi, Y. Y.; Chen, Y. S.; Li, Y.; Zeng, X. W.; Xu, J.; 
Tang, G. L. ACS Chem. Biol. 2012, 7, 646. 
 (50) Crone, W. J. K.; Leeper, F. J.; Truman, A. W. Chem. Sci. 2012, 3, 3516. 
 (51) Gomez-Escribano, J. P.; Song, L.; Bibb, M. J.; Challis, G. L. Chem. Sci. 2012, 3, 3522. 
 (52) Hou, Y.; Tianero, M. D.; Kwan, J. C.; Wyche, T. P.; Michel, C. R.; Ellis, G. A.; Vazquez-
Rivera, E.; Braun, D. R.; Rose, W. E.; Schmidt, E. W.; Bugni, T. S. Org Lett 2012, 14, 5050. 
 (53) Huo, L.; Rachid, S.; Stadler, M.; Wenzel, S. C.; Muller, R. Chem. Biol. 2012, 19, 1278. 
 (54) Lee, J.; McIntosh, J.; Hathaway, B. J.; Schmidt, E. W. J. Am. Chem. Soc. 2009, 131, 2122. 
 (55) Koehnke, J.; Bent, A.; Houssen, W. E.; Zollman, D.; Morawitz, F.; Shirran, S.; Vendome, 
J.; Nneoyiegbe, A. F.; Trembleau, L.; Botting, C. H.; Smith, M. C.; Jaspars, M.; Naismith, J. H. 
Nat. Struct. Mol. Biol. 2012. 
 (56) Bagley, M. C.; Dale, J. W.; Merritt, E. A.; Xiong, X. Chem. Rev. 2005, 105, 685. 
 (57) Harms, J. M.; Wilson, D. N.; Schluenzen, F.; Connell, S. R.; Stachelhaus, T.; Zaborowska, 
Z.; Spahn, C. M.; Fucini, P. Mol. Cell. 2008, 30, 26. 
 (58) Wieland Brown, L. C.; Acker, M. G.; Clardy, J.; Walsh, C. T.; Fischbach, M. A. Proc. Natl. 
Acad. Sci. U.S.A. 2009, 106, 2549. 
 (59) Bowers, A. A.; Walsh, C. T.; Acker, M. G. J. Am. Chem. Soc. 2010, 132, 12182. 
 (60) Kim, H. J.; Ruszczycky, M. W.; Liu, H. W. Curr. Opin. Chem. Biol. 2012, 16, 124. 
 (61) Schowen, K. B.; Schowen, R. L. Bioscience 1981, 31, 826. 
 (62) Kim, H. J.; Ruszczycky, M. W.; Choi, S. H.; Liu, Y. N.; Liu, H. W. Nature 2011, 473, 109. 
	  	   29	  
 (63) Liao, R.; Duan, L.; Lei, C.; Pan, H.; Ding, Y.; Zhang, Q.; Chen, D.; Shen, B.; Yu, Y.; Liu, 
W. Chem. Biol. 2009, 16, 141. 
 (64) Yu, Y.; Duan, L.; Zhang, Q.; Liao, R.; Ding, Y.; Pan, H.; Wendt-Pienkowski, E.; Tang, G.; 
Shen, B.; Liu, W. ACS Chem. Biol. 2009, 4, 855. 
 (65) Kelly, W. L.; Pan, L.; Li, C. J. Am. Chem. Soc. 2009, 131, 4327. 
 (66) Mocek, U.; Zeng, Z. P.; Ohagan, D.; Zhou, P.; Fan, L. D. G.; Beale, J. M.; Floss, H. G. J. 
Am. Chem. Soc. 1993, 115, 7992. 
 (67) Mocek, U.; Knaggs, A. R.; Tsuchiya, R.; Nguyen, T.; Beale, J. M.; Floss, H. G. J. Am. 
Chem. Soc. 1993, 115, 7557. 
 (68) Duan, L.; Wang, S.; Liao, R.; Liu, W. Chem. Biol. 2012, 19, 443. 
 (69) Zhang, Q.; Li, Y.; Chen, D.; Yu, Y.; Duan, L.; Shen, B.; Liu, W. Nat. Chem. Biol. 2011, 7, 
154. 
 (70) Zhang, Q.; Chen, D.; Lin, J.; Liao, R.; Tong, W.; Xu, Z.; Liu, W. J. Biol. Chem. 2011, 286, 
21287. 
 (71) Marsh, E. N.; Patterson, D. P.; Li, L. Chembiochem 2010, 11, 604. 
 (72) Banerjee, R. Chem. Rev. 2003, 103, 2083. 
 (73) Zhang, Q.; van der Donk, W. A.; Liu, W. Acc. Chem. Res. 2012, 45, 555. 
 (74) Freeman, M. F.; Gurgui, C.; Helf, M. J.; Morinaka, B. I.; Uria, A. R.; Oldham, N. J.; Sahl, 
H. G.; Matsunaga, S.; Piel, J. Science 2012, 338, 387. 
 (75) Houck, D. R.; Chen, L. C.; Keller, P. J.; Beale, J. M.; Floss, H. G. J. Am. Chem. Soc. 1988, 
110, 5800. 
 (76) Zhou, P.; Ohagan, D.; Mocek, U.; Zeng, Z. P.; Yuen, L. D.; Frenzel, T.; Unkefer, C. J.; 
Beale, J. M.; Floss, H. G. J. Am. Chem. Soc. 1989, 111, 7274. 
 (77) Grove, T. L.; Benner, J. S.; Radle, M. I.; Ahlum, J. H.; Landgraf, B. J.; Krebs, C.; Booker, 
S. J. Science 2011, 332, 604. 
 (78) Boal, A. K.; Grove, T. L.; McLaughlin, M. I.; Yennawar, N. H.; Booker, S. J.; Rosenzweig, 
A. C. Science 2011, 332, 1089.
	  	   30	  
 (79) Pierre, S.; Guillot, A.; Benjdia, A.; Sandstrom, C.; Langella, P.; Berteau, O. Nat. Chem. 
Biol. 2012, 8, 957. 
 (80) Layer, G.; Kervio, E.; Morlock, G.; Heinz, D. W.; Jahn, D.; Retey, J.; Schubert, W. D. Biol. 
Chem. 2005, 386, 971. 
 (81) Layer, G.; Moser, J.; Heinz, D. W.; Jahn, D.; Schubert, W. D. EMBO J. 2003, 22, 6214. 
 (82) Sivonen, K.; Leikoski, N.; Fewer, D. P.; Jokela, J. Appl. Microbiol. Biotechnol. 2010, 86, 
1213. 
 (83) Saleh, O.; Haagen, Y.; Seeger, K.; Heide, L. Phytochemistry 2009, 70, 1728. 
 (84) Pernin, R.; Muyard, F.; Bevalot, F.; Tillequin, F.; Vaquette, J. J. Nat. Prod. 2000, 63, 245. 
 (85) Pettus, T. R. R.; Inoue, M.; Chen, X.; Danishefsky, S. J. J. Am. Chem. Soc. 2000, 122, 
6160. 
 (86) Quillinan, A. J.; Scheinmann, F. J. Chem. Soc. D 1971, 966. 
 (87) Molohon, K. J.; Melby, J. O.; Lee, J.; Evans, B. S.; Dunbar, K. L.; Bumpus, S. B.; Kelleher, 
N. L.; Mitchell, D. A. ACS Chem. Biol. 2011, 6, 1307. 
 (88) Scholz, R.; Molohon, K. J.; Nachtigall, J.; Vater, J.; Markley, A. L.; Sussmuth, R. D.; 
Mitchell, D. A.; Borriss, R. J. Bacteriol. 2011, 193, 215. 
 (89) Liu, Z.; Budiharjo, A.; Wang, P.; Shi, H.; Fang, J.; Borriss, R.; Zhang, K.; Huang, X. Appl. 
Microbiol. Biotechnol. 2013, 97, 10081. 
 (90) Claesen, J.; Bibb, M. Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 16297. 
 (91) Claesen, J.; Bibb, M. J. J. Bacteriol. 2011, 193, 2510. 
 (92) Piwowarska, N. A.; Banala, S.; Overkleeft, H. S.; Sussmuth, R. D. Chem Commun (Camb) 
2013, 49, 10703. 
 (93) Sharma, A.; Blair, P. M.; Mitchell, D. A. Org Lett 2013, 15, 5076. 
 
	  	   31	  
CHAPTER 2: TOMM CYCLODEHYDRATASES UTILIZE ATP FOR CARBONYL 
OXYGEN ACTIVATION 
 
This chapter is taken in part from Dunbar et al.,1 Melby et al.,2 and Dunbar & Mitchell3 and is 
reproduced with permission from Nature Publishing Group and the American Chemical Society. 
 
Joyce Limm (Dixon Lab) cloned BalhA1, BalhA2, BalhB, BalhC and BalhD. Joel Melby cloned 
BalhA1 leader peptide, BalhNC, BalhNC-C40, and BcerB. Joel Melby performed the 31P-NMR 
experiment with the Balh enzymes and obtained the Michaelis-Menten kinetic parameters for 
BalhNC-C40. The microcin B17 biosynthetic enzymes were obtained from the Walsh laboratory. 
 
 
Abstract  
Thiazole/oxazole-modified microcins (TOMMs) encompass a recently defined class of 
ribosomally synthesized natural products with a diverse set of biological activities. Although 
TOMM biosynthesis has been investigated for over a decade, the mechanism of heterocycle 
formation by the synthetase enzymes remains poorly understood. Using a novel TOMM 
synthetase from an uncharacterized biosynthetic cluster in Bacillus sp. Al Hakam, substrate 
analogs and isotopic labeling, I demonstrate that adenosine 5’-triphosphate (ATP) is utilized to 
directly phosphorylate the peptide amide backbone during TOMM heterocycle formation. Such 
chemistry represents a novel utilization of ATP. Based on this information, I propose a 
mechanism for azoline formation. 
 
2.1 Introduction 
Since the enzymatic machinery responsible for TOMM biosynthesis was first characterized,4 it 
has become evident that this strategy for natural product biosynthesis has been extensively 
propagated in both bacteria and archaea.5,6 The diverse array of biological activities and 
pharmacological potential displayed by the characterized members of the TOMM family has led 
to extensive investigations into the molecular underpinnings of their biosynthesis.4,7-13 These 
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studies have provided the foundation to understanding the complex nature of substrate 
processing, but many of the finer details regarding heterocycle formation have remained elusive.  
For example, the requirement for ATP hydrolysis with respect to azoline formation 
remains undescribed.7,10 Reports of the super-stoichiometric hydrolysis of ATP relative to azole 
formation,7 and continued ATP hydrolysis after complete substrate modification,10 have been 
used as evidence for the role of ATP as a dynamic regulator of the cyclodehydratase complex (C 
and D proteins; Fig. 1.3), yet direct evidence for such a mechanism has not been reported. 
Recently, this role for ATP utilization has been referred to as the “molecular machine” 
hypothesis (Fig. 2.1B).10 An alternative mechanism implicates ATP hydrolysis in the activation 
of the peptide backbone during cyclization (Fig. 2.1B).4,13 Such an activation event would result 
in the elimination of Pi instead of water during the cyclization, and could potentially help drive 
the cyclodehydration reaction towards completion. Although isotopic labeling studies could 
readily differentiate between these mechanisms, the relative experimental intractability of 
previously characterized TOMM synthetases has precluded such a study.4,6 The discovery of a 
TOMM biosynthetic cluster from Bacillus sp. Al Hakam (Balh; Fig. 2.1A)2 yielded robust 
heterocycle-forming enzymes for in vitro characterization and allowed us to address this 
foremost question regarding TOMM biosynthesis. The findings presented in this report 
demonstrate that the TOMM synthetase utilizes ATP to phosphorylate the amide backbone of 
peptide substrates during the cyclodehydration reaction. As such, the data reported herein 
provide an improved framework to understand the factors that govern biosynthesis in this class 
of natural products that has garnered significant attention.14-26 
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Figure 2.1 | TOMM biosynthetic gene clusters and possible mechanisms of ATP utilization 
during azole formation. (a) The TOMM clusters from Bacillus sp. Al Hakam (Balh) and 
Escherichia coli (Mcb) are depicted along with the percent amino acid identity for each of the 
three key proteins. Gene assignments are given below. Note that the dehydrogenase and the 
“cyclodehydratase” in the microcin B17 cluster are assigned as McbC and McbB, respectively. 
The sequences of the peptide substrates used in this study are shown. Color-coding: green, point 
mutations; orange, residues known to be cyclized in vitro (Balh)2 or in vivo (Mcb)4; blue hyphen, 
putative leader sequence cleavage site; blue caret, known leader sequence cleavage site.4 (b) The 
two leading hypotheses for ATP utilization. ATP hydrolysis could be used to control 
conformational dynamics (molecular machine) or to directly activate the peptidic substrate as 
shown. Reactions carried out in [18O]-H2O should give different products (shown), which can be 
used to distinguish between these mechanisms. X = S, O; R = H, CH3. 
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2.2 Minimal Requirements for Balh Cyclodehydratase Activity 
In order to determine the minimal set of proteins required for azoline formation, reactions were 
initiated with one or more reaction components omitted with progress monitored by matrix 
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS, Fig. 
2.2). Samples lacking ATP, BalhC or BalhD did not display a detectable level of BalhA1 
substrate modification under the conditions employed. When the BalhA1 substrate was treated 
with both BalhC and BalhD, the majority of the peptide was converted to a penta-azoline species 
(-90 Da). Substrate treated with the full BCD synthetase (see note in experimental section) was 
converted to a penta-azole species (-100 Da) as previously reported.2 In congruence with 
previously characterized TOMM synthetases,4,6,10,27 this activity was dependent on the hydrolysis 
of ATP, as the omission of nucleotide triphosphate or the addition of a non-hydrolyzable ATP 
analog resulted in no modification (Fig. 2.2A). 
Analogous to the microcin B17 and cyanobactin synthetases, the Balh synthetase also 
hydrolyzed ATP to ADP and Pi during substrate processing (Fig. 2.2B).4,10 The rate at which Pi 
was generated under varying reaction conditions was monitored by a purine nucleoside 
phosphorylase (PNP)-coupled assay.28 Robust Pi generation was observed only when the C and 
D proteins were added to samples containing precursor peptide (BalhA1/BalhA2) and ATP (Fig. 
2.2C). While the KM for both precursor peptides was 16 µM, the kobs for BalhA1 was 
approximately 4 times higher than for BalhA2 (Table 2.1). Addition of the B-protein did not 
significantly alter the rate of ATP hydrolysis, which is consistent with earlier reports of C-D 
fusion enzymes forming azoline heterocycles in the absence of the dehydrogenase.9 In contrast to 
the Balh and the C-D fusion enzymes, the microcin B17 synthetase was not functional in the 
absence of the dehydrogenase.8 The reason for this discrepancy is currently unknown but the 
	  	   35	  
available data suggest that the Mcb dehydrogenase may play a pivotal role in the assembly of an 
active synthetase complex. Moreover, subsequent studies demonstrated that the Balh enzymatic 
machinery was able to utilize both ATP and GTP (analogous to the microcin B17 synthetase),7 
although ATP was preferred over GTP by approximately a factor of 10 due to differences mainly 
in Km (Table 2.1).  
 
Table 2.1 | Substrate kinetic parameters for Balh synthetase. Error represents the error from 
the curve fit. 1, Apparent KM; 2, obtained with 3 mM ATP; 3, obtained with 110 µM BalhA1. This 
table was adapted from Melby et al.2 and Dunbar et al.1 with permission. 
 
 
kobs, min-1 KM, µM1 kobs/KM, M-1 s-1   
 
kobs, min-1 KM, µM1 kobs/KM, M-1 s-1 
2BalhA1 12.9 ± 0.4 16 ± 2 13000   3ATP 12.2 ± 0.3 240 ± 20 850 
2BalhA2 4.4 ± 0.2 17 ± 2 4300   3GTP 9.3 ± 0.2 1500 ± 80 100 
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Figure 2.2 | Minimal requirement for cyclodehydratase activity and ATP hydrolysis 
product of the Balh synthetase. (a) MALDI-TOF spectra monitoring heterocycle formation. 
Labels represent the components of the reaction (e.g. C contains BalhC). Apart from the 
indicated samples, all reactions contained ATP. The mass shift for the major species relative to 
the unmodified substrate is displayed above the appropriate peak. NH-ATP represents β,γ-imido-
ATP (a non-hydrolyzable ATP-analog) (b) Rates of phosphate production in Balh synthetase 
reactions with and without the addition of 1 unit of pyrophosphatase (PPase) are shown. Error 
represents the standard deviation from the mean (n=2). (c) Rates of ATP hydrolysis in reactions 
lacking one or more components of the synthetase complex are displayed. Activity was 
monitored with the PNP-coupled phosphate assay and activity was normalized to a reaction 
containing both substrates (ATP and BalhA1) and the BCD complex. Error bars represent the 
standard deviation from the mean (n=3). This figure is adapted with permission from Dunbar et 
al.1 
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2.3 A Cyclizable Residue Stimulates Rapid ATP Hydrolysis 
The “molecular machine” hypothesis asserts that ATP hydrolysis regulates the conformational 
dynamics/enzymatic activity of the synthetase complex.10 While the means by which this may 
work has not yet been explicitly stated, one possible route could be that upon peptide substrate 
binding, the synthetase undergoes a conformational change that leads to an active complex (Fig. 
2.1). Previous studies on microcin B17 biosynthesis have demonstrated that the leader peptide 
and a severely truncated (non-processed) precursor peptide substrate analog were incapable of 
stimulating ATP hydrolysis.7 These results suggested that the core sequence of TOMM precursor 
peptides must be important for the ATPase activity of the synthetase. Studies conducted in the 
absence of BalhA1 demonstrated that a complex of BalhC and BalhD had a measureable level of 
ATP-hydrolysis; roughly 100-fold lower than at saturating BalhA1 concentrations (Fig. 2.3). To 
test if a non-cyclizable (NC), full-length substrate analog could potentiate this basal ATPase 
activity of the TOMM enzymatic complex, we prepared BalhA1-NC, in which every 
heterocyclizable residue in the core region was mutated to a hydrophobic amino acid (Fig. 2.1). 
Interestingly, the presence of BalhA1-NC decreased the rate of ATP hydrolysis four-fold 
compared to samples containing only BalhC and BalhD (Fig. 2.3A). Addition of the predicted 
BalhA1 leader sequence (BalhA1-LS, Fig. 2.1) to similar reactions showed a slight, but 
statistically significant, reduction in the basal ATPase activity. The marked difference between 
the levels of inhibition provided evidence that the core sequence was primarily responsible for 
suppressing the ATPase activity and indicated that there may be a direct interaction between 
residues of the core sequence and the ATP binding site. In support of this, the reinstatement of a 
naturally occurring cysteine (BalhNC-C40, Fig. 2.1) yielded a substrate that was not only 
processed by the synthetase, but increased the rate of ATP hydrolysis close to wild-type levels 
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(Fig. 2.3). These data provided substantial evidence that the ATP binding site and the residues of 
the core sequence directly communicate. Moreover, the ability of BalhA1-NC to inhibit the basal 
ATPase activity suggested that the ATP site had greater accessibility in the absence of the 
precursor peptide. While not definitive, these results are difficult to reconcile with respect to an 
ATP-utilizing mechanism consistent with the molecular machine hypothesis, which prompted us 
to explore alternative mechanistic possibilities. 
 
 
 
Figure 2.3 | BalhA1-NC inhibition and BalhNC-C40 processing. (a) The rate of ATP 
hydrolysis with and without the addition of BalhA1-NC or BalhLS as measured by the PNP 
phosphate detection assay. Due to the extremely rapid rate of ATP hydrolysis when BalhC/D are 
at this high concentration (15 µM), it is not possible to accurately measure initial rates for rapidly 
processed substrates. As such, the rates of ATP hydrolysis with the addition of BalhA1 and 
BalhNC-C40 were extrapolated from the nucleotide kinetics (BalhC/D = 1 µM) assays based on 
the measured kobs for each substrate. Error bars represent the standard deviation from the mean 
(n=3). (b) A MALDI-TOF spectrum of a reaction carried out with BalhNC-C40 either with (red) 
or without ATP (black). 
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2.4 ATP Hydrolysis is Tightly Coupled to Azoline Formation 
The microcin B17 synthetase has been shown to consume approximately 5 moles of ATP per 
mole of heterocycle formed.7 Although the super-stoichiometric consumption of ATP has not 
been observed for all TOMM biosynthetic enzymes, this observation cast doubt on the use of 
ATP to directly activate the substrate during processing and has been used as supportive 
evidence of the molecular machine.7,10 To evaluate the stoichiometry of products formed by the 
Balh synthetase, the rate of Pi and azole production were monitored in parallel time course 
assays. An overlay of Pi and azole synthesis illustrated that the formation of these products was 
tightly coupled during the reaction, and that the ATP to azole stoichiometry was essentially one–
to–one over the entire six-hour time course (Fig. 2.4A). Furthermore, when BalhA1 was fully 
heterocyclized, the rate of ATP hydrolysis returned to approximately the basal rate. This result 
was consistent with an earlier report on trunkamide biosynthesis, which employs a C-D fusion 
protein.10 
Given the markedly different ATP/azole stoichiometry in the Balh and Mcb systems, I 
revisited the ATP stoichiometry of microcin B17 processing. I hypothesized that the use of a 
truncated substrate and a synthetase complex with an abnormal ratio of the B, C and D proteins 
(due to the purification strategy) could have led to an aberrant usage of ATP.7,29 Therefore, the 
Mcb ATP stoichiometry was repeated using the full-length substrate (McbA; Fig. 1a) and a 
completely tag-free synthetase complex added in at a 1:1:1 molar ratio. As with the Balh 
synthetase, the concentration of Pi and azole heterocycles mapped almost perfectly over the time 
course assayed and an average stoichiometric ratio was calculated to be unity (Fig. 2.4B). Taken 
together, these data demonstrated that ATP hydrolysis is tightly linked to heterocycle formation, 
which appears to be a general feature of TOMM heterocycle formation. 
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Figure 2.4 | ATP/azole stoichiometry for substrate processing. The stoichiometry of ATP 
hydrolysis to azole heterocycle formation in (a) the Balh TOMM and (b) the Mcb TOMM is 
shown. Phosphate (squares), heterocycles (circles), BCD background ATPase activity (solid line, 
PNP assay; dashed line, extrapolated PNP assay; triangles, malachite green assay), maximum 
product produced based on the concentration of substrate (solid horizontal line). Error bars 
represent the standard deviation from the mean (n=3). The ATP/azole stoichiometric ratio is 
displayed and is the average of all time points. 
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2.5 ATP is Hydrolyzed by a Non-Solvent Oxygen Nucleophile  
Intrigued by the inability to artificially activate ATP hydrolysis and the 1:1 stoichiometry 
between ATP consumption and ring formation, isotopic labeling was used to determine the 
source of the oxygen in the Pi generated during the course of the reaction. If ATP were used to 
directly activate the substrate, the oxygen incorporated into the Pi byproduct would originate 
from the peptide backbone. Thus, running the reaction in [18O]-H2O would result in 16O 
incorporation into phosphate, producing [16O4]-Pi (Fig. 2.1). Alternatively, the molecular 
machine hypothesis demands that the oxygen incorporated into the Pi would originate from bulk 
solvent (water) in the same manner as with any ATPase (Fig. 2.1). The molecular machine 
mechanism, if acting, would introduce a single 18O label in the Pi produced when the reaction 
was run in [18O]-H2O, which is readily detectable by a roughly 0.02 ppm upfield shift in 31P-
NMR compared to [16O4]-Pi.30 
 Reactions of the Balh TOMM biosynthetic enzymes with the BalhA1 substrate in [18O]-
H2O resulted in the production of primarily [16O4]-Pi (Fig. 2.5A). As would be predicted from the 
earlier stoichiometry assay (Fig. 2.4) and the basal rate of ATP hydrolysis (Fig. 2.3), these 
samples also contained a small amount (~15%) of [18O116O3]-Pi. The majority production of 
[16O4]-Pi was a consequence of substrate processing and was neither a contaminant of the ATP 
buffer, nor the proteinaceous components of the synthetase reaction as assessed by the malachite 
green assay. While the direct activation of the amide carbonyl is the most logical explanation for 
this data, the possibility existed that [16O4]-Pi was generated as a consequence of nucleophilic 
attack at the β-phosphate of ATP or through isotope scrambling with the ADP byproduct. Thus, a 
liquid chromatography (LC)-MS analysis of the ADP formed during the reaction was carried out 
to determine if this byproduct contained 18O. The trace clearly demonstrated that 18O was not 
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present in the ADP and provided strong evidence that ATP consumption occurred due to the 
action of a non-solvent, oxygen nucleophile (Fig. 2.6). This assay was repeated with the microcin 
B17 synthetase, which yielded the same result (Fig. 2.5B), though the requirement for a lower 
pH buffer gave a slight perturbation in the 31P-phosphate chemical shift. Taken together, these 
results strongly suggest that the molecular machine hypothesis for ATP utilization is incorrect. 
 
 
Figure 2.5 | ATP is utilized to directly activate the amide backbone of the substrate. 31P-
NMR spectra of reactions with (a) the Balh or (b) the Mcb synthetase. The identity of the major 
product, [16O]-Pi, was confirmed by spiking with authentic [16O]-Pi. Slight pH differences 
between the Balh and Mcb samples (8.5 and 8.0, respectively) account for the altered chemical 
shifts. This figure was adapted from Dunbar et al.1 with permission. 
 
 
Figure 2.6 | Isotope composition of ADP 
produced in [18O]-water. An LCMS trace 
for the ADP byproduct of a reaction 
carried out in 18O-water. LCMS traces are 
single ion monitoring (SIM) measurements 
of [M – H]- for ADP (m/z 426) and for the 
putative [18O1]-ADP (m/z 428). A 
reference line (gray dashed line) is 
displayed which indicates the m/z 428 
signal expected from the natural 1.1% 13C 
isotope abundance (approximately 3.7%). 
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2.6 TOMM Cyclodehydrations Occur via an Activated Carbonyl Intermediate  
While the above results are most consistent with the direct activation mechanism for ATP 
utilization, these data do not directly confirm the proposed amide phosphorylation event (Fig. 
2.7A). A more direct approach would be to perform cyclodehydration reactions with a substrate 
containing 18O labels at every cyclized amide. In the event that direct activation was occurring, 
these 18O labels would be found in the phosphate byproduct. However, due to the size of BalhA1 
(57 residues; Fig. 2.1A), solid phase synthesis is impractical. While the generation of an 
appropriately labeled BalhA1 derivative could be achieved by native chemical ligation, this 
strategy would involve the synthesis and purification of two 18O-labeled large peptide fragments 
(27 and 30 residues) and would be a tedious endeavor. Conversely, azoline-mediated peptide 
backbone labeling (AMPL; see Chapter 3) provides a convenient route to access labeled peptides 
such as [18O5]-BalhA1. Trx-tagged [18O5]-BalhA1, generated from azoline hydrolysis, was 
treated with BcerB/BalhCD and the isotopic constitution of the phosphate byproduct was 
analyzed by 31P-NMR. A peak corresponding to [16O318O]-phosphate (Pi) was observed only in 
reactions with [18O5]-BalhA1 (Fig. 2.7B). Importantly, [16O318O]-Pi was not detected in control 
reactions lacking enzyme or substrate.  
  While the detection of [16O318O]-Pi provided strong support for the proposed 
phosphorylation mechanism, the detected amount of [16O4]-Pi was seemingly inconsistent with 
direct backbone activation being the sole mechanism of ATP utilization. I originally 
hypothesized that isotope scrambling with the ADP byproduct may be responsible for the [16O4]-
Pi peak; however, a mass spectrum of ADP generated during the modification of [18O5]-BalhA1 
demonstrated that this was not the case (Fig. 2.7C). Although the ATP/azole stoichiometry of the 
Balh cyclodehydratase is 1:1 (vide supra), an alternative explanation was that ATP/azole 
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stoichiometry was dysregulated for Trx-tagged [18O5]-BalhA1 as a result of the requisite, 
extensive sample preparation. To test this, an identical reaction was carried out but the 
ATP/azole stoichiometry was measured rather than the Pi isotope distribution. Indeed, the 
stoichiometry assay showed that the 1:1 ratio of ATP/azole increased to 1.9:1 following the 
hydrolysis procedure. Taking into account the isotopic enrichment of [18O5]-BalhA1 (Fig. 2.7D), 
the predicted [16O4]-Pi:[16O318O]-Pi ratio is approximately 1.3:1. This result is in accord with the 
ratio observed by 31P-NMR. Collectively, these data clearly demonstrate that TOMM 
cyclodehydratases utilize ATP to activate the carbonyl oxygen of the amide involved in azoline 
formation.  
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Figure 2.7 | 31P-NMR of 18O5-BalhA1 reactions. (a) The putative carbonyl oxygen 
phosphorylation mechanism for ATP utilization is displayed along with 31P-NMR spectra from 
both [18O5]-BalhA1 and [16O5]-BalhA1 reactions (b). The identity of the [16O4]-Pi peak was 
verified by spiking the sample with a Pi standard (spectrum 3). (c) A negative mode MALDI-
TOF spectral overlay of an ADP standard (black) and the ADP produced during 18O-BalhA1 
(red) processing is shown. If [16O4]-Pi production is due to 18O incorporation into ADP, the 
second isotope peak of ADP should be approximately the same height as the monoisotopic peak. 
(d) A high-resolution mass spectrum of [18O5]-BalhA1 is displayed below. The peaks are colored 
according to the number of 18O labels in the peptide (green, five; purple, 4; orange, 3; blue, 2; 
red, 1; black, 0). The calculated and measured masses of the [18O5]-BalhA1 peak are displayed in 
the 3+ charge state along with the ppm error of the measurement. The level of 18O enrichment 
was determined based on the intensities of the monoisotopic peaks for each of the 18O-labeled 
BalhA1 derivatives. The theoretical maximum 18O enrichment of 92% was determined based on 
the final atom % of 18O during the hydrolysis reaction. This figure was adapted with permission 
from Dunbar & Mitchell.3 
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2.7 Summary and Outlook 
Prior to this study, the utilization of ATP hydrolysis for cyclodehydration was poorly 
understood. Although it had been noted that the initial steps of this transformation could mimic 
the mechanism of protein splicing by intein domains (an ATP-independent process; Fig. 2.8), the 
absolute requirement for nucleotide triphosphate hydrolysis had never definitively been factored 
into the reaction.4,10 These findings make the TOMM cyclodehydratases only the third enzyme 
class known that can utilize ATP to directly activate an amide carbonyl oxygen,  the other two 
being the PurM and adenine nucleotide α-hydrolase (α-ANH) superfamilies. Characterized 
members of the PurM and α-ANH families conduct similar chemistry on non-peptide substrates 
(Fig. 2.9).31-33 As such, the mechanism of azoline formation in TOMM biosynthesis represents a 
novel utilization of this ubiquitous cofactor. While members of the α-ANH superfamily contain a 
canonical ATP-binding fold,33 structurally characterized members of the PurM family all contain 
a non-canonical ATP-binding domain.34,35 Despite the similarity in ATP usage between TOMM 
cyclodehydratases, PurM proteins, and α-ANH family members, the three enzyme families share 
no sequence similarity and represent an example of convergent evolution towards a common 
mode of ATP utilization.  
Members of the PurM and α-ANH families are proposed to act via the formation of an 
iminophosphate and acyl-adenylate intermediate, respectively.33,36 In both mechanisms, carbonyl 
oxygen activation (phosphorylation in PurM and adenylation in α-ANH) occurs prior to 
nucleophilic attack (Fig. 2.9). While a similar mechanism can be drawn for azoline formation by 
the TOMM synthetase (Fig. 2.10), it would require a disfavored 5-endo-trig cyclization37 and is 
inconsistent with the suppression of ATP hydrolysis in the presence of BalhA1-NC. 
Alternatively, I hypothesize that azoline formation by the TOMM synthetase occurs through a 
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hemi-orthoamide intermediate analogous to that implicated in protein autoproteolytic 
pathways.38-40 During intein splicing and other autoproteolytic events, the hemi-orthoamide is 
resolved by N-protonation and (thio)ester formation (Fig. 2.8).39 I assert that the phosphorylation 
of the amide oxygen (in lieu of O-protonation) would direct the hemi-orthoamide towards 
azoline formation and prevent the non-productive breakdown of the intermediate (Fig. 2.8). 
Phosphorylation would not only accelerate the elimination reaction (based on the lower pKa of 
phosphate relative to water), but would directly couple ATP hydrolysis to cyclodehydration, 
providing a thermodynamic drive for the reaction. The resolution of the hemi-orthoamide via the 
inclusion of a thermodynamically favorable step is seen in all autoproteolytic pathways.39 
Further evidence supporting a mechanism where cyclization precedes phosphorylation (i.e. the 
intein-like mechanism) comes from a recent report of ester formation during microcin B17 
biosynthesis41 and the discovery that engineered intein domains can catalyze azoline formation.42 
In light of earlier reports, and the data presented here, TOMM cyclodehydration and intein 
splicing proceed through a common intermediate, which I propose is the hemi-orthoamide 
depicted in Figure 2.8. 
 The mechanism for thiazole/oxazole formation presented in this report represents the 
fourth strategy identified to date to generate these moieties. Two such strategies have been 
uncovered in the biosynthesis of the primary metabolite thiamine,43 while the third is found in 
nonribosomal natural products biosynthesis (Fig. 2.11).44 Although the TOMM cyclodehydratase 
is not homologous to the nonribosomal peptide synthetase counterpart, the TOMM C protein is 
homologous to ThiF,6,45 the bacterial protein involved in sulfur mobilization in thiamine 
biosynthesis. Rather than perform amide activation, ThiF carries out the canonical carboxylate 
adenylation catalyzed by all members of the E1-superfamily.46 Further study will be necessary to 
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elucidate the component of the TOMM cyclodehydratase complex (C/D proteins) responsible for 
carrying out this unique transformation.  
 
 
Figure 2.8 | TOMM azoline installation is reminiscent of intein-mediated protein splicing. 
(a) The mechanism of protein splicing and autoproteolysis follows the N-protonation pathway to 
generate a (thio)ester. An azoline heterocycle could also be formed from the hemi-orthoamide 
intermediate if O-protonation occurred. (b) In TOMM biosynthesis, the use of ATP to 
phosphorylate the substrate could be used to drive the reaction down an O-elimination pathway 
to generate an azoline. X = S, O; R = H, CH3. 
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Figure 2.9 | The proposed enzymatic mechanism of PurM and ThiI. (a) The fifth enzyme in 
the purine biosynthesis pathway in prokaryotes is aminoimidazole ribonucleotide (AIR) 
synthetase, PurM. This enzyme is responsible for the heterocyclization of formylglycinamide 
ribonucleotide (FGAM) to afford AIR. ATP has been implicated in the phosphorylation of the 
backbone amide oxygen using isotopically labeled substrate.32 Although a mechanism wherein 
activation precedes nucleophilic attack is invoked for the transformation, evidence has not been 
provided to demonstrate this order of events. Note that the phosphorylation of an amide oxygen 
has been implicated in the transformations catalyzed by the PurM homologs, PurL, HypE, and 
SelD.36 (b) The mechanism of 4-thiourdine formation by ThiI is displayed. The ThiI homologs 
MnmA and TtuA use identical chemistry in the biosynthesis of 2-thiouridine and 2-
thiocytosine.33 This figure was adapted from Dunbar et al. with permission.1 
 
 
 
 
 
 
Figure 2.10 | Alternative mechanism of azoline formation. An alternative mechanism for 
azoline formation is presented involving phosphorylation prior to nucleophilic attack. While the 
mechanism is reminiscent of Vilsmeier-Haack dehydration chemistry, the transformation 
involves a disfavored 5-endo trig cyclization step.37 
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Figure 2.11 | Strategies for azole biosynthesis outside of TOMMs. (a) While thiamine 
biosynthesis occurs via different mechanisms in prokaryotes and eukaryotes, neither pathway 
utilizes the same chemical logic as TOMM synthetases. ThiF is involved in the installation of the 
sulfur atom during bacterial thiamine production. (b) Thiazole/oxazole biosynthesis in non-
ribosomal peptides is hypothesized to occur through a hemi-orthoamide intermediate; however, 
resolution of the intermediate is believed to occur without backbone activation.    
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2.8 Experimental 
2.8.1 Substitution of BcerB for BalhB. Because the dehydrogenase from the Balh cluster 
(BalhB) purified without FMN bound, a highly similar (78% identical/94% similar) 
dehydrogenase from Bacillus cereus 172560W (BcerB) was used as a surrogate.2 This technique 
has been successfully employed in the study of other TOMM synthetases.27 
2.8.2 Protein overexpression and purification. All proteins were overexpressed as tobacco etch 
virus (TEV) or thrombin protease-cleavable fusions to maltose binding protein (MBP) and 
purified by amylose affinity chromatography by methodology similar to that previously 
reported.6 BL21(DE3-RIPL) cells were transformed with pET28b plasmids containing the 
desired MBP fusion gene (BalhA-D, BcerB, McbD). Cells were grown overnight on Luria-
Bertani (LB) plates with 50 µg/mL kanamycin. Single colonies were picked for starter cultures 
containing 50 µg/mL kanamycin and 34 µg/mL chloramphenicol and were grown at 37 °C. A 10 
mL overnight culture was used to inoculate 1 L of LB containing 50 µg/mL kanamycin and 34 
µg/mL chloramphenicol. For the overexpression of the modification enzymes, cells were grown 
to an optical density at 600 nm (OD600) of 0.6 before a 10 min cold shock and induction with 0.4 
mM isopropyl ß-D-1-thiogalactopyranoside (IPTG) for 16 h at 22 °C. For the overexpression of 
precursor peptides, cells were grown to an OD600 of 0.8 before induction with 1 mM IPTG for 
1.5 h at 22 °C. After the indicated times, cells were harvested at 3000 x g for 15 min, washed 
with TBS (tris buffered saline; 10 mM Tris pH 7.5, 150 mM NaCl) and stored at -20 °C for up to 
one week before use. The overexpression of pET15b constructs containing McbA-C were carried 
out as above except ampicillin (100 µg/mL) was used instead of kanamycin in the relevant steps. 
Cell pellets were resuspended in lysis buffer [50 mM Tris pH 7.5, 500 mM NaCl, 2.5% glycerol 
(v/v), 0.1% triton X-100 (v/v)] containing 4 mg/mL lysozyme, leupeptin (2 µM), PMSF (200 
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µM), benzamidine (2 mM), and E64 (2 µM). After a 30 min incubation at 4 °C, cells were 
disrupted via sonication 3 x 30s with 10 min breaks at 4 °C. The insoluble debris was removed 
from the sample via centrifugation at 35,000 x g for 45 min. The resulting supernatant was 
applied to pre-equilibrated amylose resin (5 mL resin per L of cells). The column was washed 
with 10 column volumes of lysis buffer, followed by 5 column volumes of wash buffer (lysis 
buffer lacking triton X-100 and with 400 mM NaCl). The MBP-tagged proteins were eluted 
using 4 column volumes of elution buffer (wash buffer with 300 mM NaCl and 10 mM maltose) 
and the eluent was concentrated using an appropriate Amicon Ultra centrifugal filter (Millipore). 
A 10-fold buffer exchange with storage buffer [50 mM HEPES pH 7.5, 300 mM NaCl, 2.5% 
glycerol (v/v)] was performed in the filtration device before a final concentration and storage. 
After loading onto the column, all buffers used contained 1 mM tris-(2-carboxylethyl)-
phosphine. Protein concentration was assessed by both the 280 nm absorbance and a Bradford 
colorimetric assay (Thermo Scientific). Purity was determined by Coomassie-stained SDS-
PAGE gel. 
Unless otherwise stated, all proteins and substrates were used as MBP-fusions. The Balh 
TOMM synthetase proteins are highly active while MBP-tagged and largely insoluble when 
untagged.2  
2.8.3 Purine nucleotide phosphorylase-based phosphate detection assay. In general, the 
indicated synthetase proteins were added to a cuvette for a final concentration of 1 µM each. 
Reactions were initiated via the addition of a room temperature mixture of peptide substrate, 200 
µM 2-amino-6-mercapto-7-methylpurine riboside (Berry and Associates), and 0.2 units of PNP 
in synthetase buffer [50 mM Tris pH 7.5, 125 mM NaCl, 20 mM MgCl2, 10 mM dithiothreitol 
(DTT) and 3 mM ATP]. Reaction progress was monitored by the change in absorbance at 360 
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nm on a Cary 4000 UV-Vis spectrophotometer (Agilent). Initial rates of phosphate production 
were calculated based on the linear absorbance change during the first 3 min of the reaction and 
the extinction coefficient of the resulting guanine analog (11,000 M-1cm-1). For determining the 
nucleotide triphosphate kinetic constants, a synthetase buffer was used that lacked ATP, and the 
reactions were initiated by the addition of the indicated nucleotide. Given the slow rate of ATP 
hydrolysis without the presence the precursor peptide, the background ATPase activity was 
measured using 15 µM MBP-tagged BalhC/D instead of 1 µM. Reactions were carried out as 
above (n ≥ 3). Regression analyses to obtain the kinetic parameters were carried out using IGOR 
Pro version 6.12. 
2.8.4 Subtractive activity studies. The effect of each protein on heterocyclization was 
monitored by MALDI-TOF-MS. Reactions were carried out for 16 h at 23 °C with 1 µM of the 
indicated components, 50 µM MBP-BalhA1 and the synthetase buffer listed above. MBP was 
proteolytically removed from the substrate by the addition of 2 µg/ml recombinant TEV protease 
and a 30 min incubation at 30 °C. Samples were desalted via C18 ZipTip (Millipore) according to 
the manufacturer’s instructions and analyzed on a Bruker Daltonics UltrafleXtreme MALDI-
TOF spectrometer. Spectra were obtained in positive reflector mode using α-cyano-
hydroxycinnamic acid as the matrix. 
2.8.5 Substrate analog assays. Inhibition studies were performed with 15 µM MBP-BalhCD 
and either 50 µM MBP-BalhA1-NC or MBP-BalhA1-LS. Rates were measured with the PNP 
assay as described above following a 15 min equilibration at 23 °C. MBP-BalhNC-C40 reactions 
were carried out with 1 µM MBP-tagged BcerB, BalhC, BalhD and 100 µM substrate for 16 h at 
23 °C. Products were analyzed via MALDI-TOF-MS as described above. 
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2.8.6 Stoichiometry of ATP utilization. Samples were set up with 2 µM MBP-BalhC/D, 10 µM 
MBP-BcerB and 50 µM MBP-BalhA1 in synthetase buffer. Aliquots were removed at the 
indicated time points and frozen in liquid nitrogen. The samples were analyzed by LCMS to 
detect azole heterocycles and a malachite green assay to detect phosphate (Supplementary 
methods). The Mcb reactions were carried out in a similar fashion with the following exception: 
samples containing 1 µM MBP-tagged McbBCD and 20 µM MBP-McbA were digested with 
thrombin for 4 h before the reaction was initiated with the addition of ATP. The background 
ATPase activities of both synthetase complexes were analyzed using both the PNP and malachite 
green phosphate assays. 
 To determine the ATP/azole stoichiometry following azoline hydrolysis, an azoline 
hydrolysis reaction was carried out on Trx-BalhA1 in an identical fashion to the 31P-NMR 
experiment (see below) except [16O]-H2O was used in place of [18O]-H2O. Following buffer 
exchange to remove ADP and inorganic phosphate (Pi), a reaction was carried out with 50 µM 
BalhA1 and 2 µM BCD in low-salt synthetase buffer (50 mM Tris pH 8.5, 25 mM NaCl, 5 mM 
MgCl2, 10 mM DTT, and 2 mM ATP) for 3 h at 25 °C. The sample was then divided into two 
aliquots and frozen in liquid nitrogen. Azole formation and ATP hydrolysis were measured as 
indicated above. 
2.8.7 31P-NMR analysis of phosphate isotope incorporation of 18O-water reactions. Two 
samples containing either the MBP-tagged BCD (4 µM) synthetase components or MBP-BalhA1 
substrate (100 µM) with low-salt synthetase buffer (50 mM Tris pH 8.5, 25 mM NaCl, 5 mM 
MgCl2, 10 mM DTT, 2 mM ATP) were lyophilized separately for 16 h. The resulting solid was 
reconstituted in 500 µL of 97 atom% [18O]-H2O (Cambridge Isotope Laboratories) and incubated 
at 23 °C with rocking for 8.5 h, before quenching the reaction with 5.5 µL of 500 mM 
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ethylenediaminetetraacetic acid (EDTA; pH 8.0). 50 µL of D2O was added and the sample was 
transferred to a standard 5 mm NMR tube. The 31P-NMR spectrum was obtained on a 600 MHz 
Varian Unity Inova NMR with a 5 mm Varian AutoTuneX probe, using 512 transients, 32768 
points, and a spectral window of -15 to 5 ppm.  
The MBP-tagged McbBCD proteins were pooled at a 1:1:1 molar ratio and concentrated 
to 100 µM using a 3 kDa amicon centrifugal filter (Millipore). To this sample, 0.2 µg of 
thrombin (from bovine plasma) was added and the sample was proteolytically digested for 4 h at 
23 °C to remove the MBP tags. A 600 µL sample of 20 µM MBP-McbA and low-salt synthetase 
buffer (pH 8.0) was lyophilized for 16 h. The lyophilized protein was reconstituted in 600 µL of 
[18O]-H2O and the above mixture of McbBCD was added to a final concentration of 5 µM to 
initiate the reaction. After a 2 h incubation at 23 °C, the sample was frozen in liquid nitrogen and 
lyophilized to dryness. The sample was reconstituted in 220 µL of D2O with 15 mM EDTA and 
placed in a D2O-matched Shigemi NMR tube. Analysis by 31P-NMR was carried out as before 
with 2000 transients.  
For all reactions, a [16O]-H2O control and a buffer only control were run. For the 
BcerB/BalhC/D synthetase reaction, a substrate-free control was also performed in [18O]-H2O in 
an identical fashion as the BalhA1 modification reaction. All controls were carried out in an 
identical fashion to the corresponding assay. The identity of the 16O4-Pi peak in sample was 
verified by spiking the sample with a Pi standard and reacquiring the spectra under identical 
conditions. 
2.8.8 31P-NMR analysis of phosphate isotope incorporation in [18O5]-BalhA1 reactions. 
[18O5]-BalhA1 was generated in an identical strategy to the one described in Chapter 3 except 
that 100 µM Trx-BalhA1 was used instead of 100 µM MBP-BalhA1 and the fusion tags were not 
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removed. Following hydrolysis in [18O]-H2O, all contaminating ADP and Pi was dialyzed from 
the sample by a 30,000-fold buffer exchange into storage buffer [50 mM Tris pH 7.5, 150 mM 
NaCl, 2.5 % glycerol (v/v)] using a 10 kDa Amicon Ultra centrifugal filtration unit (Millipore). 
Next, the phosphate concentration in the sample was measured by a malachite green phosphate 
detection assay (BioAssay Systems) to ensure that the concentration of contaminating Pi was 
below 4 µM. The concentration of Trx-[18O5]-BalhA1 was determined both by the 280 nm 
absorbance and the Bradford colorimetric assay (Thermo Scientific). Reactions for 31P-NMR 
were carried out with 50 µM Trx-[18O5]-BalhA1 and 2 µM MBP-tagged BCD in low-salt 
synthetase buffer for 3 h at 25 °C. Subsequently, the sample was quenched by the addition of 500 
mM EDTA (pH 8.5) to a final concentration of 5 mM. D2O was added to a final concentration of 
10 % and the sample was transferred to a D2O-matched Shigemi NMR tube. The 31P-NMR 
spectrum was obtained on a 600 MHz Varian Unity Inova NMR with a 5 mm Varian AutoTuneX 
probe, 1000 transients, 32768 points, and a spectral window of -15 to 5 ppm.  
The identity of the [16O4]-Pi peak was verified by spiking the reaction with K2PO4 (pH 
8.5) at a final concentration of 200 µM and collecting a 31P-NMR spectrum under identical 
conditions. A control reaction with unlabeled Trx-BalhA1 was carried out in an identical 
manner, except that the initial azoline hydrolysis event was carried out in [16O]-H2O. 
2.8.9 LCMS detection of ring formation.  Reactions were trypsin (sequencing grade, Promega) 
digested in 50 mM NH4HCO3 (pH 8.0) for 30 min at 30 °C before quenching with the addition of 
formic acid to a final concentration of 10%. Precipitate was removed by centrifugation and the 
sample was separated on an Agilent 1200 series HPLC with a Vydac C18 250 x 4.6 mm 
protein/peptide column. Samples were loaded at 5% solvent B [acetonitrile with 0.1% formic 
acid (v/v)] and were separated with a gradient of 2% solvent B per min for 20 min.  Masses were 
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analyzed on a single quadrupole mass analyzer (G1956B) in positive ion scan mode using the 
manufacturer’s suggested parameters. Data was analyzed with ChemStation. The intensities of 
each of the ring states were calculated and used to determine the overall level of modification 
(n=3).  
2.8.10 Malachite green phosphate detection assay. Samples were diluted 1:8 in water to a final 
volume of 80 µL to remove any background signal from unreacted ATP. This solution was 
transferred to a 96-well plate where the reaction was initiated by the addition of 20 µL malachite 
green working reagent (Bioassay Systems). Reactions were allowed to develop for 30 min before 
the absorbance was recorded at 620 nm. A standard curve was made from a known concentration 
of inorganic phosphate in appropriately diluted synthetase buffer. The absorbance for each of the 
samples was corrected for any background originating from the buffers.  
Alternatively, the level of contaminating Pi in the buffer exchanged Trx-[18O5]-BalhA1 
sample was determined by conducting the malachite green assay with 80 µL of undiluted sample. 
In both cases the analysis of all samples was performed in triplicate. 
2.8.11 LCMS detection of [16O]-ADP from 18O-water reactions.  Reactions were analyzed on 
a 5 µm, 4.6 x 250 mm Luna Hilic column with a gradient from 90% solvent B (acetonitrile) and 
10% solvent A (10 mM NH4HCO3, pH 9) at 5 min to 50:50 A and B at 30 min. Nucleotides were 
detected using a diode array detector at 260 nm. Single ions were monitored at m/z 426 and 428 
on a single quadrupole mass analyzer (G1956B) in negative ion mode using the manufacturer’s 
suggested parameters to determine the 16O/18O ratio. 
2.8.12 ADP isotope composition from [18O5]-BalhA1 reactions. A portion (1 µL) of the of the 
Trx-18O5-BalhA1 sampled prepared for 31P-NMR analysis was reserved for MALDI-MS. This 
sample was spotted onto the MALDI target and overlaid with 1 µL of a saturated solution of 9-
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aminoacridine in 50% aqueous acetonitrile. As a control, 1 mM ADP in ATP-free synthetase 
buffer was spotted in an analogous fashion. Both samples were analyzed on a Bruker Daltonics 
UltrafleXtreme MALDI-TOF in negative reflector mode. 
2.8.13 Bioinformatics. Alignments were made using ClustalW2 using the standard parameters.47 
The percent identity between the Balh and Mcb biosynthetic enzymes were obtained from the 
ClustalW2 alignment. 
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CHAPTER 3: AZOLINE-MEDIATED PEPTIDE BACKBONE LABELING AS A TOOL 
FOR STUDYING TOMM BIOSYNTHESIS  
 
This chapter was taken from Dunbar & Mitchell1 and is reproduced with permission from the 
American Chemical Society. 
 
I am grateful to Joel Melby for assistance with collecting MS/MS data and Eric Schmidt 
(University of Utah) for the generous gift of ulithiacyclamide and lissoclinamide 4. Trx-BalhA1 
was cloned by Ambika Nadkarni. 
 
Abstract 
Current strategies for generating peptides and proteins bearing amide carbonyl derivatives rely 
on solid-phase peptide synthesis for amide functionalization. Although such strategies have been 
successfully implemented, technical limitations restrict both the length and sequence of the 
synthetic fragments. Herein I report the repurposing of a thiazole/oxazole-modified microcin 
(TOMM) cyclodehydratase to site-specifically install amide backbone labels onto diverse peptide 
substrates, a method I refer to as azoline-mediated peptide backbone labeling (AMPL). This 
convenient chemoenzymatic strategy can generate both thioamides and amides with isotopically 
labeled oxygen atoms. Moreover, I demonstrate the first leader peptide-independent activity of a 
TOMM synthetase, circumventing the requirement that sequences of interest be fused to a leader 
peptide for modification. Through bioinformatics-guided site-directed mutagenesis, I also 
convert a strictly dehydrogenase-dependent TOMM azole synthetase into an azoline synthetase. 
This vastly expands the spectrum of substrates modifiable by AMPL by allowing any in vitro 
reconstituted TOMM synthetase to be employed. To demonstrate the utility of AMPL for 
mechanistic enzymology studies, I demonstrate that AMPL is a useful tool for establishing the 
location of azolines on in vitro modified peptides. Furthermore, AMPL has utility in localizing 
and determining the number of azoline heterocycles in TOMM natural products.  
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3.1 Introduction 
Stable amide labels are gaining prominence in the field of chemical biology as probes that 
minimally perturb polypeptide/structure and electronics at the site of installation. For example, 
17O- and 18O- labeled amides are useful probes for the study of polypeptide dynamics by NMR 
and time-resolved 2D-IR, respectively.2-8 Thioamides, on the other hand, have garnered 
significant attention due to their ability to increase the protease stability of peptides, restrict 
conformational flexibility around the amide bond, photoisomerize from trans to cis upon 
excitation with 260 nm light, and act as minimal fluorescence quenchers for protein folding 
studies.9-13 While the utility of such labels is continually expanding, the backbone-incorporation 
techniques for these labels are currently limited to solid-phase peptide synthesis (SPPS).2-9,11-14 
This process is expensive and time-consuming, as the generation of labeled residues must be 
done prior to SPPS, and also suffers from all the limitations of SPPS (e.g. peptide length and 
sequence restrictions). An alternative approach that would obviate the requirement for SPPS 
would be heterologous expression and purification of the desired polypeptide/protein, followed 
by the posttranslational installation of the backbone label. My previous work in peptide 
heterocyclization chemistry has suggested a route for installing oxygen isotopes and thioamides 
into polypeptide/proteins using the azoline heterocycle as an entry point. 
Thiazoline and (methyl)oxazoline heterocycles are posttranslationally installed in the 
thiazole/oxazole-modified microcin (TOMM) class of peptidic natural products. These rings are 
formed from the cyclization of Cys, Ser and Thr residues onto the preceding amide carbonyl. 
Although the precise mechanism has yet to be fully elucidated, it is known that a two-protein 
cyclodehydratase complex (C and D proteins) performs the ATP-dependent cyclization of select 
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residues to afford azoline heterocycles.15,16 In the majority of TOMM natural products, a flavin 
mononucleotide (FMN)-dependent dehydrogenase (B protein) catalyzes the two-electron 
oxidation of the nascent rings to afford the aromatic azoles.15,17 In cases where oxidation does 
not occur, the azolines are often either sterically or electronically protected from nucleophiles 
(e.g. thiostrepton, ulithiacyclamide, and plantazolicin; Fig. 3.1A).18-20 As azolines lack the 
aqueous stability of their aromatic counterparts,21-23 the dearth of unprotected azoline 
heterocycles in characterized TOMMs likely represents an evolutionary bias for compounds with 
increased stability. Even so, azoline-containing TOMM natural products have been reported to 
undergo partial hydrolysis during purification.20 Based on the susceptibility of azoline 
heterocycles towards nucleophilic attack, I hypothesized that azoline heterocycles could be used 
as moieties for the site-selective modification of peptide backbones.  
Recently, we reported on the characterization of a TOMM synthetase from Bacillus sp. 
Al Hakam (Balh), and demonstrated that the Balh cyclodehydratase is catalytically competent in 
the absence of the associated dehydrogenase.24,25 This enzyme complex had exceptional in vitro 
activity and a predictable set of rules for the modification of diverse substrates.24 By coupling the 
promiscuous, yet highly predictable, nature of heterocyclization by the Balh cyclodehydratase 
with the lability of azoline heterocycles, I report a convenient and robust chemoenzymatic 
strategy for the site-selective installation of thioamides and isotopically labeled amides in vitro, 
an approach that I refer to as azoline-mediated peptide backbone labeling (AMPL; Fig. 3.1B). 
The AMPL method has a broad substrate scope, including peptides lacking an N-terminal leader 
peptide, and can even be utilized to install backbone labels on large proteins with an appropriate 
substrate sequence. Furthermore, I demonstrate that this method is generalizable and can be 
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carried out with divergent TOMM cyclodehydratases, facilitating the expansion of the 
methodology to diverse peptide scaffolds.  
  To explore the potential value of the AMPL method, I applied this labeling strategy to 
study substrate processing by TOMM cyclodehydratases. Previously I provided substantial, but 
indirect, support for a mechanism of cyclodehydration in which ATP is used to phosphorylate 
the carbonyl oxygen of the amide preceding the cyclized residue.24,25 Through AMPL, I 
generated a cyclodehydratase substrate containing 18O labels at these amides and used this 
substrate to provide direct evidence of a phosphorylated intermediate during TOMM 
cyclodehydrations (see Chapter 2). The AMPL method also proved generally useful for 
localizing azolines on cyclodehydratase-treated peptides. The lability of azoline heterocycles 
renders their detection by mass spectrometry challenging. While this can be overcome via the 
addition of a dehydrogenase to convert the azoline heterocycles to stable azoles, TOMM clusters 
have been identified that lack a dehydrogenase,26 preventing the universal application of this 
solution. Further, dehydrogenases have an inherent regio- and chemoselectivity, which can differ 
from the selectivity of the cyclodehydratase (see Fig. 3.1A).20,24,27 The selective incorporation of 
18O labels into peptide backbones at the sites of azoline heterocycles using the AMPL method 
circumvents this pitfall. As a proof of principle, I utilized AMPL to localize azoline heterocycles 
on diverse in vitro cyclized substrates. More generally, I demonstrate that AMPL can be utilized 
for azoline heterocycle detection on natural products, which has the potential to assist in 
structure determination efforts. 
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Figure 3.1 | Azolines in natural products and AMPL overview. (a) Structures of select 
azoline-containing natural products are displayed with azolines colored red. The class of natural 
product to which the compound belongs is shown, along with the known bioactivity of the 
compound in parentheses. In each instance, the azoline heterocycles are either sterically (e.g. 
ulithiacyclamide, yersiniabactin) or electronically (e.g. plantazolicin, telomestatin) protected 
from nucleophilic attack. RiPP, ribosomally synthesized posttranslationally modified peptide; 
NRP, nonribosomal peptide. (b) A general scheme for TOMM heterocycle biogenesis is 
displayed. The electrophilic azoline heterocycle can be exploited for the installation of oxygen 
isotopes and thioamides using [18O]-H2O and potassium hydrosulfide (KHS) as nucleophilic 
ring-opening agents, respectively. The mass shift relative to unmodified peptide is displayed 
underneath each product. C/D: ATP-dependent cyclodehydratase; B: FMN-dependent 
dehydrogenase. This figure is adapted with permission from Dunbar & Mitchell.1 
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3.2 Oxygen Isotope Incorporation into Peptide Backbones Through Azoline Hydrolysis  
I reasoned that since azolines hydrolyze under even mildly acidic conditions to yield an amide 
bearing a solvent-derived oxygen,20 performing the hydrolysis in [18O]-H2O would afford a 
peptide containing an 18O-labeled carbonyl directly N-terminal to every hydrolyzed azoline 
heterocycle (Fig. 3.1B). During the initial characterization of the Balh cyclodehydratase 
(complex of BalhC and BalhD), it was discovered that cyclodehydration occurred unabated in 
the absence of the dehydrogenase.25 I surmised that it would be possible to generate 
appropriately labeled substrates by first cyclizing the BalhA1 substrate and subsequently 
hydrolyzing the nascent rings in mildly acidic [18O]-H2O. To test this hypothesis, thioredoxin 
tagged-BalhA1 (Trx-BalhA1; Fig. 3.2) was treated with BalhCD to afford the previously 
reported penta-azoline species (-90 Da; Fig. 3.3A).25 Following lyophilization to remove [16O]-
H2O, the penta-azoline peptide was hydrolyzed in [18O]-H2O containing 0.5% (v/v) formic acid. 
As suspected, this treatment afforded a species with a mass 10 Da heavier than the starting 
material, suggesting that the substrate contained five 18O-labels, [18O5]-BalhA1. Moreover, the 
mass increase was predicated on azoline formation, as both an unmodified peptide and a peptide 
containing oxidized azole heterocycles were inert under the hydrolysis conditions employed (Fig. 
3.4). This result was consistent with previous reports demonstrating that acid-catalyzed isotope 
exchange of carboxylic acids occurs slowly.28,29 Following the removal of spent synthetase 
buffer, [18O5]-BalhA1 was subjected to a second treatment with BalhCD. As before, the peptide 
was modified to a penta-azoline state; however, ring formation was accompanied by a -100 Da 
mass shift, consistent with the loss of all five 18O labels (Fig. 3.3A). Fourier transform (FT) 
MS/MS was utilized to definitively localize the 18O-labeled positions to the amides immediately 
N-terminal to the cyclized cysteines (Fig. 3.3B).  
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Figure 3.2 | Peptide substrate sequences. The substrates used in this chapter are listed above. 
Known heterocyclization sites are highlighted in red, with the exception of the first 
bisheterocycle site in McbA, which is highlighted in orange. In McbA, the red underlined serine 
is the site of the ninth heterocycle that is installed in vitro and found as a minor species during 
the microcin B17 heterologous expression.30 The predicted site of the azoline heterocycle in 
BalhA2 from previous studies is colored blue.24 Putative and known leader peptide cleavage sites 
are marked with a caret and an asterisk, respectively. As SagX is an unnatural TOMM analog 
(see reference 31 for description), no residues are colored. 
 
Figure 3.3 | Site-specific incorporation of 18O labels into BalhA1. (a) An overlay of MALDI-
TOF MS spectra displaying the 18O exchange process. Mass labels correspond to the 1+ charge 
state and all mass shifts are reported relative to the pertinent non-cyclized species (spectra 1 and 
3).  The loss of the 18O labels in [18O5]-BalhA1 upon retreatment with BalhCD is evidenced by 
the loss of 100 Da (compared to -90 Da for BalhA1). 18O labels are represented by filled circles. 
(b) The FT-MS/MS spectrum of trypsin digested [18O5]-BalhA1. The b and y ions are colored 
based on the number of 18O labels present in the fragment (green, 5; purple, 4; orange, 3; blue, 2; 
red, 1; black, 0). Stars represent the location of the 18O labels. 
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Figure 3.4 | 18O labeling of BalhA1 is dependent on azoline heterocycles. To ensure that the 
installation of 18O-labels into BalhA1 was dependent on the presence of azoline heterocycles, 
both unmodified (1) and the penta-azole (2) forms of BalhA1 were treated with 0.5% formic acid 
in [18O]-H2O for 18 h. The resultant MALDI-TOF mass spectra demonstrated that in both cases, 
the peptides were insensitive to the 18O exchange conditions. These data suggested that this 
strategy for substrate labeling would be selective for azoline-containing peptides. All listed 
masses are for the 1+ charge state. The filled circle represents an 18O label.  
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3.3 Thiolysis of Oxazoline Heterocycles Allows for Site-Selective Thioamide Incorporation  
The conversion of amides into thioamides is commonly achieved through the use of thionation 
reagents (e.g. Lawesson’s reagent).12,32 Such treatments suffer from exceedingly poor site-
selectivity and are not suitable for the modification of larger peptides.33,34 An alternative strategy 
entails the thiolysis of an oxazoline heterocycle using H2S (i.e. sulfur nucleophile) for the site- 
and chemoselective formation of thioamides.35 Based on this, I hypothesized that AMPL could 
be extended accordingly. For initial tests, I chose a simplified BalhA1 substrate derivative 
designed to form only a single oxazoline heterocycle, BalhA1NC-A40T (Fig. 3.2). All other 
Cys/Ser and Thr residues in the core peptide of BalhA1 have been mutated to Ala and Val, 
respectively, and are thus non-cyclizable (BalhA1NC). Following cyclodehydration by BalhCD, 
BalhA1NC-A40T was treated with potassium hydrosulfide (KHS; a solid, readily-handled 
alternative to H2S) and analyzed by mass spectrometry (Fig. 3.5A). KHS treatment resulted in a 
32 Da mass increase from the cyclized peptide, consistent with oxazoline thiolysis. Importantly, 
no modification was seen if the oxazoline was not formed prior to KHS treatment (Fig. 3.6). 
While these data indicated that thioamide formation had occurred, attempts to locate the 
modification site by LC-MS/MS failed due to incomplete fragmentation of the peptide (data not 
shown). To demonstrate selective thioamide incorporation, a minimal substrate, BalhX (Fig. S2, 
vide infra), was subjected to thiolysis and subsequent LC-MS/MS analysis. As expected, the 
methyloxazoline on BalhX efficiently converted to a thioamide (Fig. 3.7), and the modification 
could be definitively localized to the threonine heterocyclization site (Fig. 3.8).  
Previous reports on the relative reactivity of thiazolines and oxazolines towards 
nucleophiles demonstrated that the former is substantially less reactive.21-23 To determine if this 
attenuated reactivity would preclude thiolysis of thiazoline heterocycles, an analogous study was 
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performed with BalhA1NC-A40C (Fig. 3.2). The resultant spectra demonstrated that thioamide 
formation did not occur upon KHS treatment of the thiazoline heterocycle (Fig. 3.5B). Attempts 
to promote thiolysis with higher concentrations of KHS, higher temperature, pH modulation, and 
longer reaction times all failed to generate the thioamide product (data not shown). Thus, under 
the conditions employed, the AMPL-based thiolysis is remarkably chemoselective for 
(methyl)oxazoline heterocycles. As a further illustration of chemoselectivity, BalhA2 was 
converted to a tri-thiazoline, mono-oxazoline species by BalhCD and treated with KHS. As 
predicted, only a single thiolysis event was observed (Fig. 3.5C). Previously, we have 
demonstrated that BcerB (dehydrogenase from a closely related TOMM cluster in B. cereus) was 
unable to oxidize oxazoline heterocycles.24 As such, I predicted that treatment of BalhA2 with 
BcerB and BalhCD, coupled with subsequent thiolysis, would afford the tri-thiazole, mono-
thioamide substrate. This was indeed the case, indicating that AMPL can utilized for the 
synthesis of differentially functionalized peptides (Fig. 3.5D).  
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Figure 3.5 | Thiolysis is specific for oxazoline heterocycles. MALDI-TOF MS overlays 
showing the thiolysis of (a) BalhA1-NC-A40T, (b) BalhA1-NC-A40C, (c) BalhA2 treated with 
the cyclodehydratase (CD), and (d) BalhA2 treated with both the cyclodehydratase and the 
dehydrogenase (BCD) are displayed. Mass labels correspond to the 1+ charge state and all mass 
shifts are reported relative to the pertinent unmodified species (spectrum 1). 
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Figure 3.6 | Potassium hydrosulfide (KHS) treatment of unmodified BalhNC-A40T. To 
ensure that the thiolysis of BalhNC-A40T is dependent on the presence of azoline heterocycles, 
unmodified substrate was treated with 100 mM KHS for 18 h at 25 °C. The resultant MALDI-
TOF spectra demonstrate that the peptide is insensitive to the thiolysis conditions. These data 
suggest that this strategy for thioamide formation will be selective for azoline-containing 
peptides. All listed masses are for the 1+ charge state. 
 
 
 
Figure 3.7 | BalhX thiolysis reaction and localization. (a) A MALDI-TOF spectrum of 
BalhCD-treated BalhX (a substrate lacking a leader peptide, Fig. 3.2) is displayed. The spectra 
show that upon treatment with BalhCD, the single cyclizable residue is converted to an azoline 
heterocycle. Following azoline formation, BalhX was subjected to KHS treatment. The last 
spectrum shows that the methyloxazoline on BalhX is converted to a thioamide. The masses 
correspond to the 1+ charge state of the peptide and the mass shifts relative to the unmodified 
peptide are displayed under each label. (b) An ion trap-MS/MS spectrum of the BalhX peptide 
following thiolysis is shown. The b and y ions along with the corresponding b and y ion symbols 
are colored based on the presence of the sulfur atom (+16 Da) in the fragment (red, contains the 
sulfur; black, does not). Based on the fragmentation, it is possible to definitively localize the 
thioamide moiety to the Gly (red) immediately upstream of the Thr that was cyclized in the 
starting material. 
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3.4 Leader Peptide-Independent Peptide Backbone Labeling 
An intriguing feature of ribosomally synthesized posttranslationally modified peptide (RiPP) 
natural product biosynthesis is the broad substrate tolerance of the modification enzymes.36-39 
While the basis of this promiscuity is under active investigation, it is well understood that the 
bipartite nature of the precursor peptides is a major contributor. RiPP modification enzymes 
recognize substrates primarily through binding an N-terminal leader peptide. In contrast to the 
extensively modified C-terminal core region, the leader peptide does not undergo enzymatic 
processing.40 Nonetheless, reports of leader peptide-independent RiPP processing enzymes have 
emerged.41 For example, some lanthipeptide biosynthetic enzymes can process their substrates 
without the presence of the leader peptide, although the enzymatic activity is always higher when 
the leader peptide is supplied in trans.42-44 Although a TOMM processing enzyme had not yet 
been reported to modify peptides without a leader peptide, I hypothesized that leader peptide-
independent processing might be achievable with the substrate tolerant Balh synthetase.24 To this 
end, a BalhA1 substrate derivative was generated lacking the leader peptide (BalhA1core; Fig. 
3.2) and modification by the Balh synthetase complex was assessed. Although modification by 
BalhCD alone generated the expected penta-azoline species, the addition of the dehydrogenase 
(BcerB) resulted in a complex mixture of oxidation products (Fig. 3.8). This was unexpected, as 
previous studies had demonstrated that cyclodehydration and oxidation were tightly coupled 
during BalhA1 processing,24,25 and leader peptide binding was thought to be governed by the 
cyclodehydratase, not the dehydrogenase.17,31 In an effort to promote more complete oxidation, 
the dehydrogenase concentration was doubled in a second reaction. The primary product, a tetra-
azole, mono-azoline species (Fig. 3.9), was subjected to MS/MS sequencing to localize the 
heterocycles. The fragmentation data demonstrated that the cyclized positions were identical to 
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the wild-type BalhA1 substrate and localized the single azoline to Cys20 (Cys45 in full-length 
BalhA1; Fig. 3.2, 3.9). During BalhA1 processing, Cys45 is known to be the penultimate azole 
to be installed,24 thus removing the leader peptide from the substrate appeared to disrupt both the 
order and efficiency of oxidation by the dehydrogenase.  
While a decrease in oxidation rate suggested that substrate processing was dysregulated 
upon removal of the leader peptide, oxidation is not required for AMPL. To determine the effect 
of leader peptide removal on the rate of BalhA1core cyclodehydration, I carried out a purine 
nucleoside phosphorylase-coupled phosphate detection assay as previously described.24,25,45 
Attempts to determine the kinetic parameters for BalhA1core were unsuccessful, as it was not 
possible to saturate the enzyme with substrate. This result was in agreement with the well-
established model of leader peptide-mediated substrate recognition.40 As such, the initial velocity 
of BalhA1core processing at high substrate concentrations was compared to previously reported 
values for various substrate derivatives.24 The data demonstrated that BalhA1core was modified at 
a slower rate than BalhA1, but at a rate comparable to the naturally occurring BalhA2 substrate 
(Fig. 3.8B). The origin of the different processing rates for the naturally occurring BalhA1 and 
BalhA2 peptides derives from the presence of a Ser (Ser36), rather than the preferred Gly, 
immediately preceding the first cyclized residue (Cys37) in BalhA2.24 As the KM for BalhA1core 
was significantly larger than for BalhA2 (16 µM), the similar processing reaction velocity 
between the two substrates requires that the intrinsically faster processing rate of BalhA1 (kobs = 
12.9 min-1) be retained upon the leader peptide removal.24    
 To explore the generality of leader peptide-independent processing by the Balh 
synthetase, the modification of unnatural substrates was explored. Although not explicitly stated 
in the previous section, BalhX is a minimal substrate lacking a leader peptide (Fig. 3.2). This 17-
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mer substrate contains a single heterocyclizable site that is cyclized by the Balh 
cyclodehydratase in route to thioamide formation (Fig. 3.7). I observed that the modification 
efficiency of BalhX greatly improved upon the addition of leader peptide in trans (data not 
shown). This is reminiscent of studies with lanthipeptide modification machineries in which the 
leader peptide has been proposed to place the enzyme into an active conformation for substrate 
modification.42,43,46 In the case of the Balh cyclodehydratase, it remains unclear whether the 
addition of leader peptide in trans fulfills a similar role.  
While modification of this simple 17-mer substrate demonstrated that leader peptide-
independent processing was achievable on unnatural sequences, BalhX was still derived from the 
BalhA1 core peptide (see Fig. 3.2). As such, the possibility remained that modification was due 
to inherent recognition of the core peptide by the Balh cyclodehydratase. Previous work 
demonstrated that the Balh synthetase can install azoles onto unnatural core peptides fused to the 
BalhA1 leader peptide.24 One such chimeric substrate was the fusion of a truncated version of the 
McbA (microcin B17 precursor peptide) core peptide to the BalhA1 leader peptide (BalhA1-
McbA). In order to test for leader peptide-independent conversion, wild-type McbA (Fig. 3.2) 
was treated with BcerB and BalhCD. The resultant mass spectrum demonstrated that the Balh 
synthetase was able to modify the non-cognate McbA substrate (Fig. 3.10A), albeit with a 
decreased efficiency compared to reactions carried out with the chimeric BalhA1-McbA 
substrate.24 In order to further assess the generality of the BalhCD leader peptide-independent 
activity, a similar reaction was carried out with a streptolysin S-like precursor peptide (SagX; 
Fig. 3.2). As with the other substrates, treatment with the Balh synthetase resulted in 
modification of SagX (Fig. 3.10B). In the three aforementioned cases, the substrates contained 
heterocyclization sites that adhered to the previously reported Balh synthetase modification rules 
	  	   77	  
(Gly-Cys/Ser/Thr-Xaa, where Xaa ≠ Pro).24 To determine if these rules were retained upon 
leader peptide removal, an additional three leader peptide-free substrates lacking Balh 
cyclodehydratase cyclization sites were reacted with BalhCD (Fig. 3.11). In all cases, 
cyclodehydration was not observed indicating that the predictability of the Balh synthetase is 
retained upon leader peptide removal. 
 
 
Figure 3.8 | BalhA1core processing. (a) An overlay of MALDI-TOF MS spectra displaying 
BalhCD- and BcerB/BalhCD-treated BalhA1core. Mass labels correspond to the 1+ charge state 
and all mass shifts are reported relative to the unmodified species (spectrum 1). (b) Relative 
processing rates for previously reported leader peptide-containing substrates of BalhCD are 
displayed alongside the processing rate for BalhA1core. Error bars represent standard deviation 
from the mean (n = 3). 
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Figure 3.9 | Azol(in)e localization on BCD-treated BalhA1core. (a) An FT-MS spectrum of 
BCD-treated BalhA1core is displayed. The calculated and observed masses for the tetra-azole, 
mono-azoline form of the peptide in the 4+ charge state are shown along with the ppm error of 
the measurement. (b) An FT-MS/MS spectrum of the species shown in panel (a). The b and y 
ions are colored based on the number of heterocycles found in the fragment (green, 5; purple, 4; 
orange, 3; blue, 2; red, 1; black, 0). Asterisks denote ions with a neutral loss of water. The yellow 
stars denote the sites of azole formation while the blue star denotes the lone azoline site. This 
data shows that the same positions in the BalhA1 core peptide are modified when the leader 
peptide is removed, and that the azoline oxidation is dysregulated on substrates lacking a leader 
peptide. 
 
 
 
Figure 3.10 | McbA and SagX processing by a non-cognate BCD complex. A MALDI 
spectrum of BcerB/BalhCD-treated McbA (a) and SagX (b) is shown. All displayed masses are 
for the 1+ charge state. The mass shift relative to the unmodified species is shown below the 
mass of the peak in the BCD-treated sample. These spectral overlays demonstrate that the Balh 
synthetase was able to modify non-cognate substrates irrespective of the presence of a Balh 
leader peptide.  
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Figure 3.11 | Leader peptide-free processing follows previously established rules. (a) Three 
peptides lacking this optimal heterocyclization sequence are displayed with heterocyclizable 
residues colored blue. (b) The MALDI-TOF spectra of  the BalhCD-treated peptides are shown. 
In all cases, treatment with the Balh cyclodehydratase failed to result in substrate processing, 
even at substrate:enzyme ratios of 1:1. Apart from the terminal Ser on ClosA-LP, all of the 
heterocyclizable residues are downstream of a non-Gly residue and are not processed. The C-
terminal Ser on ClosA-LP is likely not processed due to the lack of a +1 residue. All masses 
correspond to the 1+ charge state. 
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3.5 Engineering of Dehydrogenase-Dependent Synthetases for Backbone Labeling  
In principle, AMPL could be carried out with any TOMM synthetase. However, of the six 
TOMM synthetases that have been reconstituted in vitro,15,16,24,47,48 only the cyanobactin (PatD, 
patellamide; TruD, trunkamide) and Balh modification enzymes have been shown to function 
without the addition of the dehydrogenase.16,25 The AMPL methodology is not inherently 
compatible with TOMM cyclodehydratases that function in a dehydrogenase-dependent fashion, 
as the azoline heterocycles synthesized by these synthetases are typically transformed to 
hydrolytically inert azoles. In the absence of a crystal structure of a TOMM synthetase, I posited 
that such dehydrogenase-dependent cyclodehydratases would likely require precise quaternary 
interactions in order to be competent catalysts; however, I reasoned that it would be quite 
unlikely that downstream azoline oxidation was required for efficient cyclodehydration. In order 
to co-opt a dehydrogenase-dependent cyclodehydratase for the production of only azoline 
heterocycles, I used bioinformatics to aid in the identification of conserved residues in TOMM 
dehydrogenases that were important for azoline oxidation. In an attempt to avoid mutations that 
may structurally destabilize the protein, positions predicted to be directly involved in FMN-
binding were ruled out. By aligning divergent dehydrogenases, two highly conserved residues 
were identified that I hypothesized to be important for catalysis but not for FMN-binding (Fig. 
3.12). To test this hypothesis, I prepared two single-point mutants (K201A and Y202A) of the 
microcin B17 dehydrogenase (McbC), which has been long known to be required for 
cyclodehydration during microcin B17 processing.17 Following purification, McbC-K201A and -
Y202A were found to co-purify with FMN at levels similar to wild-type (Fig. 3.13). As 
designed, the McbC-K201A and -Y202A permitted the production of azoline, but not azole, 
heterocycles when co-reacted with the Mcb cyclodehydratase (Fig. 3.14). However, instead of 
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converging to the known 9-azole form of McbA,30 reactions carried out with the mutant 
dehydrogenases prematurely terminated after installing just two azolines. Due to the 
aforementioned lability of azolines, FT-MS/MS localization was not possible using standard 
methods (vide infra). Regardless, the use of this straightforward bioinformatics-guided strategy 
for conversion of dehydrogenase-dependent cyclodehydratases to azoline synthetases has the 
possibility to be a general strategy for synthetase repurposing. 
 
 
Figure 3.12 | TOMM dehydrogenase alignments. A Clustal Omega alignment of 
dehydrogenases from diverse TOMM clusters is displayed (for a larger alignment see reference 
47). Residues predicted to be involved in coordinating the phosphate moiety of FMN (based on 
the crystal structure of a non-TOMM “nitroreductase”, PDB entry 3EO7) are colored blue. The 
residues highlighted in red were chosen for the mutagenesis due to their high level of 
conservation and the prediction that they were not directly involved in FMN binding. In McbC, 
these residues are K201 and Y202. 
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Figure 3.13 | Stability and FMN loading of McbC-K201A and -Y202A. (a) A Coomassie-
stained SDS-PAGE gel of amylose resin purified WT, K201A, and Y202A MBP-McbC is 
displayed along with a table listing the yield of each protein. While the Y202A mutant was lower 
yielding, the SDS-PAGE gel indicated that the protein was not structurally destabilized to any 
significant extent, as would be evidenced by faster migrating proteolytic degradation bands. (b) 
In order to determine the effect, if any, the K201A and Y202A mutations had on FMN-binding 
in McbC, a UV-vis absorbance spectrum was acquired for each protein. The ratio of the 
absorbance at 450 and 280 nm was used to evaluate FMN-loading. While Y202A has a slightly 
lower molar absorptivity at 280 nm than WT McbC, the difference is less than 2% and within the 
error of the measurement. The graph shows the loading for each of the mutants has not been 
drastically effected by the mutations, relative to WT McbC. Error bars represent the standard 
deviation from the mean (n = 3).   
 
 
Figure 3.14 | Azoline formation by the 
microcin B17 synthetase. An overlay of 
MALDI-TOF spectra displaying McbA 
processing by the Mcb cyclodehydratase 
(McbBD) with either wild-type (WT) or the 
mutant (K201A, Y202A) Mcb 
dehydrogenases (McbC) is shown. Mass 
labels correspond to the 1+ charge state and 
all mass shifts are reported relative to the 
unmodified species (spectrum 1). In the WT 
McbC reaction (spectrum 3), partially 
processed intermediates with 5-8 azoles 
(labeled -20x) are seen in addition to the 
fully modified, 9-azole substrate. 	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3.6 Azoline Localization Provides Insights into Cyclodehydratase Substrate Processing  
The acid-labile nature of azoline heterocycles has hindered their localization due to the acidic 
conditions often employed for efficient detection by mass spectrometry. As such, AMPL has the 
potential to aid in a variety of azoline biosynthetic studies by providing a rapid and robust 
method for azoline localization that takes advantage of acid lability, rather than suffering from it. 
To demonstrate the usefulness of such a strategy, I began by investigating azoline localization on 
BalhA2 (Fig. 3.2). Upon BcerB/BalhCD treatment, BalhA2 was converted to a tri-azole, mono-
azoline form (Fig. 3.5D). While previous efforts localized the three azoles to the three N-
terminal Cys residues, the azoline heterocycle could only be generally localized to a region of 
BalhA2 containing three heterocyclizable sites; Thr34, Thr35 and Ser36 (see Fig. 3.2).24 Through 
AMPL, I generated [18O4]-BalhA2 and was able to definitively localize the fourth heterocycle to 
Thr34 using FT-MS/MS (Fig. 3.15). This result is in accord with the known Balh 
cyclodehydratase selectivity rules (the residue N-terminal to Thr34 is Gly33). 
 Encouraged by the successful utilization of AMPL for identifying previously 
indeterminable sites of azoline formation, I returned my attention to the di-azoline McbA species 
generated from reactions containing McbBD and either McbC-K201A or -Y202A (Fig. 3.14). 
Previous work on the order of ring formation in microcin B17 biogenesis demonstrated that the 
first two rings to be cyclized are Cys41 and Ser40, respectively.49 With this in mind, I predicted 
that the two azolines installed on McbA in the mutant dehydrogenase assays would be located at 
the site of this bisheterocycle. A combination of iodoacetamide labeling (Fig. 3.16) and the 
aforementioned 18O-labeling strategy coupled with FT-MS/MS, demonstrated that one of the 
cyclized residues was indeed Cys41, but that the other azoline was installed at either Cys48 or 
Cys51 (incomplete fragmentation between the two Cys precluded exact localization; Fig. 3.17, 
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3.18). While it has been shown that both Cys48 and Cys51 can be installed on mutant substrates 
lacking the Ser of the first bisheterocycle site (Ser40A),50 never before has a substrate with an 
intact, wild-type bisheterocycle site been observed to stop with only one of those heterocycles 
formed.49,51,52 These results suggest that in microcin B17 biosynthesis, either the dehydrogenase 
controls the regioselectivity of the cyclodehydratase or that azoline oxidation is required for 
correct substrate processing. While the data cannot distinguish between these two possibilities, it 
has been previously demonstrated that proper installation of the earlier rings is required for 
formation of the later rings, potentially through conformational control of the substrate.24,50 As 
such, I favor a mechanism where azoline oxidation induces the requisite conformational 
restraints to facilitate modification of downstream residues. In this model, Cys41 would be 
heterocyclized first, but without oxidation, Ser40 is unable to be cyclized. This “roadblock” takes 
the cyclodehydratase off-pathway and results in the cyclization of a second Cys (either 48 or 51), 
at which point processing stalls. Although further study will be required to definitively determine 
the collaborating role that the dehydrogenase plays in cyclodehydration, these data provide yet 
another glimpse into the exquisite orchestration of substrate handling during TOMM 
biosynthesis and demonstrate the utility of the AMPL method. 
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Figure 3.15 | Azoline localization on BalhA2 via 18O labeling. Following treatment with 
BalhCD and 18O-hydrolysis, BalhA2 was subjected to FT-MS/MS. (a) An intact mass spectrum 
for [18O4]-BalhA2 in the 4+ charge state is displayed. The monoisotopic masses for the most 
prominent 18O-labeled species are displayed and colored based on the number of 18O labels 
(purple, 4; orange, 3; blue, 2). Note that the isotope distribution of the [18O4]-peak is skewed to 
higher m/z values, indicating that a [18O5]-labeled species also exists. The ppm error for the 
major species is displayed. (b) A MS/MS spectra of the [18O4]-BalhA2 species from panel (a) 
demonstrates that the oxazoline site is the first Thr, as was previously hypothesized.24 The b and 
y ions are colored based on the number of 18O present in the fragment (purple, 4; orange, 3; blue, 
2; red, 1; black, 0). Stars represent the sites of 18O labels from hydrolysis of the azoline 
heterocycles and asterisks label peaks with neutral water loss. Based on the y ion series, the C-
terminal carboxylate bears a single 18O label (denoted by red residue). This is a consequence of 
the sample preparation and is a known reaction occurring on acidified tryptic peptides.53    
	  	   86	  
 
 
Figure 3.16 | Iodoacetamide labeling of McbA following treatment with McbC variants. To 
determine if the azolines installed on McbA following treatment with McbBD and mutants of 
McbC were thiazolines or oxazolines, the products were subjected to iodoacetamide (IA) 
labeling. In the case of unmodified McbA (McbA + McbBD, top spectrum), up to five IA labels 
were installed. As McbA contains four Cys residues (see Figure S2), the presence of a low 
intensity peak corresponding to a substrate with five IA labels is likely due to the IA-dependent 
labeling of amines. Upon treatment with the all wild-type McbBCD (WT) complex, the peptide 
is no longer reactive towards IA, as all cysteines have been converted to thiazoles (Thz). In 
contrast, for samples treated with McbBD and either McbC-K201A or -Y202A, the di-azoline 
substrate undergoes two labeling events. As with the unclyclized McbA sample, both the WT 
and K201A/Y202A treated peptides have a low intensity peak corresponding to the non-specific 
IA-labeling of amines. Masses correspond to the 1+ charge state of the species and the number of 
IA labels, and Thz, oxazole (Oxz) and thiazoline (ThH) heterocycles are displayed beneath each 
mass.  
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Figure 3.17 | Azoline localization on McbA following treatment with McbC-K201A. Azoline 
heterocycles on McbA were subjected to 18O hydrolysis to form [18O2]-McbA, and the labeled 
peptide was analyzed by FT-MS/MS to locate the sites of azoline formation. The b and y ions are 
colored based on the number of 18O present in the fragment (blue, 2; red, 1; black, 0). Asterisks 
indicate peaks with a neutral loss of water. Based on the fragmentation pattern and the 
iodoacetamide labeling data (Figure S16), one of the thiazoline heterocycles can be definitively 
localized to Cys41 (red). The other thiazoline is formed at either Cys48 or Cys51 (blue). 
Incomplete fragmentation in this region precluded the precise localization of the modification 
site.  
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Figure 3.18 | Azoline localization on McbA following treatment with McbC-Y201A. Azoline 
heterocycles on McbA were subjected to 18O hydrolysis to form [18O2]-McbA, and the labeled 
peptide was analyzed by FT-MS/MS to locate the sites of azoline formation. The b and y ions are 
colored based on the number of 18O present in the fragment (blue, 2; red, 1; black, 0). Asterisks 
indicate peaks with a neutral loss of water. Based on the fragmentation pattern and the 
iodoacetamide labeling data (Figure S12), one of the thiazoline heterocycles can be definitively 
localized to Cys41 (red). The other thiazoline is formed at either Cys48 or Cys51 (blue). 
Incomplete fragmentation in this region precluded the precise localization of the modification 
site. 
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3.7 Azoline Stoichiometry of Natural Products Obtained via Backbone Labeling  
The labeling of azoline heterocycles using selective hydrolysis is not restricted to in vitro 
reactions. In principle, the AMPL method for azoline labeling could be extended to determine 
the number and location of azoline rings on natural products. To demonstrate this, the azoline-
containing TOMMs plantazolicin, ulithiacyclamide, and lissocinamide 4 (Fig. 3.1A) were 
subjected to the AMPL method for 18O-labeling. In all cases 18O labeling was achieved (Figure 
3.19-3.21), demonstrating that AMPL can be utilized to derivatize both thiazolines and 
methyloxazolines on natural products. This suggests that the method could be generalized to 
provide the number and type (thiazoline vs. oxazoline) of azoline heterocycles in any natural 
product. Given that emerging natural products are most often available only in vanishingly small 
quantities, AMPL may prove valuable in assisting with the structural elucidation of these 
compounds. 
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Figure 3.19 | 18O-labeling of plantazolicin. A MALDI-TOF spectrum demonstrating that 
AMPL can be utilized to selectively 18O-label the TOMM natural product plantazolicin (Pzn; 
Fig. 3.1A) is displayed. As expected based on the structure of Pzn, exposure to acid in [18O]-H2O 
results in the incorporation of a single 18O label (+20 Da) into Pzn due to the hydrolysis of the 
single methyloxazoline ring. The ratio between the 18O- and 16O-labeled hydrolysis species (m/z 
1356 and 1354, respectively) is due to the presence of  ~10% [16O]-H2O in the sample.  All 
masses are for the 1+ charge state and the mass shift relative to the unmodified species (m/z 
1336) is shown below the mass label.  
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Figure 3.20 | 18O-labeling of ulithiacyclamide. A MALDI-TOF spectrum demonstrating that 
AMPL can be utilized to selectively 18O-label the TOMM natural product ulithiacyclamide (Uli; 
Fig. 3.1A) is displayed. Based on the structure of Uli, exposure to acidified [18O]-H2O should 
result in the incorporation of two 18O-labels (m/z 803.2). Although this peak is not detected, both 
the +Na (m/z 825.2) and +K (m/z 841.2) species are observed. All masses are for the 1+ charge 
state and the mass shift relative to the unmodified species (m/z 763.2) is shown below the mass 
label.  
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Figure 3.21 | 18O-labeling of lissoclinamide 4. A MALDI-TOF spectrum demonstrating that 
AMPL can be utilized to selectively 18O-label the TOMM natural product lissoclinamide 4 (Lis; 
Fig. 3.1A) is displayed. While Lis contains two azoline heterocycles (a thiazoline and a 
methyloxazoline) a spectrum of the starting material (black) indicates that a majority of the 
species is hydrolyzed to begin with (+18 Da). As such, treatment with acidified [18O]-H2O is 
expected to generate a species containing both a 16O and an 18O label (m/z 780.2). Indeed this 
dual labeled product is obtained. All masses are for the 1+ charge state and the mass shift relative 
to the unmodified species (m/z 742.2) is shown below the mass label. 
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3.8 Summary and Outlook 
Prior to this work, the primary strategy for generating thioamides and oxygen isotope-labeled 
amides was SPPS. The method reported herein, which I refer to as azoline-mediated peptide 
backbone labeling (AMPL), provides the first chemoenzymatic strategy for accessing such 
derivatives. AMPL is compatible with both large and small peptides and peptide substrates fused 
to large proteins. Conveniently, labeling can be performed in the same pot as cyclodehydration, 
minimizing the amount of sample handling required during derivatization. In exploring the scope 
of AMPL, I have not only identified leader peptide-independent processing by a TOMM 
cyclodehydratase, but also converted the naturally azole-producing Mcb synthetase into an 
azoline-only synthetase. Although my studies focused on the Balh and Mcb enzymes, AMPL can 
theoretically be applied to any TOMM synthetase, provided the enzymes can function 
independently of a dehydrogenase or the dehydrogenase can be inactivated without disrupting 
cyclodehydratase activity. The major limitation of the AMPL methodology is the inherent local 
sequence selectivity of the cyclodehydratase, which can be overcome by selecting the 
appropriate synthetase to modify a sequence of interest. As such, the in vitro reconstitution and 
characterization of additional TOMM cyclodehydratases will expand the sequence space 
accessible to the AMPL method.  
In addition to providing a convenient strategy for generating polypeptides bearing 
unnatural amide derivatives, the utility of the AMPL method should also be of interest to 
enzymologists and natural products chemists, as I have used this labeling strategy to both 
investigate the mechanism of cyclodehydration (see chapter 2) and elucidate the localization of 
previously unresolvable heterocyclization sites. For the latter, I have focused the use of AMPL 
on identifying the location of enzymatically installed azoline heterocycles and through this 
	  	   94	  
simple labeling strategy have provided new insights into substrate processing by divergent 
TOMM cyclodehydratases. Furthermore, I demonstrate that the AMPL method can be extended 
to the modification of natural products, which opens up the possibility of using AMPL for both 
azoline-containing natural product discovery and structure elucidation. 
 
3.9 Experimental 
3.9.1 General methods. Unless otherwise specified, all chemicals were purchased from Sigma 
or Fisher Scientific. DNA sequencing was performed by either the Roy J. Carver Biotechnology 
Center (UIUC) or ACGT Inc. Restriction enzymes were purchased from New England Biolabs 
(NEB), Pfu Turbo was purchased from Agilent, and dNTPs were purchased from either NEB or 
GenScript. Oligonucleotide primers were synthesized by Integrated DNA Technologies (IDT). 
Unless otherwise stated, all proteins and substrates were used as MBP fusions to circumvent 
solubility issues. 
3.9.2 Protein overexpression and purification. Apart from the Trx-BalhA1 substrate, all 
proteins were overexpressed as tobacco etch virus (TEV) protease- or thrombin-cleavable 
fusions to maltose-binding protein (MBP) and purified by amylose affinity chromatography as 
previously reported.25 Unless otherwise stated, all reactions were carried out with tagged 
substrates and enzyme to avoid solubility issues. 
3.9.3 Overexpression and purification of Trx-BalhA1. BL21(DE3-RIPL) cells were 
transformed with a pET32b plasmid containing Trx-BalhA1 (E. coli thioredoxin fusion protein 
that bears an N-terminal His-tag). Cells were grown overnight on Luria-Bertani (LB) plates with 
100 µg/mL ampicillin. Single colonies were picked for starter cultures containing 100 µg/mL 
ampicillin and 34 µg/mL chloramphenicol and were grown at 37 °C. A 10 mL overnight culture 
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was used to inoculate 1 L of LB containing 100 µg/mL ampicillin and 34 µg/mL 
chloramphenicol. Cultures were grown to an optical density at 600 nm (OD600) of 0.8 before 
induction with 1 mM isopropyl ß-D-1-thiogalactopyranoside (IPTG) for 1.5 h at 22 °C. 
Subsequently, cells were harvested at 3000 × g for 15 min, washed with TBS (Tris buffered 
saline; 10 mM Tris pH 7.5, 150 mM NaCl) and stored at -20 °C for up to one week before use. 
Cell pellets were resuspended in lysis buffer [50 mM Tris pH 8, 500 mM NaCl, 25 mM 
imidazole, 2.5% glycerol (v/v), 0.1% Triton X-100 (v/v)] containing lysozyme (4 mg/mL), 
leupeptin (2 µM), PMSF (200 µM), benzamidine (2 mM), and E64 (2 µM). After a 30 min 
incubation at 4 °C, cells were disrupted via sonication 3 × 30s with 10 min equilibration periods 
at 4 °C. The insoluble debris was removed from the sample via centrifugation at 20,000 × g for 
45 min. The resulting supernatant was applied to pre-equilibrated Ni-NTA resin (Qiagen, 5 mL 
resin per L of cells). The column was washed with 10 column volumes of lysis buffer, followed 
by 5 column volumes of wash buffer (lysis buffer with NaCl concentration increased to 300 mM 
and Triton X-100 omitted). The His-tagged proteins were eluted using 4 column volumes of 
elution buffer (wash buffer with 150 mM NaCl and 200 mM imidazole) and the eluent was 
concentrated using an appropriate Amicon Ultra centrifugal filter (Millipore). A 100-fold buffer 
exchange with storage buffer [50 mM HEPES pH 7.5, 150 mM NaCl, 2.5% glycerol (v/v)] was 
performed in the filtration device before a final concentration and storage. After loading onto the 
column, all buffers used contained 1 mM tris-(2-carboxylethyl)-phosphine (TCEP). Protein 
concentration was determined both by the 280 nm absorbance and a Bradford colorimetric assay 
(Thermo Scientific). Purity was visually assessed by Coomassie-stained SDS-PAGE gel. 
3.9.4 BalhA1 18O-labeling studies. Reactions containing 100 µM MBP-BalhA1, 2 µM MBP-
BalhC/D and 0.2 µg/mL TEV protease (to remove the MBP tags) were carried out in synthetase 
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buffer [50 µM Tris pH 7.5, 125 mM NaCl, 20 mM MgCl2, 3 mM ATP, and 10 mM dithiothreitol 
(DTT)] at 25 °C for 18 h. Subsequently, the samples were frozen in liquid nitrogen, lyophilized 
to dryness to remove all [16O]-H2O, and the resultant solids were reconstituted to half of the 
initial volume with 97 atom % [18O]-H2O. To this solution, 10% formic acid in [16O]-H2O (v/v) 
was added to a final concentration of 0.5 % (v/v). This resulted in a final isotopic enrichment of 
~92 atom %. Azoline hydrolysis was allowed to proceed for 18 h at 25 °C. The sample was then 
desalted via C18 ZipTip (Millipore) according to the manufacturer’s instructions and 18O 
incorporation was analyzed on a Bruker Daltonics UltrafleXtreme MALDI-TOF spectrometer. 
Spectra were obtained in positive reflector mode using α-cyano-hydroxycinnamic acid (CHCA) 
as the matrix. Control samples with either unmodified BalhA1 or fully oxidized BalhA1 (5 
azoles instead of 5 azolines) were treated in an analogous fashion, except that MBP-BalhC/D 
were omitted or 2 µM MBP-BcerB was added, respectively.  
For the remodification of [18O5]-BalhA1, the labeled substrate was C18 ZipTip desalted, 
to remove contaminating ADP and Pi, and subjected to a second treatment with fresh BalhC/D 
under identical conditions to the initial reaction. Following an 18 h reaction at 25 °C, the sample 
was analyzed by MALDI-TOF MS as described above. 
3.9.5 FT-MS/MS localization of 18O labels. Following azoline-mediated 18O label 
incorporation, peptides were trypsin (sequencing grade, Promega) digested in 50 mM NH4HCO3 
(pH 8.0) for 30 min at 37 °C before quenching with formic acid at a final concentration of 10 % 
(v/v). Precipitate was removed via centrifugation at 11,000 × g and the samples were analyzed 
via reverse-phase, high-performance liquid chromatography-Fourier transform mass 
spectrometry (FT-MS). All FT-MS was carried out on an Agilent 1200 HPLC system with an 
autosampler connected directly to a Thermo Fisher Scientific LTQ-FT hybrid linear ion trap 
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operating at 11 T. Separations were conducted using a 1 × 150 mm Jupiter C18 column (300 Å, 5 
µM, Phenomenex) with 0.1 % formic acid (A) and acetonitrile containing 0.1 % formic acid (B) 
as the mobile phases. The LC gradient was held at 5 % B for 2 min before being increased to 50 
% B over 43 min. All methods contained a full FT-MS scan followed by MS/MS of selected ions 
conducted in the FT. FT-MS scan parameters: minimal target signal counts: 5,000; resolution: 
25,000; m/z range: variable. FT-MS/MS parameters: minimum target signal counts: 5,000; 
resolution: 25,000; m/z range: dependent on target m/z; isolation width: 5 m/z; normalized 
collision energy: 35; activation q value: 0.25; activation time: 30 ms. Data analysis was 
conducted using the Qualbrowser application of Xcalibur v 2.2 (Thermo Fisher Scientific).  
3.9.6 Processing of leader peptide-free substrates. 100 µM MBP-BalhA1core was reacted with 
10 µM MBP-tagged BalhC/D, either with or without 10 µM MBP-BcerB, and 0.2 µg/mL TEV 
protease in synthetase buffer for 18 h at 25 °C. Samples were then desalted and analyzed by 
MALDI-MS as above. Processing of the unnatural substrates, MBP-SagX, MBP-McbA, and 
BalhX, were carried out in an analogous fashion with the following minor variations: all 
substrate concentrations were reduced to 50 µM, proteolytic cleavage in the MBP-McbA sample 
was carried out using 0.02 µg/mL thrombin (from bovine plasma), and MBP-tagged BalhA1 
leader peptide was added to the BalhX sample at a final concentration of 50 µM. 
3.9.7 Rate of BalhA1core processing. The rate of MBP-BalhA1core processing was determined 
using slight modifications to a previously described method.25 Briefly, MBP-BalhC and MBP-
BalhD were added to a cuvette for a final concentration of 1 µM each. Reactions were initiated 
via the addition of a mixture of 100 µM MBP-BalhA1core, 200 µM 2-amino-6-mercapto-7-
methylpurine riboside (Berry and Associates), and 0.2 units of purine nucleotide phosphorylase 
in synthetase buffer at 25 °C. Reaction progress was monitored by the change in absorbance at 
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360 nm on a Cary 4000 UV-vis spectrophotometer (Agilent). Initial rates of phosphate 
production were calculated based on the linear absorbance change during the first 3 min of the 
reaction and the extinction coefficient of the resulting guanine analog (11,000 M-1cm-1). Error is 
reported as the standard deviation of the mean (n = 3).  
3.9.8 Mcb synthetase reactions. 20 µM MBP-McbA was reacted with 1 µM MBP-tagged 
McbB/D and either WT, K201A or Y202A McbC in synthetase buffer for 18 h at 25 °C. 
Reactions were the initiated by the removal of MBP with the addition of 0.02 µg/mL thrombin. 
As above, heterocycle formation was monitored after desalting by MALDI-MS. A control 
sample lacking McbC was treated in an identical fashion. 
3.9.9 Thiolysis of azoline heterocycles. Heterocyclization reactions of MBP-BalhA1NC-A40T 
and -A40C were carried out with 50 µM substrate and 1 µM MBP-BalhC/D in synthetase buffer 
for 18 h at 25 °C. For BalhX modification, the enzyme concentration was increased to 10 µM 
and MBP-tagged BalhA1 leader peptide was added in trans to a final concentration of 50 µM. In 
the A40T and A40C samples, MBP was proteolytically removed by the addition of 2 µg/mL 
TEV protease. To each of samples, the proper volume of a fresh 1 M solution of potassium 
hydrosulfide (KHS; Strem Chemicals) was added to achieve a final concentration of 100 mM 
KHS, and thiolysis was allowed to proceed for an additional 18 h at 25 °C. The samples were 
then desalted and analyzed by MALDI-MS as above. For each substrate, a control reaction 
lacking MBP-BalhC/D was also subjected to thiolysis.  
 For reactions with BalhA2, 50 µM MBP-tagged substrate was incubated with 1 µM 
MBP-BalhC/D with and without 1 µM MBP-BcerB. MBP was removed via the addition of 2 
µg/mL TEV protease. Following an 18 h reaction at 25 °C, the samples were treated with KHS 
and analyzed by MALDI-TOF MS as above.  
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3.9.10 BalhX Synthesis: The synthetic peptide was ordered from GenScript 
(www.genscript.com) and received as a lyophilized powder (92 % purity).  
3.9.11 Dehydrogenase Alignments. Alignments were made with Clustal Omega using the 
standard parameters.54  
3.9.12 McbC mutagenesis. The K201A and Y202A mutants of McbC (dehydrogenase involved 
in microcin B17 biosynthesis) were generated via site-directed mutagenesis of a pET15b plasmid 
containing MBP-McbC using QuikChange as per the manufacturer’s instructions. The primers 
used are listed in table A.1. 
3.9.13 18O labeling of BalhA2 and McbC-K201A/Y202A reactions. 100 µM MBP-BalhA2 
was incubated with 1 µM MBP-BalhC/D in synthetase buffer for 18 h at 25 °C. The resultant 
tetra-azoline peptide was trypsin digested with 0.02 mg/mL trypsin (sequence grade, Promega) 
for 2 h at 25 °C before being lyophilized to dryness to remove all [16O]-H2O. The resultant solid 
was reconstituted with ½ of the initial volume of 97 atom % [18O]-H2O and 10% formic acid in 
[16O]-H2O (v/v) was added to a final concentration of 0.5% (v/v). This resulted in a final isotopic 
enrichment of approximately 92 atom %. Azoline hydrolysis was allowed to proceed for 18 h at 
25 °C. Following hydrolysis, the localization of the 18O labels was carried according to Fourier-
transform MS/MS procedure listed in the main text. 
In the case of the McbC-K201A and -Y202A reactions, 20 µM MBP-McbA was 
incubated with 1 µM MBP-tagged McbB/D and either K201A or Y202A McbC in synthetase 
buffer for 18 h at 25 °C. Reactions were then initiated by the addition of 0.02 µg/mL thrombin 
(from bovine plasma) to remove the MBP tags. Unlike the Balh cyclodehydratase, the Mcb 
synthetase requires the removal of MBP to be catalytically active. Processing of McbA with 
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concurrent thrombin cleavage was allowed to proceed for 18 h at 25 °C. Following cyclization, 
the sample was handled as described above.  
3.9.14 MS/MS localization thioamides and azol(in)e heterocycles. To locate the thioamide on 
BalhX and the heterocyclized sites of BalhA1core, ion trap (IT)-MS/MS was used instead of FT-
MS/MS. In both cases, samples were directly infused onto a Thermo Fisher Scientific LTQ-FT 
hybrid linear ion trap operating at 11 T using an Advion Nanomate 100. A full FTMS scan was 
conducted on all samples followed by IT-MS/MS of selected ions. FTMS scan parameters: 
minimal target signal counts: 5,000; resolution: 100,000; m/z range: variable. IT-MS/MS 
parameters: minimum target signal counts: 5,000; m/z range: dependent on target m/z; isolation 
width: 5 m/z; normalized collision energy: 35; activation q value: 0.25; activation time: 30 ms. 
Data analysis was conducted using the Qualbrowser application of Xcalibur v 2.2 (Thermo 
Fisher Scientific). 
3.9.15 Iodoacetamide labeling of McbA in McbC-K201A and -Y202A reactions. Reactions 
were carried out with 20 µM MBP-McbA, 1 µM MBP-McbB/D (cyclodehydratase), and 1 µM of 
either WT, K201A or Y202A McbC (dehydrogenase) in synthetase buffer. A reaction lacking 
McbC was also performed as a control. MBP tag removal was performed concurrently with 
cyclodehydration by the addition of 0.02 µg/mL thrombin (from bovine plasma). Following an 
18 h reaction at 25 °C, the samples were C18 ZipTip (Millipore) purified according to the 
manufacturer’s instructions and eluted into 50% acetonitrile in 10 mM MOPS pH 8.0 with 50 
mM iodoacetamide. Labeling proceeded at 25 °C for 8 h before analysis on a Bruker Daltonics 
UltrafleXtreme MALDI-TOF in positive reflector mode with α-cyano-hydroxycinnamic acid 
(CHCA) as the matrix. 
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3.9.16 18O-labeling of TOMM natural products. Purified samples of plantazolicin, 
ulithiacyclamide and lissoclinamide 4 were dissolved in [18O]-H2O to a final concentration of 
250 µg/mL and each sample was acidified via the addition of 1% formic acid. Azoline hydrolysis 
was allowed to proceed for 40 h at 25 °C before the samples were ZipTip desalted and analyzed 
on a Bruker Daltonics UltrafleXtreme MALDI-TOF as described above.  
3.9.17 BalhA1 core cloning. BalhA1core was amplified from the previously prepared pET28-
MBP-BalhA1 vector using the primers listed in table A.1. Polymerase reactions were performed 
with PFU Turbo and the amplified product was digested with BamHI and NotI following gel 
extraction. The digested gene was PCR-purified and ligated into an appropriately digested, 
modified pET28 vector containing a tobacco etch virus (TEV) protease cleavable, N-terminal 
MBP-tag. 
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CHAPTER 4: BIOCHEMICAL AND STRUCTURAL CHARACTERIZATION OF THE 
YCAO SUPERFAMILY 
 
This chapter was taken in part from Dunbar et al.1 and Dunbar & Chekan et al.2 All material is 
reproduced with permission from Nature Publishing Group. 
 
I am grateful to Jonathan Chekan for the Ec-YcaO crystal structure, Courtney Cox for the 
maximum likelihood tree and Cytoscape network, Joel Melby for assistance with collecting 
MS/MS data, and Kelley Taylor for assistance with BalhD mutagenesis. Joel Melby cloned 
BalhNC-CCG*. Jonathan Chekan and Satish Nair generated all crystal structure figures and the 
LigPlot diagram. 
 
Abstract 
 
Despite intensive research, the cyclodehydratase responsible for azoline biogenesis in 
thiazole/oxazole-modified microcin (TOMM) natural products remains enigmatic. The 
collaboration of two proteins, C and D, is required for cyclodehydration. The C protein is 
homologous to E1 ubiquitin-activating enzymes, while the D protein is within the YcaO 
superfamily. Recent studies have demonstrated that TOMM cyclodehydratases phosphorylate 
amide carbonyl oxygens to facilitate azoline formation. Here I present the first experimental 
evidence that the D protein component of the heterocycle-forming synthetase (YcaO/DUF181 
family member), formerly annotated as a docking/scaffolding protein involved in complex 
formation and regulation, is able to perform the ATP-dependent cyclodehydration reaction in the 
absence of the other TOMM biosynthetic proteins. Using an X-ray crystal structure of an 
uncharacterized YcaO from Escherichia coli (Ec-YcaO), I demonstrate that Ec-YcaO harbors an 
unprecedented fold and ATP-binding motif. This motif is conserved among TOMM YcaOs and 
is required for cyclodehydration. By identifying the active site of the TOMM cyclodehydratase, I 
also demonstrate that the proline-rich C-terminus of the D protein is involved in C protein 
recognition and catalysis. Together, these data pave the way for the characterization of the 
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numerous YcaO domains not associated with TOMM biosynthesis and prompt a reclassification 
of the enzymes involved in azoline installation. 
 
4.1 Introduction 
The YcaO/DUF181 (domain of unknown function) family of proteins is currently comprised of 
nearly 5000 members distributed across the bacterial and archaeal domains. Disparate functions 
have been ascribed to members of the YcaO family. In Escherichia coli, the deletion or 
overexpression of the eponymous YcaO protein (Ec-YcaO; Fig. 4.1A) suggested that it 
potentiates the methythiolation of ribosomal protein S12 and influences biofilm formation, 
respectively.3,4 However, a molecular explanation for these observations is currently unavailable. 
Another YcaO-associated activity is the ATP-dependent cyclodehydration of Ser, Thr and Cys 
residues to azoline heterocycles, which is the defining modification of thiazole/oxazole-modified 
microcin (TOMM) natural products (Fig. 1.3).5 TOMMs display diverse structures and 
activities,5,6 with some implicated in bacterial pathogenesis,7 making the ~1000 bioinformatically 
identifiable TOMM YcaO proteins noteworthy members of the larger superfamily. 
 Although the TOMM YcaO domain was first implicated in cyclodehydration reactions in 
the mid-1990s,8 its exact role remains unclear.1,9 The function of the TOMM YcaO (D protein) is 
intimately linked to members of the E1 ubiquitin-activating enzyme family (C protein) found in 
canonical TOMM biosynthetic clusters.8,10,11 Underscoring this linked function, roughly half of 
known TOMM clusters express C and D as a single polypeptide.5,11 Studies on both fused and 
unfused cyclodehydratases have demonstrated that these domains are necessary and sufficient for 
TOMM azoline formation.1,12 Consequently, the C-D complex is referred to as the TOMM 
cyclodehydratase (or alternatively, heterocyclase9,11). However, a definitive function for each 
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domain could not discerned as early studies on multiple TOMM cyclodehydratases were unable 
to observe activity from either protein in isolation.8,10,13  
Despite the challenges in separating the enzymatic activities of the C and D proteins, 
functional assignments have been postulated. Based on the ATP dependence of the reaction14 and 
the primary sequence/structural homology of C to members of the E1 ubiquitin-activating 
superfamily,9-11 which includes other ATP-utilizing enzymes (e.g. MccB, ThiF and MoeB),15 it 
was assumed that C was responsible for cyclodehydration, while the uncharacterized YcaO (D 
protein) played a regulatory or scaffolding role.10,11 On this basis, the D protein has previously 
been referred to as a docking/scaffolding protein.10  
These functional assignments are called into question for two reasons. Firstly, no 
characterized TOMM C protein contains a bioinformatically recognizable nucleotide-binding 
site. Although the D protein from the microcin B17 synthetase has been suggested to be 
responsible for ATP utilization because it contains sequences of weak resemblance to nucleotide 
binding motifs,14 these residues are not conserved in other D proteins, which casts doubt on their 
importance in TOMM biosynthesis. Secondly, although YcaO proteins lack recognizable ATP-
binding motifs, the presence of one or more YcaOs in the bottromycin and trifolitoxin 
biosynthetic clusters, which lack recognizable C proteins, suggests that the TOMM YcaOs may 
perform the requisite ATP-dependent cyclodehydration (Fig. 4.2).16-20  
 Using the highly active TOMM synthetase from Bacillus sp. Al Hakam (Fig. 4.1A), I 
report the first in vitro activity for a member of the YcaO superfamily, and demonstrate that the 
TOMM D protein is an ATP-dependent cyclodehydratase. In collaboration with the Nair 
laboratory, I report the structure of a non-TOMM YcaO from E. coli in various nucleotide-bound 
and nucleotide-free forms and demonstrate that the most conserved residues in YcaOs comprise 
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a previously uncharacterized ATP-binding motif. I show that these ATP-binding residues are 
critical for catalysis in TOMM YcaOs using BalhD as a model cyclodehydratase. I further 
identified the active site of TOMM cyclodehydratases and demonstrated that the conserved, 
proline-rich C-termini are involved in active site organization and C protein binding. These 
results strongly support a model where ATP utilization is a universal feature of YcaOs (TOMM 
and non-TOMM) and where TOMM YcaOs catalyze backbone activation chemistry. 
 
 
Figure 4.1 | YcaO gene clusters and sequence of precursor peptides used in this study. (a) 
The local genomic environment for the E. coli non-TOMM YcaO (Ec-YcaO), E. coli TOMM 
YcaO (Mcb) and the Bacillus sp. Al Hakam TOMM YcaO (BalhD) is depicted along with the 
percent amino acid identity between Ec-YcaO and BalhD. Gene assignments are shown. (b) The 
sequences of the peptide substrates used in this study are shown. Color-coding: green, point 
mutations; orange, residues known to be cyclized in vitro (Balh)21 or in vivo (Mcb);8 blue 
hyphen, putative leader sequence cleavage site; blue caret, known leader sequence cleavage site.8 
The site of the ninth heterocycle installed on the McbA precursor peptide is underlined. This 
figure was adapted from Dunbar & Chekan et al.2 with permission. 
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Figure 4.2 | The biosynthetic gene clusters for trifolitoxin and bottromycin do not contain a 
recognizable TOMM C protein. (a) The gene clusters for bottromycin A2 and trifolitoxin 
biosynthesis are displayed along with the amino acid sequence of the precursor peptide. 
Although each cluster contains at least one YcaO homolog, neither cluster contains a 
recognizable TOMM C protein (homolog of the E1 ubiquitin-activating enzyme superfamily).16-
20 Asterisks indicate the leader and follower peptide cleavage sites on the trifolitoxin and 
bottromycin, respectively. (b) The structure of bottromycin A2 and the partial structure of 
trifolitoxin are displayed. Post-translational modifications presumably installed by the YcaO 
proteins encoded in each cluster are colored blue. The red Xs in in the trifolitoxin structure 
denote an uncharacterized post-translational modification involving Arg and Gln.22 
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4.2 The TOMM D Protein Alone is Sufficient for Azoline Formation 
With the elucidation of the role of ATP in heterocycle formation (see Chapter 2), I sought to 
more precisely assign functions to the individual BalhC and BalhD proteins, which collectively 
comprise the cyclodehydratase (see Fig. 2.2). Given the homology between the C protein, 
previously labeled as the cyclodehydratase, and MccB,9-11 an adenylating protein involved in 
microcin C7 biosynthesis,23 I hypothesized that BalhC catalyzed the direct activation of the 
peptidic substrate. BalhD was suspected to be involved with general substrate handling and 
enzymatic regulation, thus allowing BalhC to perform multiple turnovers. To test these putative 
assignments, I performed a pseudo-single turnover experiment with a stoichiometric amount of 
either BalhC or BalhD and the BalhA1 substrate (see Fig. 4.1B for sequence), under saturating 
ATP. Unexpectedly, no modifications were detected when BalhC alone was added to BalhA1, 
but up to 4 dehydrations (-90 Da) were observed on BalhA1 treated with BalhD alone (Fig. 
4.3A). Subsequent studies showed that these modifications were ATP-dependent (Fig. 4.3A) and 
competent intermediates in the production of the penta-azole product (Fig. 4.3B). Similar 
reactions on substrates containing a reduced number of heterocyclizable residues (BalhNC-C40 
and BalhNC-CCG*; Fig. 4.1B), subjected to either tandem MS spectroscopy or iodoacetamide 
labeling, proved that the BalhD-installed modifications were cyclodehydration products (to yield 
an azoline) and not dehydrations (to yield a dehydroalanine/dehydrobutyrine; Fig. 4.3C and 4.4). 
These data confirmed that BalhD, formerly assigned as a docking/scaffold protein, was necessary 
and sufficient for azoline formation. Importantly, the rate of BalhD-only catalyzed 
heterocyclization was nearly three orders of magnitude slower than when BalhC was present 
(Fig. 4.5). Analysis of the BalhD-only catalyzed reaction products revealed that the ATP/azoline 
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stoichiometric ratio significantly deviated from unity (Fig. 4.6). Thus, I recommend that the term 
cyclodehydratase should be reserved for describing the C-D complex. 
 
 
Figure 4.3 | BalhD is an ATP-dependent cyclodehydratase. (a) MALDI-TOF-MS spectra of 
BalhA1 treated with a stoichiometric amount of either BalhC or BalhD are displayed. For the 
BalhD reaction, a control lacking ATP is also displayed. The numbers indicate the number of 
dehydrations on the substrate. (b) The addition 2 µM BcerB and BalhC to the BalhD-induced 2-
dehydration sample (-36 Da species) showed conversion to mostly a 4-azole species after 2 
hours. A control sample where buffer was added instead of BcerB and BalhC did not show a 
similar modification. Increasing the reaction time to 6 h resulted in complete processing (only 
the penta-azole species was observed at -100 Da, data not shown). (c) MALDI-TOF MS spectra 
of reactions of BalhNC-C40 and BalhD with or without ATP and subsequent labeling with 
iodoacetamide are displayed. All masses are in the +1 charge state. This figure was adapted from 
Dunbar et al.1 with permission. 
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Figure 4.4 | MS/MS localization of the BalhD installed dehydration product. FT-ICR MS 
spectra of the BalhD-induced cyclodehydration product (top). The expected mass for the 5+ 
charge state is shown. The low intensity of the 1-ring species is caused by the rapid hydrolysis of 
the azoline ring in the acidic ESI solution. Note that there is a third species 2 Da lighter than the 
monoisotopic peak of the unmodified substrate (blue). This peak corresponds to the internal 
disulfide adduct. The ppm error for each of these species is displayed next to their respective 
theoretical mass. MS/MS fragmentation of the modified species (bottom). Red ions indicate the 
presence of an 18 Da mass loss indicative of a cyclodehydration. The fragment map indicates 
that the modification has occurred in the immediate vicinity of position 43. In BalhNC-CCG* 
this is Cys40 (red, underlined). 
	  	   113	  
 
Figure 4.5 | BalhC potentiates the BalhD ATPase activity. (a) The addition of BalhA1 
substrate (100 µM) to a sample containing BalhD (15 µM) did not result in a significant increase 
in the rate of ATP hydrolysis as measured by the purine nucleoside phosphorylase (PNP) 
phosphate detection assay. (b) The addition of BalhA1 (100 µM) to BalhC/D (1 µM) resulted in 
robust ATP hydrolysis (compare Y-axis values). Error bars represent the standard deviation from 
the mean (n=3). 
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Figure 4.6 | BalhD ATP/ring stoichiometry is dysregulated in the absence of BalhC. Product 
progress curves are shown for both phosphate (blue diamonds) and azoline heterocycles (red 
squares) at different concentrations of BalhD (a-d). The ATP/azoline stoichiometry at each of 
the time points for all four BalhD concentrations is displayed (e). The graph demonstrates that as 
the reaction progresses, and as the concentration of BalhD is increased, the stoichiometry 
increases significantly. A red box highlights the expected ATP/azoline stoichiometry for the 
BalhD-only 31P-NMR sample and predicts that roughly half of the ATP hydrolyzed will be non-
productive and occur through the action of a solvent nucleophile. If BalhD was able to activate 
the BalhA1 substrate in an identical fashion as the BalhC-BalhD complex, this would correspond 
to a 50:50 ratio of [16O4]-Pi: [18O1,16O3]-Pi when the reaction is carried out in [18O]-water.  
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4.3 TOMM YcaOs Utilize ATP for Amide Backbone Activation 
The discovery that BalhD could independently install azolines on BalhA1 in an ATP-dependent 
manner, but that ATP consumption was dysregulated in the absence of BalhC, led us to 
investigate if BalhD could independently activate the amide backbone of BalhA1. As before, a 
reaction was carried out in [18O]-H2O and the 16O/18O isotopic ratio in the resultant Pi was 
analyzed by 31P-NMR spectroscopy. Samples containing BalhD, BalhA1 and ATP showed a 
significant [16O4]-Pi peak (Fig. 4.7). However, if any of these essential components were omitted, 
[16O4]-Pi was not detectable (Fig. 4.7). While these data clearly demonstrated that BalhD was 
responsible for the amide activation event, the nearly identical heights of the [16O4]-Pi and 
[18O116O3]-Pi NMR signals provided further evidence that ATP consumption was dysregulated in 
the absence of BalhC. Unlike the BalhC-BalhD complex, which had a strong enhancement in the 
rate of ATP hydrolysis upon the addition of BalhA1, the ATPase activity of BalhD remained 
unchanged upon the addition of BalhA1 (Fig. 4.5A). These findings implicate the C protein as a 
potentiator of the D protein, which is the stark opposite of the original assignments.  
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Figure 4.7 | TOMM YcaOs activate carbonyl oxygens with ATP. 31P-NMR spectra of BalhD 
reactions conducted in [18O]-water are displayed. Peak identities were confirmed by spiking the 
samples with authentic [16O4]-Pi. Buffer control, ATP-synthetase buffer alone; precipitation 
control, control in which both BalhA1 and BalhD were precipitated by the addition of 25% 
acetonitrile prior to adding ATP; BalhD control, BalhA1 was omitted from the sample. This 
figure was adapted from Dunbar et al.1 with permission. 
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4.4 Non-TOMM YcaO Proteins Also Utilize ATP 
With the ATP-dependent cyclodehydratase activity of BalhD established, I attempted to locate 
the ATP-binding site in BalhD by 8-azido-ATP crosslinking; however, these experiments were 
unsuccessful. Furthermore, the TruD crystal structure (a CD fusion protein involved in 
trunkamide biosynthesis) did not reveal an obvious ATP-binding site9 and BalhD was refractory 
to numerous crystallization attempts. Attempts to crystallize other TOMM YcaOs were equally 
unsuccessful (see appendix 3). I reasoned that since TOMM YcaOs evolved to interact with their 
cognate C proteins, working with a non-TOMM (with no C protein partner) might alleviate the 
previously encountered challenges. The local genomic environment of Ec-YcaO does not contain 
an E1 homolog (i.e. TOMM C protein, Fig. 4.1A), nor is Ec-YcaO known to interact with an E1 
homolog, making it an attractive candidate for structural and biochemical characterization. Ec-
YcaO was cloned into a tobacco etch virus (TEV) protease-cleavable maltose-binding protein 
(MBP)-fusion vector and expressed in E. coli. While the function of Ec-YcaO was unknown, 
characterized cyclodehydratases hydrolyze ATP in the absence of peptide substrates.1 
Consequently, I measured the ATPase activity of Ec-YcaO using an established purine 
nucleoside phosphorylase assay.24 This assay revealed that Ec-YcaO indeed hydrolyzed ATP, 
preferentially generating AMP and PPi (Fig. 4.8). Although ATP hydrolysis was slow, perhaps 
because the native substrate was not present, Ec-YcaO displayed a KM for ATP of ~80 µM (Fig. 
4.8), comparable to several characterized cyclodehydratases.1,12,14  
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Figure 4.8 | Ec-YcaO hydrolyzes ATP to AMP and pyrophosphate. (a) The ATPase activity 
of Ec-YcaO was screened using the purine nucleoside phosphorylase (PNP)-coupled assay24 with 
and without 1 unit of pyrophosphatase (PPase). The addition of PPase increased the rate of 
chromophore production in the assay by 5-fold after the signal amplification achieved during PPi 
cleavage is taken into account. Error bars represent the standard deviation from the mean (n=3). 
(b) An ATP kinetic curve was obtained for Ec-YcaO using the PPase-supplemented PNP assay. 
Error bars represent the standard deviation from the mean (n=3). Regression analyses to obtain 
Michaelis-Menten kinetic parameters were carried out in IGOR Pro version 6.12 (Wavemetrics). 
The error on the kinetic parameters represents the standard deviation from the curve fitting.  
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4.5 Structural Characterization of ATP-binding in Ec-YcaO 
The structure of nucleotide-free Ec-YcaO (contains a mercurial salt for phasing) was determined 
to a Bragg limit of 2.63 Å and revealed a circularly symmetric homodimer in the asymmetric 
unit. The overall structure consists of an N-terminal YcaO domain of ~400 residues and a 150 
residue C-terminal domain resembling a tetratricopeptide repeat (TPR) that mediates 
dimerization. A structure-based comparison against the PDB revealed similarity solely with 
TruD, the only other solved YcaO structure (RMSD of 3.1 Å over 279 aligned Ca atoms),25 
confirming that YcaOs constitute a new structural fold (Fig. 4.9). To identify the ATP-binding 
site, the structure of Ec-YcaO in complex with multiple nucleotides was also determined. Co-
crystallization of Ec-YcaO with ATP produced an AMP-bound structure (2.25 Å), suggesting 
that in situ hydrolysis had occurred (Fig. 4.10). To clarify the residues involved in ATP binding, 
the co-structure of Ec-YcaO with α, β-methyleneadenosine 5’-triphosphate (AMPCPP, a non-
hydrolyzable ATP analog) was also solved. 
Analysis of the 2.25 Å resolution AMP-bound and 3.29 Å resolution AMPCPP-bound co-
crystal structures revealed that the adenine ring is recognized by Glu191 and Asn187 via 
interactions through the N7 nitrogen and between Ser16 and the exocylic-N6 (Fig. 4.11A). 
Additionally, Lys9 resides above one face of the adenine ring, while Ala70, Ser71, and Gly74 
are found within an α-helix that extends below the adenine and ribose rings, forming a 
hydrophobic surface. The ribose within the AMP- and AMPCPP-bound structures is oriented 
perpendicular to the adenine ring, with Ser184 and Glu78 coordinating the 2’- and 3’-hydroxyls, 
respectively (Fig. 4.11B and C). While Ser71 coordinates the α-phosphate in both structures, 
Arg286 coordinates to the α-phosphate in only the AMP-bound form (Fig. 4.11B and C).  
Surprisingly, two Mg2+ ions are found in the nucleotide-binding pocket in both structures. In the 
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AMP structure, Glu199 and Glu78 ligate one Mg2+ ion while Glu290 and Glu75 bind the second 
(Fig. 4.11B). The Mg2+ ions are coordinated in a similar fashion in the AMPCPP structure with 
the subtle difference that Glu202, rather than Glu75, coordinated the second Mg2+ (Fig. 4.11C). 
This slight change in the coordination of the second Mg2+ ion positions the metal ions on 
opposite sides of the β- and γ-phosphates. Furthermore, Arg203 coordinates the γ-phosphate of 
AMPCPP (Fig. 4.11C). The interactions between Ec-YcaO and AMPCPP are summarized in 
Figure 4.11D. 
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Figure 4.9 | Structural homology between Ec-YcaO and TruD and structure of AMP-
bound Ec-YcaO. (a) Structural alignment of TruD (green) and Ec-YcaO (purple). The 
alignment demonstrates that the ATP-binding region of Ec-YcaO is also conserved in TruD. (b) 
TruD structure with the conserved domain shown in green. (c) Ec-YcaO structure with the 
conserved region shown in purple. 
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Figure 4.10 | Structure of AMP-bound Ec-YcaO. Structure of the Ec-YcaO homodimer with 
one monomer colored in purple (ATP-binding domain) and green (TPR domain) and the other 
monomer colored in gray. AMP is displayed as spheres in both monomers. This figure is adapted 
with permission from Dunbar & Chekan et al.2 
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Figure 4.11 | ATP coordination in Ec-YcaO. Orthogonal views of the Ec-YcaO AMP-bound 
structure in the vicinity of the active site, showing residues responsible for adenine/ribose 
binding (a) and Mg2+/Pi binding (b). AMP and Mg2+ ions are colored cyan and gray, 
respectively. The superimposed difference Fourier maps are contoured at levels of 2.0σ (blue) 
and 8.0σ (red). (c) AMPCPP (cyan) and Mg2+ (grey) bound in the Ec-YcaO active site 
coordinates with superimposed difference Fourier maps contoured at levels of 2.0σ (blue) and 
6.0σ (red). Residues responsible for Pi, ribose and Mg2+ binding are indicated. (d) A ligand 
interaction diagram for the AMPCPP-bound structure is shown. Putative hydrogen bonds are 
displayed in orange with distances indicated, while red arcs denote hydrophobic interactions. 
Due to slight differences in residue orientation in the monomer subunits, only a subset of the 
interactions is displayed for clarity. This figure was adapted with permission from Dunbar & 
Chekan et al.2 
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4.6 The Ec-YcaO ATP-Binding Site is Conserved in TOMM YcaOs  
Utilizing the nucleotide-bound structures of Ec-YcaO, I established the conservation of the ATP-
binding residues across the superfamily. First, a Cytoscape sequence similarity network26 of all 
YcaO members in InterPro (IPR003776) was generated.27 During assembly, redundant sequences 
were removed, leaving ~2000 sequences in the network. While the sequence of TOMM 
precursor peptide dictates the structure of the natural product, there is also a strong correlation 
between TOMM structure and the sequence similarity of the cognate YcaO.5 For the network, all 
YcaO sequences were manually annotated based on neighboring genes. YcaOs were categorized 
as being involved in TOMM biosynthesis if there was a gene encoding for a recognizable C 
protein in the local region (~10 kb on either side of the ycaO gene) or if the protein had an 
experimentally verified link to a known TOMM (e.g. bottromycin16-19 and trifolitoxin20). The 
remaining YcaOs were separated into two other categories, non-TOMM YcaOs (e.g. Ec-YcaO) 
and TfuA-associated non-TOMM YcaOs. The latter were found within 10 kb of a gene encoding 
for the protein TfuA, which is implicated in trifolitoxin biosynthesis.28 Whenever possible, 
TOMM YcaOs were further subdivided by expected structural class. Based on these 
classifications, I determined that an expectation value of 10-80 gave an optimal separation of 
YcaO sequences into isofunctional clusters (Fig. 4.12).  
Using the sequence similarity network as a guide, 349 of the ~2000 members in the non-
redundant network were selected from across all clusters and a maximum likelihood tree was 
generated (Fig. 4.13A). Among the 349 were all singletons, defined as divergent family members 
not grouping with any other YcaO at an e-value of 10-80. Using this diversity-maximized tree, a 
sequence logo for each of the regions involved in ATP binding was generated using WebLogo 
(Fig. 4.13B).29 The logos clearly demonstrate that the ATP-binding pocket is highly conserved in 
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the YcaO family across all three groups (i.e. TOMM, non-TOMM, and TfuA-associated non-
TOMM).  The ATP-binding residues were found to be the most conserved feature in the YcaO 
superfamily (Fig. 4.13C). This is in stark contrast to TOMM C proteins, which do not harbor the 
ATP-binding residues conserved in all characterized non-TOMM E1 ubiquitin-activating 
superfamily members (Fig. 4.14).15 Furthermore, the conservation in the YcaO ATP-binding 
residues is maintained in all characterized TOMMs (Fig. 4.15), suggesting that the previously 
reported carbonyl activation mechanism is likely a universal biosynthetic feature.1,30  
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Figure 4.12 | Cytoscape sequence similarity network for the YcaO superfamily. A similarity 
network for non-redundant YcaO sequences is displayed. Each node represents a unique YcaO, 
while lines between nodes exist if the proteins bear significant similarity (in this case, a BLAST 
expectation value lower than 10-80). At this e-value, YcaO proteins from characterized TOMM 
biosynthetic clusters primarily form isofunctional clusters. TOMM YcaOs are defined as having 
a bioinformatically identifiable C protein within 10 kb of the YcaO protein. Stand-alone TOMM 
YcaOs are proteins found in a characterized TOMM biosynthetic clusters that lack a C protein 
(e.g. bottromycin and trifolitoxin). It is noteworthy that many non-TOMM YcaOs appear to exist 
in RiPP biosynthetic gene clusters, indicating that additional stand-alone YcaO 
cyclodehydratases may exist. Nodes are colored according to the legend and the clusters 
containing Ec-YcaO and BalhD are indicated. 
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Figure 4.13 | Conservation of the Ec-YcaO ATP-binding residues in the superfamily. (a) A 
diversity-maximized tree for the YcaO superfamily is displayed. Red asterisks denote YcaOs 
associated with clusters of functionally or structurally characterized natural products, while the 
proteins used in this study are circled and colored blue. (b) WebLogo frequency plots for the 
ATP- and Mg2+-binding residues of YcaO domains for each subclass (TOMM, non-TOMM, 
TfuA non-TOMM). Due to the high level of diversity in the sequences, WebLogos for the N-
terminal ATP-binding residues were not generated. The ATP-binding motif identified in Ec-
YcaO is displayed above each of the ATP-binding regions with the number representing the 
residue in Ec-YcaO, and conserved residues colored orange. (c) YcaO superfamily sequence 
conservation was mapped onto the structure of Ec-YcaO, which highlights strong conservation 
of the ATP-binding region. This figure is adapted with permission from Dunbar & Chekan et al.2 
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Figure 4.14 | The canonical E1 domain ATP-binding site is not conserved in TOMM C 
proteins. Alignments of TOMM C proteins associated with cyanobactin biosynthesis to E. coli 
MoeB, ThiF and MccB are displayed. Residues responsible for ATP- and Mg2+-binding in E1 
superfamily members were identified in the nucleotide-bound crystal structures for the following 
E1 superfamily members: ThiF (1ZFN), MoeB (1JWA), and MccB (3H5N). The ATP- and 
Mg2+- binding residues identified in these crystal structures were highlighted in orange. The two 
CxxC motifs responsible for coordination of the structural Zn2+ found in all characterized E1 
ubiquitin-activating family members are highlighted in blue.10,15,31 To improve the alignments, 
the highly variable N-terminal “peptide clamp” domain found in MccB homologs was manually 
removed. Similarly, the highly variable N-terminal residues of each C protein and the YcaO 
domain of each CD fusion were removed. While non-TOMM E1 sequences are identified by GI 
number and the subclass of the E1 superfamily they belong to, TOMM E1 sequences are 
identified by the natural product they produce. 
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Figure 4.15 | The ATP-binding pocket is conserved in characterized TOMM YcaOs. 
WebLogo frequency plots of all of the YcaO sequences from the indicated TOMM subclasses 
are displayed. The ATP-binding motif identified in Ec-YcaO is displayed above each of the 
ATP-binding regions. Residues that are similar to the ATP-binding motif identified in Ec-YcaO 
are colored orange. Due to the high level of diversity in the sequences, WebLogos for the N-
terminal ATP-binding residues could not be generated. The number of sequences represented in 
each WebLogo is displayed in parentheses. 
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4.7 The Ec-YcaO ATP-Binding Site is Vital for BalhD Cyclodehydratase Activity 
Because the native substrate of Ec-YcaO is unknown, I validated the ATP-binding residues by 
conducting structure-function studies on BalhD. An alignment of BalhD and Ec-YcaO permitted 
the mapping of the nucleotide- and Mg2+-binding residues onto BalhD (Fig. 4.16). Subsequently, 
an alanine mutagenesis scan was performed on the polar residues of BalhD predicted to bind 
ATP. Every mutation was well tolerated in terms of protein yield/stability. The effect on 
heterocycle formation on BalhA1 (the peptide substrate) by the mutant BalhD proteins, in the 
presence of BalhC, was monitored in a 16 h endpoint assay (Fig. 4.16). Of the 11 mutated 
residues in the ATP-binding pocket, four were able to convert BalhA1 to the previously reported 
penta-azoline species,1 three showed intermediate levels of processing (2-4 heterocycles), while 
the remaining four generated no heterocyclic products within the limit of detection (Table 4.1). 
To quantify the effect of each mutation to BalhC/D activity, the rate of ATP hydrolysis was 
monitored using the KM concentration of BalhA1 (15 µM) and a concentration of ATP that 
would be saturating for wild-type BalhD (3 mM). Mutants unable to cyclize BalhA1, even after 
extended reaction times, displayed no detectable ATP hydrolysis over the assay background (Fig. 
4.17). Likewise, mutants that installed five azolines on BalhA1 in the endpoint assay had the 
highest ATP hydrolysis rates. These data are consistent with my earlier work showing that ATP 
hydrolysis is tightly coupled to heterocycle formation.1 The YcaO mutations examined here did 
not appear to disrupt this feature of TOMM cyclodehydration. 
While mutation of the BalhD ATP-binding pocket reduced cyclodehydratase activity, an 
alternative interpretation of the above data could be that these mutations interfered with the 
association of BalhC and BalhD. A unique feature of the Balh cyclodehydratase is that BalhD is 
catalytically active in the absence of BalhC.1 This permitted the use of BalhD-only activity 
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measurements to determine if the alanine mutations affected the intrinsic cyclodehydratase 
activity. Heterocycle formation endpoint assays (16 h) were again conducted, but this time with 
50 µM BalhA1 and 25 µM BalhD mutant to account for the expected ~103 drop in catalytic 
activity in the absence of BalhC.1 The resultant mass spectra confirmed that the decrease in 
cyclodehydration arose from a perturbation in BalhD activity (Table 4. 2 and Fig. 4.18).  
 For all BalhD mutants with measureable cyclodehydratase activity, I obtained the 
Michaelis-Menten kinetic parameters for BalhA1 and ATP (Table 4.1 and Fig. 4.19). Every 
mutation negatively affected the observed kcat (kobs), indicating that the selected residues were of 
catalytic importance. Apart from K281A, and to a lesser extent S72A, all ATP-binding site 
mutations of BalhD substantially increased the KM for ATP. In contrast, the only mutant in this 
series to substantially raise the KM for BalhA1 was R198A (Table 4.1). 
Four BalhD mutants (i.e. E76A, E79A, E194A, E197A) did not exhibit detectable 
cyclodehydratase activity. Potential explanations include an inability to bind the substrates 
(BalhA1 and/or ATP), hydrolyze ATP, or a structural perturbation with these mutants. Previous 
work demonstrated that BalhC and BalhD hydrolyze ATP slowly in the absence of BalhA1.1 In 
reactions with wild-type BalhD, addition of BalhC increases the rate of ATP hydrolysis by 2.5-
fold over an additive rate of both proteins; however, when the four inactive mutants were 
assayed, no potentiation was observed (Fig. 4.20). This suggested that the lack of BalhD activity 
was due to a structural perturbation or the inability to bind/hydrolyze ATP. Unfortunately, 
attempts to directly measure ATP binding or a secondary structure perturbation of BalhD with 
isothermal titration calorimetry or circular dichroism spectroscopy, respectively, were 
problematic owing to the solubility characteristics of BalhD. However, I reasoned that the latter 
could be assayed indirectly by monitoring the interaction between BalhC and a mutant BalhD 
	  	   132	  
through a competition assay and size-exclusion chromatography. While all of the BalhD mutants 
were able to associate with the BalhC (Fig. 4.21), E76A and E194A did so with reduced affinity, 
suggesting that these mutations affected the BalhC-BalhD interaction surface. Conversely, the 
wild-type-like affinity that BalhD E79A and E197A displayed for BalhC suggested that these 
mutants were inactive due to inability to bind/hydrolyze ATP.  
 
Table 4.1 | Mutations to the ATP-binding pocket of BalhD decrease cyclodehydratase 
activity. a% processing = (5⋅P5 + 4⋅P4 + 3⋅P3 + 2⋅P2 + 1⋅P1)/(5); where Px is the percentage of the 
substrate with x number of azolines. The number of heterocycles formed in the assay is listed in 
parentheses. bApparent KM. cNot determined. Error on the Michaelis-Menten parameters 
represents the standard deviation from the regression analysis.  
 
 
 
 
      Ring Formationa                 BalhA1 Kinetics                    ATP Kinetics
Mutation CD D-only kobs,  min-1 KM, µMb kobs/KM, M-1 s-1 kobs,  min-1 KM, µMb kobs/KM, M-1 s-1
WT (5); 100% (2-3); 45% 12.9 ± 0.4 16 ± 2 13000 12.2 ± 0.3 240 ± 20 850
S72A (5); 100% (2); 40% 8.3 ± 0.2 11 ± 1 12500 8.0 ± 0.4 360 ± 60 370
E76A (0); 0% (0); 0% n.d.c n.d.c n.d.c n.d.c n.d.c n.d.c
E79A (0); 0% (0); 0% n.d.c n.d.c n.d.c n.d.c n.d.c n.d.c
R80A (2-4); 63% (0-1); 10% 0.79 ± 0.05 16 ± 5 823 0.88 ± 0.02 620 ± 50 24
Q186A (5); 100% (0-2); 10% 3.9 ± 0.1 12 ± 1 5400 7.5 ± 0.3 2500 ± 200 50
N190A (5); 100% (0-2);15% 5.1 ± 0.2 27 ± 3 3150 4.7 ± 0.2 920 ± 110 85
E194A (0); 0% (0); 0% n.d.c n.d.c n.d.c n.d.c n.d.c n.d.c
E197A (0); 0% (0); 0% n.d.c n.d.c n.d.c n.d.c n.d.c n.d.c
R198A (2-4); 40% (0); 0% 3.3 ± 0.2 50 ± 8 1100 2.4 ± 0.2 760 ± 65 52
K281A (5); 100% (2-3); 45% 7.9 ± 0.2 16 ± 2 8200 6.1 ± 0.1 230 ± 20 440
E286A (2-4); 64% (0); 0% 0.49 ± 0.03 27 ± 3 272 0.42 ± 0.01 1200 ± 100 6
	  	   133	  
 
 
 
Figure 4.16 | Mapping ATP-binding residues from Ec-YcaO to BalhD. Structure-based 
sequence alignment of YcaO domain-containing proteins with the secondary structure of Ec-
YcaO superimposed. Residues mutated in BalhD for this study are denoted by black triangles. A 
summary of the BalhD mutants made, along with their predicted roles in ATP recognition is 
provided. This figure was adapted with permission from Dunbar & Chekan et al.2 
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Figure 4.17 | Mutations to the BalhD ATP-binding site affect heterocycle formation. (a) A 
MALDI-TOF MS spectral overlay for BalhA1 treated with BalhC and either wild-type (WT) or 
mutant BalhD is displayed. The level of processing is summarized in Table 4.1. †, laser-induced 
deamination. A loss of 90 Da indicates the formation of 5 azolines, a full in vitro processed 
BalhA1 substrate.21 (b) The rate of ATP hydrolysis was measured with BalhC and either wild-
type (WT) or mutant BalhD using the PNP assay. Error represents the standard deviation from 
the mean (n ≥ 3). 
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Figure 4.18 | Mutations to the ATP-binding site that decrease cyclodehydratase activity 
also affect BalhD-only activity. MALDI-TOF MS spectra for BalhA1 treated with wild-type 
(WT) or mutant BalhD is displayed. Apart from BalhD S72A, all of the mutants displayed a 
decreased level of D-only processing consistent with the rate of ATP hydrolysis measured in the 
presence of the C protein. The level of processing is summarized in Table 4.1. †, laser-induced 
deamination. 
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Figure 4.19 | The KM for ATP does not depend on the concentration of BalhA1. Due to 
solubility limitations, saturating concentrations of BalhA1 were not obtainable for all of the 
BalhD mutants. To determine if the KM for ATP changed at non-saturating concentrations of 
BalhA1, an ATP kinetic curve was carried out at the KM for BalhA1 (15 µM). The resultant KM is 
within error of the previously reported KM for ATP, 240 ± 20 µM, obtained with a saturating 
concentration of BalhA1.1 Error on the Michaelis-Menten parameters represents the standard 
deviation from the regression analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20 | Mutations of the Mg2+-binding residues prevent ATPase potentiation by 
BalhC. The background ATP hydrolysis rate of mutant BalhD proteins lacking the ability to 
modify BalhA1 was measured with and without BalhC using the PNP assay. Although the 
ATPase activity of wild-type BalhD was potentiated 2.5-fold by the addition of BalhC, none of 
the mutants displayed similar increases in ATP hydrolysis. For reactions with BalhC, the 
horizontal lines indicate the expected rate of ATP hydrolysis after accounting for the slight 
ATPase rate of BalhC Error bars represent the standard deviation to the mean (n > 3). 
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Figure 4.21 | Effect of the ATP-binding site mutations on BalhC binding. (a) Size-exclusion 
chromatography was used to monitor the effect the ATP-binding site mutations had on complex 
formation. Although BalhD retained as a monomer (3), BalhC had a retention volume consistent 
with a dimer (2). When the proteins were mixed, the intensity of the BalhC dimer peak decreased 
and a new peak corresponding to the BalhC/D complex appeared (1). Absorbance values were 
normalized to the peak at ~3.5 mL. (b) To better quantify the BalhC binding affinity of the 
mutant BalhD proteins, ATP hydrolysis rates were monitored for wild-type cyclodehydratase 
reactions with the addition of variable concentrations of inactive BalhD mutants. As the reactions 
were carried out with 1 µM wild-type BalhD, mutants with an unperturbed BalhC interaction 
would display IC50 values of approximately 1 µM. Error bars represent the standard deviation 
from the mean (n ≥ 3). Regression analysis to determine the IC50 values for each inhibition curve 
was determined in IGOR Pro version 6.12 (Wavemetrics). The error on the IC50 values 
represents the standard deviation from the curve fitting. 
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4.8 The Proline-Rich C-terminus of TOMM YcaOs Affects C Protein Binding and Catalysis 
In addition to the conserved ATP-binding site, TOMM YcaO proteins have a highly conserved, 
proline-rich C-terminus. In the most pronounced cases, the final five residues of the YcaO are 
PxPxP (Fig. 4.22).10 The proline-rich C-terminus is not conserved in non-TOMM or TfuA-
associated YcaO domains (Fig. 4.22), implicating the motif in either C protein recognition or 
cyclodehydratase activity. This hypothesis is supported by the observation that the C-terminus of 
TruD is in close proximity to the YcaO ATP-binding site and is surface-accessible (Fig. 4.22). I 
first interrogated the importance of this motif by truncating 5 residues from the BalhD C-
terminus. This minor perturbation abolished the catalytic activity of BalhC/D (Table 4.2 and Fig. 
23). Removing the C-terminal three residues of BalhD produced an identical result, while 
removal of the C-terminal residue of BalhD (BalhD P429*; * stop codon) decreased activity by > 
100-fold (Table 4.2 and Fig. 4.23). Similarly, extending the C-terminus by a single amino acid 
(BalhD PxPxPG), or deleting two amino acids upstream of the PxPxP motif (BalhD ∆418-419), 
also resulted in inactive cyclodehydratases (Table 4.2 and Fig. 4.23). 
 To establish if altering the BalhD C-terminus affected the interaction with BalhC, I 
assessed the ability of BalhC to potentiate the background ATPase activity of BalhD mutants 
lacking detectable activity. Potentiation was not observed in any case (Fig. 4.24), indicating that 
mutants of the BalhD PxPxP motif had lost the ability to bind/hydrolyze ATP or to bind BalhC. I 
next assessed the ability of select PxPxP mutants to bind BalhC. Utilizing a combination of size-
exclusion chromatography and a competition assay, all truncations to the BalhD PxPxP motif 
were shown to have decreased affinity to BalhC (Fig. 4.25). Moreover, the order of heterocycle 
formation was dysregulated in BalhD P429*, reminiscent of wild-type BalhD reactions lacking 
BalhC (Fig. 4.26; see Chapter 5).30  
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 Intrigued by the loss of activity observed upon extending or truncating the C-terminus, I 
next investigated the importance of the amino acid composition of the BalhD PxPxP motif 
(PHPFP429). As with the truncations, any mutation to the C-terminal 5 residues of BalhD 
decreased cyclodehydratase activity (Table 4.2 and Fig. 4.27). The decrease in activity ranged 
from ~2.5-fold (P429G) to 100-fold (H426A), with the severity diminishing the closer the 
mutation was to the C-terminus. This result was consistent with the observation that the C-
terminal residues of TruD are located in a channel leading to the active site. As with the PxPxP 
truncations, every mutant tested, apart from F428A, displayed a decreased affinity for BalhC 
(Fig. 4.28). Consistent with this observation, mutation of the terminal amino acid (P429G) 
resulted in an aberrant order of heterocycle formation (Fig. 4.29). Increasing the flexibility of the 
PHPFP motif, by substituting it with GHGFG, yielded an inactive cyclodehydratase (Table 4.2 
and Fig. 4.27).  
 While these results implicated the C-terminus of BalhD in BalhC recognition, a decrease 
in BalhC affinity could not explain the data in its entirety. For example, both BalhD P425* and 
P429* displayed reduced interactions with BalhC, but only P425* was catalytically inactive 
(Table 4.2 and Fig. 4.25). Furthermore, BalhD PxPxPG displayed a wild-type level of interaction 
with BalhC, despite being catalytically inactive. Based on these results, the activity of each 
mutant was tested in the absence of BalhC. Analogous to the mutations to the ATP-binding 
pocket, mutations to the PxPxP motif affected the intrinsic activity of BalhD (Fig. 4.30). For all 
tractable BalhD mutants, BalhA1 and ATP Michaelis-Menten kinetic curves were obtained for 
the mutant BalhC-D complexes. While the largest effects were on kobs, the mutations also 
affected the KM for ATP and BalhA1 (Table 4.2). Unlike the ATP-binding mutants, the changes 
to KM for the two substrates were similar in the PxPxP mutants, suggesting that the C-terminus is 
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involved in active site organization/catalysis, not substrate binding. Furthermore, the importance 
of the YcaO C-terminus appears to be general for TOMM biosynthesis, given that the 
cyclodehydratase activity of McbD (microcin B17 YcaO protein) was also abolished when the 
C-terminus was truncated (Fig. 4.31).  
 
Table 4.2 | Mutations to the C-terminus of BalhD disrupt catalysis. a% processing = (5⋅P5 + 
4⋅P4 + 3⋅P3 + 2⋅P2 + 1⋅P1)/(5); where Px is the percentage of the substrate with x number of 
azolines. The number of heterocycles formed in the assay is listed in parentheses. bApparent KM. 
cNot determined. *, stop codon; ∆2 AA, BalhD (∆A418, ∆K419).  Error on the Michaelis-
Menten parameters represents the standard deviation from the regression analysis.  
 
 
      Ring Formationa                       BalhA1 Kinetics                       ATP Kinetics
Mutation D-only C+D kobs, min-1 KM, µMb kobs/KM, M-1 s-1 kobs, min-1 KM, µMb kobs/KM, M-1 s-1
WT (1-3); 45% (5); 100% 12.9 ± 0.4 16 ± 2 13 x 103 12.2 ± 0.3 240 ± 20 8.5 x 102
P425* (0); 0% (0); 0% n.d.c n.d.c n.d.c n.d.c n.d.c n.d.c
P427* (0); 0% (0); 0% n.d.c n.d.c n.d.c n.d.c n.d.c n.d.c
P429* (0); 0% (1-2); 36%  0.19 ± 0.03 80 ± 20 31 0.21 ±  0.05 110 ± 10 32
Δ2 AA (0); 0% (0); 0% n.d.c n.d.c n.d.c n.d.c n.d.c n.d.c
PxPxPG (0); 0% (0); 0% n.d.c n.d.c n.d.c n.d.c n.d.c n.d.c
H426A (0); 0% (0-2); 25% n.d.c n.d.c n.d.c n.d.c n.d.c n.d.c
P427G (0); 0% (3-5); 80% 0.43 ± 0.04 35 ± 8 204 0.41 ± 0.02 700 ± 100 10
F428A (0); 0% (3-4); 80% 0.70 ± 0.02 22 ± 2 530 0.69 ± 0.03 480 ± 60 24
P429G (0-2); 6% (4); 80% 4.7 ± 0.1 14 ± 1 5.6 x 103 5.0 ± 0.1 75 ± 4 1.1 x 103
GxGxG (0); 0% (0-3); 45% n.d.c n.d.c n.d.c n.d.c n.d.c n.d.c
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Figure 4.22 | The C-terminal PxPxP motif conserved in TOMM YcaOs is near the ATP-
binding site in TruD. (a) Alignment of C-termini of select TOMM YcaO proteins. Prolines are 
colored blue and CD fusion proteins are underlined. Numbers denote the location of the residue 
in BalhD. McbD: microcin B17, SagD: streptolysin S, TruD: trunkamide, BalhD: Bacillus sp Al 
Hakam, Pzn: plantazolicin, TsrH: thiostrepton (b) Graphs displaying the proline content of the 
C-terminus of all members of the YcaO superfamily (TOMM and non-TOMM) are shown. (c) 
The structure TruD9 (PDB code 4BS9) is displayed. Residues implicated in ATP-binding are 
colored cyan while the PxPxP motif is colored orange. A zoom in of the YcaO active site (red 
circle) is displayed in panel d. The C-terminus of TruD is proximal (<8 Å) to the conserved 
ExxERD and RxxE motifs. 
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Figure 4.23 | The PxPxP motif of BalhD is critical for cyclodehydratase activity. (a) A 
MALDI-TOF MS spectral overlay for BalhA1 treated with BalhC and either wild-type (WT) or 
mutant BalhD is displayed. The level of processing is summarized in Table 4.2. (b) The rate of 
ATP hydrolysis was measured with BalhC and either wild-type (WT) or mutant BalhD using the 
PNP assay. Error represents the standard deviation from the mean (n ≥ 3). *, stop codons; †, 
laser-induced deamination; ∆2 AA, BalhD (∆A418, ∆K419). 
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Figure 4.24 | Mutations that relocate the C-terminus of BalhD prevent ATPase potentiation 
by BalhC. The background ATP hydrolysis rate of BalhD C-terminus mutants lacking the ability 
to modify BalhA1 was measured with and without BalhC. Although the mutants displayed a 
higher rate of ATP hydrolysis than wild-type BalhD, none of the mutants could be potentiated by 
the addition of BalhC (P > 0.1). Error bars represent the standard deviation to the mean (n ≥ 3). 
For reactions with BalhC, the horizontal lines indicate the expected rate of ATP hydrolysis after 
accounting for the slight ATPase rate of BalhC. *, stop codons; ∆2 AA, BalhD (∆A418, ∆K419). 
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Figure 4.25 | C-terminal truncations of BalhD affect BalhC binding. (a) Size-exclusion 
chromatography was used to monitor the effect the C-terminal truncations had on complex 
formation. Although BalhD retained as a monomer (3), BalhC had a retention volume consistent 
with a dimer (2). When the proteins were mixed, the intensity of the BalhC dimer peak decreased 
and a new peak corresponding to the BalhC/D complex appeared (1). Absorbance values were 
normalized to the peak at ~3.5 mL. (b) ATP hydrolysis rates were monitored for wild-type 
cyclodehydratase reactions with the addition of variable concentrations of a C-terminal BalhD 
truncated protein. As the reactions were carried out with 1 µM wild-type BalhD, mutants with an 
unperturbed BalhC interaction would display IC50 values of approximately 1 µM. *, stop codon. 
Error bars represent the standard deviation from the mean (n ≥ 3). Regression analysis to 
determine the IC50 values for each inhibition curve was determined in IGOR Pro version 6.12 
(Wavemetrics). The error on the IC50 values represents the standard deviation from the curve 
fitting.  
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Figure 4.26 | Removal of the C-terminal residue of BalhD dysregulates the order of azole 
formation. BalhA1 was treated with BcerB, BalhC, and BalhD P429* for 16 h at 25 ˚C. (a) A 
high-resolution, intact mass spectrum of the processed substrate is displayed. The error (ppm) 
associated with each measurement from the calculated m/z is shown. (b) MS/MS fragmentation 
of the 0, 1 and 2 ring species was performed and the resultant fragmentation maps are displayed. 
The b- and y-ions are colored based on the number of azoles in the fragment (black = 0, orange = 
1, purple = 2). Stars indicate the location of the azole heterocycles. In the di-azole species, the 
second heterocycle is found at both Cys45 and Cys31. The MS/MS spectrum for the di-azole 
species is shown in (c). Cys45 is the penultimate residue cyclized by a wild-type Balh 
cyclodehydratase.21,32 As such, these data indicate that the ring order of the complex has been 
perturbed in the P429* mutant. 
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Figure 4.27 | Mutagenesis of the C-terminus of BalhD affects cyclodehydratase activity. (a) 
MALDI-TOF MS spectra for BalhA1 treated with BalhC and either wild-type (WT) or mutant 
BalhD are displayed. These data indicate that the sequence of the C-terminus of BalhD is critical 
for cyclodehydratase activity. The level of processing is summarized in Table 4.2. (b) The rate of 
ATP hydrolysis was measured with BalhC and either wild-type (WT) or mutant BalhD using the 
PNP assay. Error represents the standard deviation from the mean (n ≥ 3). These data provided 
further evidence that the C-terminal residues of BalhD are critical for cyclodehydratase activity. 
†, laser-induced deamination. The wild-type sequence for the C-terminal PxPxP is 425PHPFP429. 
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Figure 4.28 | The sequence of the C-terminus of BalhD is important for binding BalhC. (a) 
Size-exclusion chromatography was used to monitor the effect the C-terminal mutations had on 
complex formation. Although BalhD retained as a monomer (3), BalhC had a retention volume 
consistent with a dimer (2). When the proteins were mixed, the intensity of the BalhC dimer peak 
decreased and a new peak corresponding to the BalhC/D complex appeared (1). Absorbance 
values were normalized to the peak at ~3.5 mL. (b) ATP hydrolysis rates were monitored for 
wild-type cyclodehydratase reactions with the addition of variable concentrations of a 
catalytically deficient BalhD mutant. As the reactions were carried out with 1 µM wild-type 
BalhD, mutants with an unperturbed BalhC interaction would display IC50 values of 
approximately 1 µM. All of the BalhD mutants had a disrupted BalhC affinity. (c) As the 
competition assay is only compatible with BalhD mutations displaying almost no activity, the 
interaction between F428A and P429G could not be determined with this assay. For these active 
mutants, the interaction between BalhC and mutant BalhD was interrogated by measuring an 
apparent “KM” for BalhC. A BalhC “KM” was obtained by holding the concentration of mutant 
BalhD and BalhA1 constant and adding variable concentrations of BalhC. The rate of processing 
was monitored using the PNP-phosphate detection assay. For clarity, the initial processing rates 
were normalized to the rate obtained with a 1:1 ratio of BalhC and mutant BalhD. Together, 
these data indicated that the prolines in the PxPxP motif are more important for BalhC 
recognition than the intervening “x” residues and that residues closer to the active site (more C-
terminal) are less important for BalhC binding. Error bars represent the standard deviation from 
the mean (n ≥ 3). Regression analysis to determine the IC50 and KM values for each inhibition 
curve was determined in IGOR Pro version 6.12 (Wavemetrics). The error on the IC50 and KM 
values represents the standard deviation from the curve fitting.  
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Figure 4.29 | BalhD P429G displays an altered order of heterocycle formation. Although 
BalhD P429G had an initial rate of substrate processing that is 1/3 of wild-type BalhD, the 
mutant produced primarily a tetra-ring species following a 16 h reaction. Based on the aberrant 
ring order observed in BalhD P429* reactions, I hypothesized that the inability to generate the 
penta-azole species could be due to perturbation of ring order. To locate the sites of 
heterocyclization, BalhA1 was treated with BcerB, BalhC, and BalhD P429G for 16 h at 25 ˚C. 
(a) A high-resolution, intact mass spectrum of the processed substrate is displayed. The error 
(ppm) associated with each measurement from the calculated m/z is shown. (b) MS/MS 
fragmentation of the 5, 4 and 3 ring species was performed and the resultant fragmentation maps 
are displayed. The b- and y-ions are colored based on the number of azoles heterocycles in the 
fragment (black = 0, orange = 1, purple = 2, blue = 3, pink = 4, green = 5). Stars indicate the 
location of the azoles. In the tri-azole species, the third heterocycle was found at both Cys45 and 
Cys34. The MS/MS spectrum for the tri-azole species is shown in (c). Based on the b- and y-ion 
intensities, both positions appeared to be cyclized to approximately the same extent. In wild-type 
reactions, the tri-azole species has rings at Cys31, Cys34, and Cys40.21,32 The deviation from the 
wild-type processing order was not observed in the tetra- or penta-azole species. Although less 
severe than the dysregulation in cyclization order found with BalhD P429*-treated BalhA1, the 
identification of partial processing at Cys45 in the tri-azole species suggested that the BalhC/D 
interaction was perturbed.  
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Figure 4.30 | Mutations to the C-terminus of BalhD also affect BalhC-independent catalysis. 
A MALDI-TOF MS spectral overlay for BalhA1 treated with either wild-type (WT) or mutant 
BalhD is displayed. Only BalhD P429G showed detectable levels of azoline formation. These 
data indicated that the C-terminus of BalhD is important for catalysis in addition to BalhC 
recognition. The level of processing is summarized in Table 2. *, stop codon; †, laser-induced 
deamination; ∆2 AA, BalhD ∆A418-K419. 
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Figure 4.31 | The conserved TOMM YcaO C-terminus is critical for activity in the microcin 
B17 cyclodehydratase. A MALDI-TOF MS spectral overlay for McbA treated with McbB/C 
and either wild-type (WT) or mutant McbD lacking the C-terminal 5 amino acids is displayed. *, 
stop codon; †, laser-induced deamination. 
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4.9 Summary and Outlook 
While previous studies on fused C-D proteins implicated the YcaO/DUF181 domain in the 
cyclodehydration reaction, the exact role of the D domain in this complex was never elucidated. 
Besides the TOMM D protein, only one other YcaO/DUF181 family member has had a 
biological function reported. A recent study linked the function of E. coli YcaO to ribosomal 
methylthiolation, but did not reveal any mechanistic details or physiological ramifications of this 
process.3 Thus, these data assign the first definitive function to a member of this uncharacterized 
protein family and necessitates a reclassification of the roles of the C/D proteins.  
I have discovered that Ec-YcaO contains a novel ATP-binding fold. Based on steric and 
electrostatic complimentary requirements, the YcaO strategy for binding ATP is reminiscent of 
other structurally characterized ATP-binding proteins. For example, the Lys/α-helix “sandwich” 
involved in adenine recognition is similar to the conserved Arg and Gly motif found in class I 
amino acyl tRNA synthetases.33 Furthermore, select members of the ATP-grasp and PurM 
families have been shown to bind ATP through the use of multiple divalent cations;34,35 however, 
in these proteins, the Mg2+ ions are coordinated to all three phosphates, not just the β- and γ-
phosphates. Since these similarities in ATP-binding occur despite a lack of structural and 
primary homology between YcaO and all other known ATP-binding proteins, this represents an 
example of convergent evolution in ATP-binding domains.  
The ATP-binding residues are the most highly conserved motifs in the YcaO superfamily 
and, appropriately, represent a prominent signature for the hidden Markov model that 
bioinformatically defines the YcaO/DUF181 family (IPR003776). The extensive bioinformatics 
analysis, X-ray crystallographic data on Ec-YcaO, and biochemical characterization of BalhD 
presented in this report confirm that ATP-utilization is a conserved feature in the superfamily. In 
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spite of the low level of overall similarity between Ec-YcaO and BalhD, I was able to 
demonstrate that the YcaO ATP-binding motif was critical for cyclodehydratase activity. While 
the mutations affected BalhD activity to differing extents, the impact of mutating a particular 
residue on Balh cyclodehydratase activity was proportional to the level of conservation within 
the YcaO family (Fig. 4.13B).  
During my analysis of the YcaO ATP-binding motif, I observed a striking difference 
between the TOMM and non-TOMM YcaO domains. TOMM YcaOs (D proteins) almost 
invariably harbor proline-rich C-termini, with PxPxP most often serving as the terminal five 
residues of the protein. While the widespread nature of the PxPxP motif had been previously 
recognized10, prior to this work, it was unclear if this motif played any role in TOMM 
biogenesis. My data indicate that the C-terminus of TOMM YcaOs assists in both C protein 
recognition and cyclodehydration. It is rare for the C-terminus of an enzyme to be important for 
catalysis.36-40 In fact, the terminal regions are often highly sequence variable within a protein 
family. Intriguingly, the C-terminal proline content of a YcaO protein has powerful predictive 
value. If present, the YcaO is quite probably involved in TOMM biosynthesis. This tentative 
assignment can be confidently made even without knowledge of the flanking genes. As such, I 
hypothesize that a subset of the 249 (~8%) non-TOMM YcaOs that contain a proline-rich C-
terminus may actually be stand-alone TOMM YcaOs (akin to the bottomycin YcaOs). 
In addition to providing significant insight into the mechanism of TOMM 
cyclodehydration, the results presented here provide an initial framework to explore the elusive 
functions of the 4,000 uncharacterized non-TOMM YcaOs currently in GenBank. While I cannot 
confidently comment on the function of the remaining 4000 genes, the capacity to bind ATP (or 
possibly other nucleotide triphosphates) appears to be ubiquitous in the YcaO superfamily. 
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However, it remains unclear whether the TOMM cyclodehydratase-like direct activation of 
carbonyls is a universal feature. It is intriguing that YcaOs have recently been implicated in the 
formation of thioamides41 and macroamidine rings,16-19 as both of these modifications could 
conceivably occur through carbonyl activation.  
My dissection of the cyclodehydratase complex and reclassification of the roles the C/D 
proteins poses an interesting question as to the role of the C protein in TOMM biosynthesis. 
While I have shown that BalhC acts cooperatively with BalhD to accelerate azoline formation 
and govern the proper utilization of ATP, this study did not allow me to conclusively deduce the 
role of BalhC. Nonetheless, it is conceivable that the C protein could partake in one of three 
plausible functions: (1) BalhC activates BalhD through an allosteric mechanism, increasing the 
rate of heterocyclization, (2) BalhC catalyzes the nucleophilic attack of the proceeding side chain 
by providing the requisite general acid/base residues, or (3) BalhC forms key contacts with both 
the substrate and BalhD to facilitate the interaction of the core region of BalhA1 and the BalhD 
active site. This topic will be discussed further in Chapter 5. 
 
4.10 Experimental 
4.10.1 General methods. Unless otherwise specified, all chemicals were purchased from Sigma 
or Fisher Scientific. DNA sequencing was performed by either the Roy J. Carver Biotechnology 
Center (UIUC) or ACGT Inc. Restriction enzymes were purchased from New England Biolabs 
(NEB), Pfu Turbo was purchased from Agilent, and dNTPs were purchased from either NEB or 
GenScript. Oligonucleotide primers were synthesized by either Integrated DNA Technologies 
(IDT) or Eurofins MWG Operon. Unless otherwise stated, all proteins and substrates were used 
as MBP fusions to circumvent solubility issues.  
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4.10.2 Single-turnover activity studies. Individual MBP-tagged synthetase components (45 
µM) were set up with MBP-BalhA1 substrate at a 1:1 ratio in synthetase buffer [50 mM Tris (pH 
7.5), 125 mM NaCl, 10 mM DTT, 20 mM MgCl2 and 3 mM ATP]. After an 18 h reaction at 23 
°C, MBP was proteolytically removed from the substrate by the addition of 0.2 mg/ml 
recombinant TEV protease and a 30 min incubation at 30 °C. Samples were desalted via C18 
ZipTip (Millipore) according to the manufacturer’s instructions and analyzed on a Bruker 
Daltonics UltrafleXtreme MALDI-TOF spectrometer. Spectra were obtained in positive reflector 
mode using α-cyano-hydroxycinnamic acid as the matrix. 
4.10.3 Iodoacetamide labeling. Reactions were set up with 45 µM MBP-BalhD, 45 µM MBP-
BalhNC-C40 (see Fig. 4.1B for amino acid sequence), and 0.2 mg/mL TEV protease in TCEP 
synthetase buffer [50 mM Tris (pH 7.5), 125 mM NaCl, 10 mM TCEP, 20 mM MgCl2 and 3 mM 
ATP] and allowed to react for 18 h at 23 °C. Next, 50 mM iodoacetamide was added for 1 h at 
23 °C before ZipTip (Millipore) desalting and analysis on a Bruker Daltonics UltrafleXtreme 
MALDI-TOF mass spectrometer in positive reflector mode with α-cyano-hydroxycinnamic acid 
used as the matrix. 
4.10.4 Heterocycle localization via FT-MS/MS. For BalhD-only ring localization, reactions 
were set up with 45 µM MBP-BalhD, 45 µM MBP-BalhNC-CCG* (see Fig. 4.1B for amino acid 
sequence), and 0.2 mg/mL TEV in synthetase buffer and allowed to react for 18 h at 23 °C. Next 
the large proteins were precipitated via the addition of 25% acetonitrile, the precipitate was 
removed from the sample by centrifugation, and the soluble fraction was dried in a Savant 
SpeedVac (Thermo Fisher). The resultant solid was resuspended in 10 µL water and desalted by 
ZipTip according to the manufacturer’s instructions. The desalted sample was diluted 2-fold in 
80% acetonitrile with 1% acetic acid and was analyzed on a ThermoFisher Scientific LTQ-FT 
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hybrid linear ion trap-FTMS system, operating at 11 T. Ions were introduced by direct infusion 
using an Advion Nanomate 100. An accurate mass was collected using the FTMS set at a 
resolution at 100,000. Fragmentation data was collected in the ion trap with the following 
settings: isolation width: 3 m/z, normalized collision energy (NCE): 35; activation q value: 0.25; 
activation time: 30 ms.  
 The localization of heterocycles on BalhA1 treated with a mutant BCD complex was 
performed in a similar fashion. 50 µM MBP-BalhA1 was modified by 2 µM MBP-tagged BcerB, 
BalhC, and BalhD in synthetase buffer for 18 h at 25 ˚C. Proteins were digested with 0.02 
mg/mL sequencing grade trypsin (Promega) in 50 mM NH4CO3 (pH 8.0) for 30 min at 37 ˚C 
before the sample was quenched via the addition of formic acid to a final concentration of 10% 
(v/v) and precipitate was removed via centrifugation at 17,000 x g. FT-MS/MS analysis was 
carried out as described above. 
4.10.5 BalhD-only ATP/ring stoichiometry. Reactions were initiated via the addition of 60 µM 
TEV cleaved MBP-BalhA1 to a sample containing the indicated amount of MBP-BalhD in 
synthetase buffer. Aliquots were removed at the indicated time points and frozen in liquid 
nitrogen. The samples were then analyzed by MALDI-TOF MS to determine an approximate 
azoline concentration (calculated by the relative peak heights of the different ring states) and 
malachite assay was used to quantify the amount of phosphate produced in the samples. 
4.10.6 Malachite green phosphate detection assay. Samples were diluted 1:8 in water to a final 
volume of 80 µL to remove any background signal from unreacted ATP. This solution was 
transferred to a 96-well plate where the reaction was initiated by the addition of 20 µL malachite 
green working reagent (Bioassay Systems). Reactions were allowed to develop for 30 min before 
the absorbance was recorded at 620 nm. A standard curve was made from a known concentration 
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of inorganic phosphate in appropriately diluted synthetase buffer. The absorbance for each of the 
samples was corrected for any background originating from the buffers.  
4.10.7 31P-NMR analysis of phosphate isotope incorporation of 18O-water reactions. Two 
samples containing either the MBP-tagged BalhD (20 µM) synthetase components or MBP-
BalhA1 substrate (60 µM) with low-salt synthetase buffer (50 mM Tris pH 8.5, 25 mM NaCl, 5 
mM MgCl2, 10 mM DTT, 2 mM ATP) were lyophilized separately for 16 h. The resulting solid 
was reconstituted in 500 µL of 97 atom% [18O]-H2O (Cambridge Isotope Laboratories) and 
incubated at 23 °C with rocking for 3 h before quenching the reaction with the addition 
acetonitrile to a final concentration of 25%. The sample was dried using a Savant SpeedVac 
(Thermo Fisher), the non-proteinaceous components were reconstituted in 220 µL D2O with 5 
mM EDTA, and reconstituted sample was placed in a D2O-matched Shigemi NMR tube. The 
31P-NMR spectrum was obtained on a 600 MHz Varian Unity Inova NMR with a 5 mm Varian 
AutoTuneX probe, 1000 transients, 32768 points, and a spectral window of -15 to 5 ppm.  
A [16O]-H2O control, an enzyme only control in [18O]-H2O, a buffer only control, and a 
control in which the BalhD and BalhA1 were precipitated with acetonitrile prior to the addition 
of ATP synthetase buffer was also performed. 31P-NMR spectra for each control were obtained 
as indicated above. 
4.10.8 Cloning of MBP-YcaO. Ec-YcaO was amplified by PCR from Escherichia coli BL21 
cells using the forward and reverse primers listed in table A.2. Polymerase reactions were carried 
out with PFU Turbo and the amplified product was digested with BamHI and NotI following a 
gel extraction. The digested gene was PCR-purified and ligated into an appropriately digested, 
modified pET28 vector containing a tobacco etch virus (TEV) protease cleavable, N-terminal 
MBP-tag. 
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4.10.9 Preparation of BalhD PxPxP mutants. BalhD was amplified by PCR from the 
previously described pET28-BalhD plasmid21 using the primers listed in table A.2. Polymerase 
reactions were performed with PFU Turbo and the amplified product was digested with BamHI 
and NotI following gel extraction. The digested gene was PCR-purified and ligated into an 
appropriately digested, modified pET28 vector containing a tobacco etch virus (TEV) protease 
cleavable, N-terminal MBP-tag.  
4.10.10 Site-directed mutagenesis. Site-directed mutagenesis of BalhD and McbD was carried 
out using the QuikChange method according to the manufacturer’s instructions. All mutagenesis 
primers are listed in table A.2.  
4.10.11 Overexpression and purification of MBP-tagged proteins. All proteins were purified 
with amylose resin (NEB) according to previously described procedures.1 
4.10.12 Multiple sequence alignments. Alignments were made with Clustal Omega using the 
standard parameters.42  
4.10.13 Cytoscape sequence similarity network. A sequence similarity network was created 
using the Enzyme Function Initiative Enzyme Similarity Tool (EFI-EST, enzymefunction.org).43 
Sequences from the YcaO superfamily (InterPro number IPR003776) were used for the analysis. 
The network was constructed at an expectation-value (e-value) of 10-80. Networks were 
visualized by Cytoscape using the organic layout.26 Sequences with 100% identity were 
visualized as a single node in the network and all nodes were manually annotated. 
4.10.14 Maximum likelihood phylogenetic analysis. A set of YcaO sequences representing the 
full diversity of the YcaO family were selected based on the Cytoscape sequence similarity 
network (Fig. 4.12). This included at least one protein from each cluster and all singletons 
(proteins that fail to cluster with any other YcaO) for a total of 349 proteins (~17% of the non-
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redundant Cytoscape sequence similarity network). The phylogenetic analysis was performed 
with Molecular Evolutionary Genetics Analysis (MEGA5).44 An amino acid sequence alignment 
was created using the standard parameters of ClustalW45 and a maximum likelihood 
phylogenetic tree was created using standard parameters in MEGA5.  
4.10.15 ATP-binding site conservation. The ligand interaction network for AMPCPP was 
generated using LigPlot plus46 using the standard parameters. A WebLogo29 frequency plot for 
the ATP-binding motif was generated from a Clustal Omega alignment of all of the sequences 
from the specified family using the standard parameters. The conservation map for the YcaO 
family was generated by aligning 150 unique YcaO sequences with at least 35% sequence 
similarity to Ec-YcaO (e-value < 10-5) and mapping the resulting conservation data onto the Ec-
YcaO structure using ConSurf.47 The structure based YcaO alignment was generated using 
Clustal Omega42 and ALINE,48 while the structural overlay of YcaO and TruD was generated 
using PyMOL version 1.5 (Schrödinger).  
4.10.16 Proline-rich C-terminus analysis. The proline content of the C-termini of all YcaOs in 
the Cytoscape sequence similarity network was determined. Proteins were deemed to have a 
proline-rich (P-rich) C-terminus if at least 4 of the final 30 residues were Pro. In the most 
pronounced cases, the terminal 6 residues of the YcaO contain a PxPxP motif. Proteins were 
identified as containing a PxPxP C-terminus if they contained a PxP motif in the final 6 residues 
and at least 3 Pro in the final 30 residues.  
4.10.17 Ec-YcaO crystallization and structural solution. Crystallization and structural 
solution was carried out by Jonathan Chekan (Nair lab). See Dunbar & Chekan et al.2 for 
detailed methods. Coordinates for the APO YcaO, AMP bound YcaO, and AMPCPP Bound 
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YcaO structures were deposited to the Protein Data Bank as codes 4Q84, 4Q86, and 4Q85 
respectively. 
4.10.18 Endpoint heterocycle formation assays. For the reactions with the BalhD mutants, 50 
µM MBP-BalhA1 was mixed with either 2 µM MBP-BalhC/D (CD activity) or 25 µM MBP-
BalhD (D-only activity) in synthetase buffer [50 mM Tris (pH 7.5), 125 mM NaCl, 10 mM DTT, 
20 mM MgCl2 and 3 mM ATP]. The MBP tags were removed using 0.05 mg/mL of TEV 
protease and reactions were carried out for 18 h at 25 ˚C. Reactions with the Mcb enzymes were 
carried out identically except that the dehydrogenase (McbC) was also added to the reaction and 
proteins were cleaved with 0.1 µg/mL thrombin protease (from bovine plasma). Processing was 
monitored by MALDI-TOF MS. 
4.10.19 BalhD mutant kinetic studies. Substrate processing kinetics for the BalhD mutants 
were determined using a previously described purine nucleoside phosphorylase (PNP)-coupled 
assay.1,24 For BalhA1 kinetic experiments, variable concentrations of MBP-BalhA1 (1-120 µM) 
were reacted with 1-10 µM MBP-tagged BalhC/D while ATP was held constant at 3 mM. ATP 
kinetic experiments were carried out in an identical fashion except that MBP-BalhA1 was fixed 
at 80 µM and variable concentrations of ATP (0.1- 5 mM) were used. Although this does not 
provide a saturating level of BalhA1 for all mutants, the KM for ATP does not change with varied 
BalhA1 concentration (Fig. 4.19). Reactions were carried out in triplicate. Regression analyses to 
obtain the kinetic parameters for both substrates were carried out with IGOR Pro version 6.12 
(WaveMetrics).  
4.10.20 Size-exclusion chromatography. A 200 µL sample containing 25 µM MBP-tagged 
BalhC/D was prepared in cleavage buffer [20 mM Tris (pH 7.5), 500 mM NaCl, 10 % glycerol 
(v/v), 0.5 mM tris(2-carboxyethyl)phosphine (Gold Biotechnology)] and treated with 0.05 
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mg/mL TEV protease for 12 h at 4 ˚C. The amount of protein in a BalhC/BalhD complex was 
assessed on a Flexar HPLC (Perkin Elmer) equipped with an analytical Yarra SEC-3000 (300 x 
4.6 mm, Phenomenex) equilibrated with cleavage buffer. Peaks of interest were collected and 
their composition was determined via a Coomassie stained 12% SDS-PAGE gel. The 
approximate molecular weights were determined by generating a standard curve with a 12-200 
kDa molecular weight standard kit (Sigma). Control runs were also performed in which one of 
the two proteins was omitted. Chromatograms were exported using Flexar Manager (Perkin 
Elmer) and analyzed using Microsoft Excel.  
4.10.21 Mutant BalhD IC50 determination. 1 µM MBP-tagged BalhC and BalhD were mixed 
in synthetase buffer [50 mM Tris (pH 7.5), 125 mM NaCl, 10 mM DTT, 20 mM MgCl2 and 3 
mM ATP] with 0.25-20 µM mutant BalhD protein. Reactions were initiated by the addition of 15 
µM MBP-BalhA1 and progress was measured using the PNP phosphate detection assay. All 
reactions were performed in triplicate. IC50 values were calculated with IGOR Pro version 6.12 
(WaveMetrics).  
4.10.22 BalhC “KM” for active BalhD mutants. The affinity of catalytically active BalhD 
mutants for BalhC was determined using the PNP phosphate detection assay and a previously 
described procedure.13 25 µM MBP-BalhA1 was mixed with 1 µM MBP-BalhD in synthetase 
buffer and reactions were initiated via the addition of 0.15-4 µM BalhC. All reactions were 
performed in triplicate. Regression analyses to obtain kinetic parameters for BalhC were carried 
out with IGOR Pro version 6.12 (WaveMetrics). 
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CHAPTER 5: THE ROLE OF TOMM E1-HOMOLOGS IN AZOLINE BIOSYNTHESIS 
Sections of this chapter were published in Dunbar & Mitchell1 and Dunbar & Chekan et al.2 and 
are reproduced with permission from the American Chemical Society and Nature Publishing 
Group, respectively. 
 
I am grateful to Joel Melby for assisting with the collection of MS/MS data and Nhat Trinh 
assisting with Balh3A cloning. Brandon Burkhart carried out the fluorescence polarization 
experiment.  
 
 
Abstract 
Although the TOMM C protein was originally thought to be responsible for performing the ATP-
dependent cyclodehydration of TOMM precursor peptides, this activity has recently been 
assigned to TOMM YcaO proteins (see chapter 4). Rather the role of the C protein appears to be 
in the potentiation of the YcaO cyclodehydratase activity; however, the basis for this activity 
increase remained enigmatic. Using diverse TOMM synthetases, I demonstrate that TOMM E1-
homologs provide substrate recognition and potentiate catalysis of their cognate YcaO. Together 
these results allow us to assign a revised function to over 1,000 proteins in GenBank and propose 
an updated biosynthetic scheme for TOMM natural products. 
 
5.1 Introduction  
The TOMM C protein, found in all canonical TOMM biosynthetic clusters, is one of two 
domains required for azoline formation during TOMM biogenesis (Fig. 1.3).3,4 TOMM C 
proteins are members of the E1 ubiquitin-activating superfamily. As all characterized E1 
superfamily members are ATP-utilizing enzymes,5 TOMM C proteins were originally thought to 
catalyze azoline formation and be the ATP-utilizing component of the TOMM synthetase.4 
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Consequently, the TOMM C protein was annotated as the TOMM cyclodehydratase.6 However, 
recent work demonstrated that the D protein (TOMM YcaO) is responsible for carrying out this 
transformation2,3 and that the C protein potentiates the activity of the D protein via an unknown 
mechanism.3 Although the basis for this potentiation was not investigated in these studies, it was 
hypothesized that the TOMM C protein might provide peptide substrate recognition for TOMM 
YcaO proteins. Precursor peptide recognition in the majority of ribosomally synthesized post-
translationally modified peptides (RiPPs) occurs in a bipartite fashion. An N-terminal sequence 
(leader peptide), serves as the recognition sequence by the modification enzymes, while the C-
terminal sequence (core peptide) contains the sites of post-translational modification.7,8 Previous 
work on a TOMM C protein involved in streptolysin S biosynthesis (SagC), demonstrated that C 
proteins have the ability to bind leader peptide;6 however, it remains unclear whether this 
function is conserved within the protein family. Complicating matters further, previous work on 
the microcin B17 synthetase demonstrated that the YcaO protein (McbD), not the C protein, was 
responsible for leader peptide recognition.9 
In addition to the canonical TOMM C protein, a subset of TOMM biosynthetic clusters 
contains an additional E1 homolog. These auxiliary proteins, annotated as ocin-ThiF-like 
proteins in GenBank, are much larger than a standard TOMM C protein (~600 vs ~325 amino 
acids), and serve an as of yet uncharacterized role in TOMM biosynthesis. These ThiF-like 
proteins are found in all heterocycloanthracin and a diverse subset thiopeptide biosynthetic 
clusters.10,11 Notably these ThiF homologs are found in clusters that contain truncated CD fusion 
proteins, in which the C domain is truncated. Based on homology modeling to the X-ray crystal 
structure of the CD fusion protein TruD12 and the non-TOMM RiPP biosynthetic enzyme 
MccB,13,14 this truncation appears to remove an N-terminal capping domain that has been 
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implicated in peptide recognition in MccB.13 Due to the confusion surrounding the role of the 
TOMM C protein, the roles of each E1-homolog and the effect of the truncation on azoline 
formation are not understood. 
In an attempt to assign a definitive role to TOMM C proteins, the E1-homologs from two 
divergent TOMM biosynthetic clusters in Bacillus sp. Al Hakam (Balh) were investigated. The 
results demonstrate that in addition to providing substrate recognition, TOMM E1-homologs also 
increase the catalytic efficiency of their cognate YcaO. Although the molecular details for these 
interactions remain unresolved, the data presented in this report allow us to ascribe a function to 
this previously mischaracterized protein. 
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5.2 TOMM C Proteins Direct YcaO Cyclodehydratase Activity 
Previously, I demonstrated that BalhD is able to catalyze cyclodehydration in the absence of 
BalhC, albeit with a drastically reduced efficiency.3 Although the role of BalhC was not 
explicitly interrogated, previous work carried out on SagC demonstrated that C proteins play an 
important role in substrate recognition.6 If the C protein was required for proper substrate 
recognition, I hypothesized that the highly regulated order of azoline installation would be 
disrupted in reactions lacking BalhC. In order to test this hypothesis, BalhD-treated BalhA1 was 
subjected to the AMPL methodology (see Chapter 3) to afford [18O2]-BalhA1, and the isotope 
labels were localized by FT-MS/MS. While one of the azolines was localized to Cys45, the 
second 18O label was found at Gly37 and Gly39, indicating that the second azoline was installed 
at Thr38 and Cys40, but not both simultaneously (Fig. 5.1). In reactions containing BalhC, 
Cys40 is the first ring cyclized, Cys45 is the penultimate ring, and the cyclization of Thr38 is not 
detected.15 Thus, these data suggest that BalhC is at least partially responsible for dictating the 
regio- and chemoselectivity of substrate processing by the Balh cyclodehydratase.  
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Figure 5.1 | Azoline localization on BalhD-treated BalhA1 via 18O-labeling. Following 
treatment with BalhD and 18O-hydrolysis, BalhA1 was subjected to FT-MS/MS. (a) An intact 
mass spectrum for [18O3]-BalhA1 in the 4+ charge is displayed. The monoisotopic masses for the 
most prominent 18O-labeled species are given and colored based on the number of 18O labels 
(orange, 3; blue, 2; red, 1; black, 0). Prior to hydrolysis the peptide had two azoline heterocycles. 
The presence of a third 18O label indicates that a non-specific labeling event occurred. The ppm 
error for the major species is displayed. (b) A MS/MS spectra of the [18O3]-BalhA1 species from 
panel (a) demonstrates that the two azolines are spread across three sites: Thr38, Cys40 and 
Cys45. Based on the b and y ion intensities, Cys45 was always found as a thiazoline, while 
azoline formation at Thr38 and Cys40 occurred in equal amounts. The b and y ions are colored 
based on the number of 18O present in the fragment (orange, 3; blue, 2; red, 1; black, 0). Stars 
represent the sites of 18O labels from hydrolysis of the azoline heterocycles and asterisks label 
peaks with neutral water loss. The y ion series indicates that the C-terminal carboxylate has a 
single 18O label (denoted by red residue). 
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5.3 TOMM C Proteins are Responsible for Leader Peptide Recognition 
The above results are consistent with the hypothesis that TOMM C proteins are responsible for 
peptide substrate recognition. To directly assess the role of the C and D proteins in peptide 
substrate recognition, a fluorescein-labeled BalhA1 leader peptide was employed to monitor 
binding to BalhC and BalhD by fluorescence polarization. While BalhD was found to not bind 
the BalhA1 leader peptide to any significant extent, BalhC displayed a Kd of 11 µM (Fig. 5.2), 
near the previously measured KM for BalhA1 of 16 µM.16 Moreover, the addition of BalhD did 
not significantly alter BalhC’s affinity for the BalhA1 leader peptide (p > 0.05). Consequently, 
these data support a model where TOMM C proteins bind leader peptide and present the core 
peptide to the YcaO domain for modification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 | BalhC is responsible for leader peptide recognition. A fluorescent polarization 
curve for fluorescein-labeled BalhA1 leader peptide recognition by BalhC and BalhD is 
displayed. Error bars represent the standard error of the mean of three independent titrations. 
Errors on the Kd values represent the error from curve fitting. 
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5.4 TOMM C Proteins Potentiate YcaO Cyclodehydratase Activity 
During the mutagenesis of the proline-rich C-terminus of BalhD (see Chapter 4), a derivative 
containing a C-terminal His6 tag was generated (PA4LEH6; where P is the last residue of wild-
type BalhD). As expected from earlier experiments with BalhD PxPxPG (Table 4.2), addition of 
the longer tag abolished heterocycle formation (Fig. 5.3). Although heterocycle formation is 
stoichiometric with ATP hydrolysis for wild-type cyclodehydratase,3 the C-terminal His6 tagged 
BalhD displayed robust ATPase activity, irrespective of the presence of BalhA1 (Fig. 5.4A). 
Moreover, this high level of unproductive ATP hydrolysis was potentiated by the addition of 
BalhC to the same extent observed with wild-type BalhD (2.5-fold increase; see Fig. 4.20), 
indicating that the His6 tag did not interfere with BalhC recognition (Fig. 5.4A). With a BalhD 
derivative displaying robust BalhC-independent ATPase activity in-hand, I evaluated the role of 
BalhC on ATP utilization by BalhD by obtaining ATP Michaelis-Menten kinetics parameters for 
BalhD-A4LEH6 alone and in complex with BalhC (Fig. 5.4B). These data indicated that the 
addition of BalhC modulated BalhD activity by increasing the kobs and decreasing the KM for 
ATP. 
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Figure 5.3 | A C-terminal His6 tag on BalhD abolishes cyclodehydratase activity. A MALDI-
TOF MS spectral overlay for BalhA1 treated with BalhD-A4LEH6 either (a) with or (b) without 
BalhC is displayed. A reaction carried out with wild-type (WT) BalhD is shown for a 
comparison. †, laser-induced deamination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 | BalhC modulates ATP binding and hydrolysis by BalhD. (a) ATP hydrolysis 
rates measured by the PNP assay. (b) ATP kinetic curves for BalhD-A4LEH6 with and without 
BalhC. Error bars represent the standard deviation from the mean (n=3), while error on the 
Michaelis-Menten parameters represents the standard deviation from the regression analysis. 
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5.5 The Role of Auxiliary E1-Homologs in Azoline Biogenesis 
There are two TOMM biosynthetic clusters in Bacillus sp. Al Hakam (Fig. 5.5). The enzymes 
characterized in Chapters 2-4 of this thesis were from the canonical TOMM cluster (BalhA1, 
BalhC, etc.). The second cluster is a member of the uncharacterized heterocycloanthracin 
subfamily of TOMM natural products. Akin to all other heterocycloanthracin biosynthetic 
clusters,10 the second TOMM biosynthetic cluster in Bacillus sp. Al Hakam (Balh2) contains a 
dehydrogenase (Balh2B), a CD fusion protein (Balh2CD), and an enigmatic ThiF-like protein 
(Balh2F). Unlike Balh cluster 1, the Balh2 precursor peptide (Balh2A; see Fig. 5.5 for sequence) 
is located elsewhere on the genome and was identified based on similarity to other 
heterocycloanthracin precursor peptides.15  
The genes for the Balh2 modification enzymes and the precursor peptide were cloned 
from the Balh genome and expressed in E. coli as His6- or MBP-fusion proteins, respectively. 
Although Balh2CD and Balh2F expressed well, Balh2B was heavily truncated and purified 
without the necessary FMN cofactor. In order to determine the minimal set of proteins required 
for azoline formation, reactions were initiated with Balh2F alone, Balh2CD alone or both 
Balh2CD and Balh2F, and processing of Balh2A was monitored matrix assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS, Fig. 5.6). Samples 
lacking either of the enzymes or ATP did not display a detectable level of Balh2A substrate 
modification under the conditions employed. Increasing the concentrations of the individual 
components to 25 µM, similarly resulted in no modification. However, when the Balh2A 
substrate was treated with both Balh2CD and Balh2F, 13 azoline heterocycles (resulting in a 234 
Da mass shift) were installed on the substrate. Using N-ethyl maleimide labeling, these 
modifications were localized to the 13 cysteines in the core peptide (Fig. 5.7). Although studies 
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carried out on other TOMM synthetases have demonstrated that cyclodehydratase activity can be 
dependent of the presence of the dehydrogenase,17-19 no additional domains have been shown to 
be required for azoline formation. As such, the absolute requirement for the presence of the 
ThiF-like protein is unprecedented. Given the size and cysteine rich nature of the substrate, the 
ability to convert the azolines to stable azoles would greatly assist in the characterization of 
substrate processing. Unfortunately attempts to obtain a full synthetase by using a Balh2B 
homolog were stymied by the inability to find a homolog that purified with FMN (see table A.4 
for list of other dehydrogenases cloned).  
In order to better understand the role of Balh2F in the cyclodehydration of Balh2A, the 
ability of Balh2F to associate with Balh2CD and the ability of each protein to bind Balh2A was 
interrogated by analytical size-exclusion chromatography (SEC; Fig. 5.8). Under the conditions 
tested, Balh2F and Balh2CD formed a heterodimeric complex. The addition of MBP-tagged 
Balh2A leader peptide (see Fig. 5.4) to this sample generated a new peak with a retention time 
consistent with a 2:1:1 complex of Balh2A:2F:2CD. In order to determine which protein was 
responsible for Balh2A leader peptide recognition, the control SEC traces were obtained in 
which either Balh2CD or Balh2F was omitted. While Balh2CD did not appear to interact with 
the Balh2A leader peptide, incubation of Balh2F and Balh2A leader peptide resulted in the 
appearance of a new peak with a retention time consistent with a 2:1 complex of Balh2A:2F 
(Fig. 5.8). Importantly, this association was unperturbed upon the addition of Balh2CD. These 
data provide definitive proof that Balh2F is responsible for leader peptide recognition in Balh 
cluster 2. As Balh2F homologs are found in all heterocycloanthracin biosynthetic clusters, it is 
likely that this strategy for precursor peptide recognition is universal in this TOMM subfamily.  
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Figure 5.5 | Overview of the Balh TOMM biosynthetic clusters. The gene clusters for each of 
the Balh TOMM clusters is displayed. Gene assignments are provided in the legend. The 
sequences of the precursor peptides for each cluster are shown along with the sequence of the 
Balh2A leader peptide used in this report. A blue hyphen denotes the putative leader peptide 
cleavage site, while the orange residues are positions known to be cyclized in vitro.  
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Figure 5.6 | Heterocycle formation on Balh2A is Balh2F and Balh2CD dependent. An 
uncalibrated linear positive mode MALDI-TOF MS spectral overlay for the Balh2A endpoint 
modification assays is displayed. Apart from the final trace, ATP is included in each sample. The 
mass of the major peaks is labeled along with the mass difference for the modified form. The 
theoretical mass for the peptide is displayed along with the ppm error for the measurement.  
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Figure 5.7 | The cyclized Balh2A product contains 13 thiazolines. A linear mode MALDI-
TOF MS spectral overlay for N-ethylmaleimide (NEM) reacted Balh2A and Balh2CD/2F-treated 
Balh2A is displayed. The masses of the unmodified and cyclized peaks are displayed along with 
the mass shift relative to the unmodified species. The number of NEM labels on the peptide is 
indicated for the relevant peaks. The spectra were internally calibrated to the unmodified Balh2A 
peak. 
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Figure 5.8 | Balh2F is responsible for leader peptide recognition in Balh cluster 2. Analytical 
size-exclusion chromatography 280 nm absorbance traces are displayed. Numbers are assigned 
to each of the peaks in the traces and the calculated molecular weight for each numbered peak is 
displayed along with the calculated oligomeric state. For peaks 5 and 6, the oligomeric state in 
parenthesis is for a complex containing two molecules of MBP-Balh2A LP. The remained of the 
oligomeric states are calculated based off a 1:1 ratio of the binding partners. Asterisks denote the 
void peak.   
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5.6 Summary and Outlook 
The data presented in this report demonstrate that TOMM E1 proteins play two distinct roles in 
azoline formation. First, the results demonstrate that TOMM E1 domains are responsible for 
leader peptide recognition, thus efficiently bringing the substrate in close proximity to the 
TOMM YcaO active site. These results are in accord with previous work implicating SagC in 
leader peptide recognition during streptolysin S biosynthesis,6 and the recent observation that 
TOMM C proteins house a MccB-like N-terminal “peptide clamp”,12 which is responsible for 
leader peptide binding in microcin C7 biosynthesis.13 Secondly, the serendipitous identification 
of a C-terminal His-tagged construct of BalhD with robust ATP hydrolysis (BalhD-A4LEH6) 
allowed us to show that the presence of BalhC increases kobs and lowers the KM for ATP. 
Although these data suggest that C protein potentiation occurs via allosteric activation, follow-up 
studies will be required to validate this hypothesis. Combined with the fact that TOMM E1 
proteins lack the ATP-binding site that is conserved in all characterized non-TOMM E1 
ubiquitin-activating family members, all lines of evidence suggest that TOMM C proteins 
engage the leader peptide while simultaneously potentiating the carbonyl activation chemistry of 
their cognate YcaO domain (D protein; Fig. 5.9A).  
 Based on the extensive bioinformatics that I have performed with TOMM synthetases, 
the above strategy is likely utilized in approximately 800 of the 1000 identifiable TOMM 
biosynthetic clusters in GenBank. In the remainder of the clusters, the canonical C protein is 
truncated and appears to have lost the N-terminal “peptide clamp”. My work with Balh cluster 2 
demonstrates that in such clusters an auxiliary and highly divergent TOMM E1 homolog is 
responsible for leader peptide recognition. Although my data do not address the role that the 
truncated C domain plays on azoline formation, the simplest model is one in which the truncated 
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C domain is responsible for YcaO activation, while the ThiF-like protein provides leader peptide 
recognition (Fig. 5.9B). Further study is required to test this hypothesis. 	  
Based on the data presented in this report, it is not yet clear how stand-alone TOMM 
YcaO proteins (i.e. for bottromycin and trifolitoxin production) perform cyclodehydrations in the 
absence of a C protein. Given the diversity between these stand-alone and canonical (C protein-
containing) TOMM YcaOs, I envision that multiple solutions to the substrate recognition 
problem could exist. For example, it is possible that these biosynthetic pathways utilize an 
unidentified companion protein to bind the precursor peptide. Alternatively, these YcaO proteins 
may have evolved to bind a specific motif within the core peptide and modify the substrate a 
single time. Accordingly, the bottromycin and trifolitoxin stand-alone YcaO domains are each 
predicted to install a single heterocycle.20-24 This is in stark contrast to canonical TOMMs that 
process a wide array of core peptides, often at numerous locations.4,15,25 Such promiscuity is 
common in other RiPPs and likely accounts for the existence of leader peptides (i.e. the 
modification enzymes can be specific for motifs within the leader peptide, but promiscuous on 
the core once the enzyme-substrate complex is formed).26,27 Further work, including the 
reconstitution of a stand-alone YcaO, will be required to test these hypotheses. 
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Figure 5.9 | An updated model for azoline formation by TOMM cyclodehydratases. Based 
on the data presented in this report, two models for azoline formation are provided. (a) In 
TOMM cyclodehydratase complexes with a full length C protein (similar to Balh cluster 1) the 
TOMM E1 homolog (C protein) allosterically activates the YcaO domain (D protein) and binds 
the leader peptide (LP). Leader peptide binding by the C protein places the core peptide in 
proximity of the YcaO active site to facilitate the cyclodehydration reaction. (b) In TOMM 
cyclodehydratase complexes with a truncated C protein (similar to Balh cluster 2), the canonical 
C protein is not responsible for leader peptide recognition. Instead the ThiF-like protein binds the 
leader peptide.	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5.7 Experimental 
5.7.1 General methods. Unless otherwise specified, all chemicals were purchased from Sigma 
or Fisher Scientific. DNA sequencing was performed by the Roy J. Carver Biotechnology Center 
(UIUC). Restriction enzymes were purchased from New England Biolabs (NEB), Pfu Turbo was 
purchased from Agilent, and dNTPs were purchased from either NEB. Oligonucleotide primers 
were synthesized by Integrated DNA Technologies (IDT). Fluorescein labeled BalhA1 leader 
peptide was purchased from GenScript as an N-terminal FITC-Ahx (fluorescein isothiocynate, 
aminohexyl linker) conjugate with a single glycine spacer. 
5.7.2 Balh cluster 2 cloning. Balh2A, 2CD, 2B and 2F were amplified by PCR from Bacillus sp. 
Al Hakam cells using the forward and reverse primers listed in table A.4. Polymerase reactions 
were carried out with PFU Turbo and the amplified product was digested with the indicated 
restriction enzymes following a gel extraction. The digested gene was PCR-purified and ligated 
into an appropriately digested, modified pET28 vector. For Balh2A the vector contained a 
tobacco etch virus (TEV) protease cleavable, N-terminal MBP-tag. For Balh2CD, 2B and 2F the 
vector contained a thrombin protease cleavable N-terminal His6-tag.  
5.7.3 Protein overexpression and purification. All MBP-tagged and His6-tagged proteins were 
overexpressed and purified as previously described (see Chapters 2 and 3).1,3  
5.7.4 18O labeling of BalhD-treated BalhA1 reactions.	  25 µM BalhD and 50 µM BalhA1 (both 
fused to MBP) were incubated with 0.2 µg/mL TEV protease in synthetase buffer for 18 h at 25 
°C. Following treatment, BalhD, MBP and TEV were precipitated from the sample by the 
addition of acetonitrile to a final concentration of 50% (v/v). The precipitated proteins were 
removed from the sample by centrifugation at 15,000 × g and the supernatant was dried on a 
SpeedVac (Savant, Thermo Scientific). The resultant solid was resuspended in [18O]-H2O and 
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isotope labeling, trypsin digestion, and FT-MS/MS sequencing was carried out as described in 
Chapter 3.   
5.7.5 BalhC leader peptide recognition. Equilibrium BalhC/BalhD fluorescence polarization 
binding assays were performed at 25 ˚C in non-binding surface, 384 black well, polystyrene 
microplates (Corning) and measured using a FilterMax F5 multi-mode microplate reader 
(Molecular Devices) with default settings. For each titration, protein was serially diluted into 
binding buffer [50 mM HEPES pH 7.5, 300 mM NaCl, 2.5% (v/v) glycerol, 0.5 mM TCEP], 
mixed with 10 nM fluorescein-labeled BalhA1 leader peptide (FP-BalhA1-LP), and equilibrated 
for 15 minutes with shaking prior to measurement. Data from three independent titrations were 
background subtracted and fitted using a non-linear dose response curve in OriginPro9 
(OriginLab).  
5.7.6 BalhD-A4LEH6 activity. Heterocycle formation assays were carried out with 50 µM MBP-
BalhA1 and either 2 µM MBP-BalhC/D (CD activity) or 25 µM MBP-BalhD (D-only activity) in 
synthetase buffer [50 mM Tris (pH 7.5), 125 mM NaCl, 10 mM DTT, 20 mM MgCl2 and 3 mM 
ATP]. The MBP tags were removed using 0.05 mg/mL of TEV protease and reactions were 
carried out for 18 h at 25 ˚C. Samples were desalted via C18 ZipTip (Millipore) according to the 
manufacturer’s instructions and analyzed on a Bruker Daltonics UltrafleXtreme MALDI-TOF 
spectrometer. Spectra were obtained in positive reflector mode using α-cyano-hydroxycinnamic 
acid as the matrix. 
 Kinetic studies were performed using a previously described purine nucleoside 
phosphorylase (PNP)-coupled assay.3,28 The rate of ATP hydrolysis at variable ATP 
concentration (0.1-5 mM) was measured for 3 µM MBP-tagged BalhD-A4LEH6 with and 
without 3 µM MBP-tagged BalhC. Potentiation experiments were carried with 1 µM of the 
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indicated MBP-tagged enzymes and 100 µM BalhA1 (where applicable). Reactions were carried 
out in triplicate. Regression analyses to obtain the kinetic parameters for both substrates were 
carried out with IGOR Pro version 6.12 (WaveMetrics). 
5.7.7 Balh cluster 2 overnight heterocyclization assays. Heterocycle formation assays were 
carried out with 50 µM MBP-Balh2A and 2 µM His6-Balh2CD/2F in synthetase buffer [50 mM 
Tris (pH 7.5), 125 mM NaCl, 10 mM TCEP, 20 mM MgCl2 and 3 mM ATP]. The MBP tag was 
removed using 0.05 mg/mL of TEV protease and reactions were carried out for 18 h at 25 ˚C. 
Samples were desalted via C18 ZipTip (Millipore) according to the manufacturer’s instructions, 
eluted in a saturated solution of sinapinic acid in 70% ACN, and analyzed on a Bruker Daltonics 
UltrafleXtreme MALDI-TOF spectrometer. Spectra were obtained in linear positive mode. 
5.7.8 Size-exclusion chromatography. A 200 µL sample containing 25 µM of the indicated 
proteins (MBP-Balh2A LP, His6-Balh2CD, His6-Balh2F) was prepared in SEC running buffer 
[20 mM Tris (pH 7.5), 500 mM NaCl, 10 % glycerol (v/v), 0.5 mM TCEP]. Samples were 
incubated at 4 ˚C for 30 min prior to analysis via analytical SEC. The oligomeric state of the 
proteins and size of the pertinent protein complexes were assessed on a Flexar HPLC (Perkin 
Elmer) equipped with an analytical Yarra SEC-3000 (300 x 4.6 mm, Phenomenex) equilibrated 
with running buffer. Peaks of interest were collected and their composition was determined via a 
Coomassie stained 12% SDS-PAGE gel. The approximate molecular weights were determined 
by generating a standard curve with a 12-200 kDa molecular weight standard kit (Sigma). 
Chromatograms were analyzed using Flexar Manager (Perkin Elmer). 
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APPENDIX A: LIST OF PRIMERS 
 
Table A.1 | Primers for chapter 3 constructs. 
Primer Sequence Cut Site 
BalhA1 Core F AGGATCCTCTGGTTGTGCAGGATGTATGG 5'- BamHI 
BalhA1 Core R TTTGCGGCCGCTTATTTACCTGAGCATTTTTTCCAAACACCC 3'- NotI 
BalhA1 EPL F GCAGCCATATGAAAATCGAAGAAGGT 5'- NdeI 
BalhA1 EPL R ATATATCCCGGGCGCGCCTGCG 3'- SmaI 
McbC (K201A) F CATTATTTTTGAAAAAGCTTTGTTCGCATATCGCTACAGAGGATATCGGATG NA 
McbC (K201A) R CATCCGATATCCTCTGTAGCGATATGCGAACAAAGCTTTTTCAAAAATAATG NA 
McbC (Y202A) F TCTATTGCATTATTTTTGAAAAAGCTTTGTTCAAAGCTCGCTACAGAGGATATCG NA 
McbC (Y202A) R CGATATCCTCTGTAGCGAGCTTTGAACAAAGCTTTTTCAAAAATAATGCAATAGA NA 
 
Note: BalhA1 EPL F/R were used to generate an expressed protein ligation vector for the semi-
synthetic preparation of an 18O-labeled BalhA1 substrate. The yields from the EPL synthetic 
strategy were not high enough to be useful for mechanistic investigations of the TOMM 
cyclodehydratase. 
 
Table A.2 | Primers for chapter 4 constructs. *, denote stop codons. 
Primer Sequence Cut Site 
BalhD F CCGGATCCATGGGTATACAGAATGC 5'- BamHI 
BalhD (S72A) F CAGCACTAATAGCGGCAGTTGGAGAAATTCTTGAGCGTTATTGC   
BalhD (S72A) R TCTCCAACTGCCGCTATTAGTGCTGATTCAGCAGAATC   
BalhD (E76A) F CTAATATCGGCAGTTGGAGCAATTCTTGAGCGTTATTGC   
BalhD (E76A) R GCAATAACGCTCAAGAATTGCTCCAACTGCCGATATTAG   
BalhD (E79A) F GGCAGTTGGAGAAATTCTTGCGCGTTATTGCTCATGTTATC   
BalhD (E79A) R GATAACATGAGCAATAACGCGCAAGAATTTCTCCAACTGCC   
BalhD (R80A) F CGGCAGTTGGAGAAATTCTTGAGGCTTATTGCTCATGTTATCTAAATA   
BalhD (R80A) R TATTTAGATAACATGAGCAATAAGCCTCAAGAATTTCTCCAACTGCCG   
BalhD (Q186A) F CTACAAGGTTGGCAGCAATAGAAAACGCGGCACTAGAATG   
BalhD (Q186A) R GTTTTCTATTGCTGCCAACCTTGTAGAACCTGTTGCTAAACCAG   
BalhD (N190A) F GGTTCTACAAGGTTGCAAGCAATAGAAGCCGCGGCACTAGAAT   
BalhD (N190A) R ATTCTAGTGCCGCGGCTTCTATTGCTTGCAACCTTGTAGAACC   
BalhD (E194A) F TAGAAAACGCGGCACTAGCATGTATAGAAAGAGACGC   
BalhD (E194A) R GCGTCTCTTTCTATACATGCTAGTGCCGCGTTTTCTA   
BalhD (E197A) F CGCGGCACTAGAATGTATAGCAAGAGACGCGATTAT   
BalhD (E197A) R ATAATCGCGTCTCTTGCTATACATTCTAGTGCCGCG   
BalhD (R198A) F AATGTATAGAAGCAGACGCGATTATGATCACATGGTTAAATG   
BalhD (R198A) R ATAATCGCGTCTGCTTCTATACATTCTAGTGCCGCGTTTTCTATTG   
BalhD (K281A) F CGATCCTCTTATAGCATTGGCGGGAGCTTTAATGGAGACG   
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Table A.2 Continued 
Primer Sequence Cut Site 
BalhD (K281A) R CGTCTCCATTAAAGCTCCCGCCAATGCTATAAGAGGATCG   
BalhD (E286A) F GAAGGGAGCTTTAATGGCGACGTTGGCAAGTCTAA   
BalhD (E286A) R TTAGACTTGCCAACGTCGCCATTAAAGCTCCCTTC   
BalhD (P425*) F GGATATGCACCAGCAAAAGCTTTTAATAAGAATTAGCATCCATTTCCGTAAGCG   
BalhD (P425*) R CGCTTACGGAAATGGATGCTAATTCTTATTAAAAGCTTTTGCTGGTGCATATCC   
BalhD (P427*) F AAAGCTTTTAATAAGAATCCACATTAGTTTCCGTAAGCGGCCGCACTCG   
BalhD (P427*) R CGAGTGCGGCCGCTTACGGAAACTAATGTGGATTCTTATTAAAAGCTTT   
BalhD (P429*) F AGCTTTTAATAAGAATCCACATCCATTTTAGTAAGCGGCCGCACTC   
BalhD (P429*) R GAGTGCGGCCGCTTACTAAAATGGATGTGGATTCTTATTAAAAGCT   
BalhD (P429G) R GTGCGGCCGCTTACCCAAATGGATGTGG 3'- NotI 
BalhD (*430A) R GTGCGGCCGCTGCCGGAAATGGATGTGG 3'- NotI 
BalhD (PxGxG) R 
AGCGGCCGCTTACCCAAATCCATGTGGATTCTTATTAAAAGCTTTTGCTGGTGCATAT
CC 3'- NotI 
BalhD (GxGxG) R 
AGCGGCCGCTTACCCAAATCCATGTCCATTCTTATTAAAAGCTTTTGCTGGTGCATAT
CC 3'- NotI 
BalhD (P427G) R 
TGCGGCCGCTTACGGAAATCCATGTGGATTCTTATTAAAAGCTTTTGCTGGTGCATAT
CC 3'- NotI 
BalhD (F428A) R 
TGCGGCCGCTTACGGAGCTGGATGTGGATTCTTATTAAAAGCTTTTGCTGGTGCATAT
CC 3'- NotI 
BalhD (H426A) R  
AAGCGGCCGCTTACGGAAATGGAGCTGGATTCTTATTAAAAGCTTTTGCTGGTGCATA
TC 3'- NotI 
BalhD (PxPxPG) R TTGCGGCCGCTTATCCCGGAAATGGATGTGGATTCTTATTAAAAGCTTTTGCTGGTGC 3'- NotI 
BalhD (∆A418/K419) F CATGGGATATGCACCAGCAAAAAATAAGAATCCACATCCATTTC   
BalhD (∆A418/K419) R GAAATGGATGTGGATTCTTATTTTTTGCTGGTGCATATCCCATG   
YcaO F AAGGATCCATGACGCAAACATTTATCCCCGGCAAAG 5'- BamHI 
YcaO R TTGCGGCCGCTTATTTTGCCCAGAATGCTGCTTTGGCGCGC 3'- NotI 
McbD (M392*) F GAGAATCAAAGTAGGTACCATTCCCATAAAAGCTTGCGGCCGC   
McbD (M392*) R GGGAATGGTACCTACTTTGATTCTCTGACTTTAATACCGTCCC   
 
Table A.3 | Primers for YcaO constructs cloned for crystallography screens. All proteins are 
identified by locus tag. Primers required for cloning the construct into a vector different than the 
standard pET28-MBP vector have the vector listed in parentheses. Additional information for 
each protein can be found in table C.1. 
 
Primer Sequence Cut Site 
Azl_d00180 F AAAGGATCCATGCCCTTCGATCTGCTCGATGTCAAAGC 5'-BamHI 
Azl_d00180 R TTTCTCGAGTCATGCCGCCTTCTCCGTGGATTGG 3'-XhoI 
Azl_022710 F AAAGGATCCATGCGAGCTTCGACAAATCCGGCAACG 5'-BamHI 
Azl_022710 R TTTAAGCTTTCACGCCACGCCTGCCC 3'-HindIII 
Azl_a09740 F AAAGGATCCATGAGCCCGCAAGCCTCGACCGC 5'-BamHI 
Azl_a09740 R TTTCTCGAGCTATCGGGCGTGGTGGTTGGCGAGG 3'-XhoI 
BalhD 1-414 R TTGCGGCCGCTTATCCCATGTTTTTCGGAGCATCTAATAACCTATTACAAC 3'-NotI 
BalhD ∂57 F AAGGATCCGGTTTAGGATATAGCTATGATTCTGCTGAATCAGCAC 5'-BamHI 
BpumD F AAAAGTCGACA ATGGTTAATAAATGGACAACATTAGAAGAGTCATGGGAGATAC 5'-SalI 
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Table A.3 Continued 
Primer Sequence Cut Site 
BpumD R AATTGCGGCCGCTTA AGGAAATGGATGCGGAATTGGATTCAGTTCTTC 3'-NotI 
Ec-YcaO ∆59 F AAGGATCCGGTAAAGGCGCAACCAAGAAAGCGGC 5'-BamHI 
Ec-YcaO 1-420 R TTGCGGCCGCTTAGCTGCCTGGTAGCGAAAGAATCGTTTCACGTAAATG 3'-NotI 
M446_2287 F AAAGGATCCATGACGAGCGACACGCCCCG 5'-BamHI 
M446_2287 R TTTAAGCTTTCACGCGGCCCTCCCG 3'-HindIII 
ERDMAN_1534 F AAAGGATCCATGTTGTCGGGCCCGAATTGGTCG 5'-BamHI 
ERDMAN_1534 R TTTAAGCTTTCATTCAGCCTCCTGTAGGGGTGTGC 3'-HindIII 
HMPREF9018_0535 F AAAGGATCCATGCTGATTTCCAATCAGTTTGGAATTGTAAATC 5'-BamHI 
HMPREF9018_0535 R TTTGCGGCCGCTTAAGGGAATGGATGTGGATATACATTTAATTCTTC 3'-NotI 
Scab_1701 F1 AAACTCGAGATGTCAGCGGACGGCGTCACCTTG 5'XhoI 
Scab_1701 F2 (pALM) AAAAAGCTTCCATGTCAGCGGACGGCGTCACCTTG 5'-HindIII 
Scab_1701 R TTTCTCGAGCTACGCGTGCGGCAGCGGAAAG 5'XhoI 
Scab_56671 F AAAGTCGACAAATGCGCGAAGCGACGGCGACGGAGTGCG 5'-SalI 
Scab_56671 R TTGCGGCCGCTCAGGCGGAACGTCTTCCTTCGCGGCC 3'-NotI 
Scab_56661 (∆100) F AAAGGATCCATGGCGAGCGCGCTGTTCGAGAGCG 5'-BamHI 
Scab_56661 F2 AAGGATCCATGACCCGTCCCGCCCATCCGCAGAC 5'-BamHI 
Scab_56661 R TTAAGCTTTCACCGGCGCGCACCCCC 3'-HindIII 
SO_0795 F AAAGGATCCATGGAAATCAAAGTTAATTTTCTCGACAACCTAAGACTCG    5'-BamHI 
SO_0795 R TTTAAGCTTTTAGAAAGTAATGCACTTAACCGCGTTGGC 3'-HindIII 
 
Table A.4 | Primers for chapter 5 constructs. *, denote stop codons. Note, BAT_3535 and 
bcer0022_47460 are Balh2B homologs from B. pumilus ATCC 7061 and B. cereus Rock3-44, 
respectively. 
 
Primer Sequence Cut Site 
Balh2A F AAGTCGACAACGATGAATCAGTTTCAACAAGAACTACAATCATTAAACC 5'-SalI 
Balh2A R TTGCGGCCGCTTAAATGATCCACCAGTTCCAGCAATTAAAGCAACCG 3'-NotI 
Balh2A LP F CCGCATCCGCCGCACTAACGTGCATCGTCTTGAATATAGTAGTA   
Balh2A LP R TACTACTATATTCAAGACGATGCACGTTAGTGCGGCGGATGCGG   
Balh2B F AAGGATCCATGCAACTAGATACTTTTTTACATCATCTCCATTTCTCTATCG 5'-BamHI 
Balh2B R TTGCGGCCGCCTAATTACGCAAATCCCCTTTTAACCAATTCCGC 3'-NotI 
Balh2CD F AAGGATCCATGACTCAAAATATATTACTTATAGGGGATGGCATTCTTGCAGACTATGTAC 5'-BamHI 
Balh2CD R TTGCGGCCGCCTATGGAAACGGGTGCGGATGTGGATTTAATTGTTC 3'-NotI 
Balh2F F AAGGATCCATGAGTAACCTTCCAGCACATGCAAAACTAAAAG 5'-BamHI 
Balh2F R AAAGCGGCCGCTCATAGACCGTCCTCCTTTGCAATTAATACCC 3'-NotI 
BAT_3535 F AAAGGATCCATGAATCTAGACGATTTTTTGCACAATCTTCATTATGAAAATG 5'-BamHI 
BAT_3535 R TTTGCGGCCGCTTAATTATGCAAGCTCCCCTGTAATCTAGGATGAGG 3'-NotI 
bcere0022_47460 F AAAGGATCCATGGAGTTAGAAACATTTCTACACAATTTACATTTTTCTATCG 5'-BamHI 
bcere0022_47460 R TTTGCGGCCGCTTAATTATGCAAATATCCTTTAAGCCAAGTGCGAG 3'-NotI 
BalhD F CCGGATCCATGGGTATACAGAATGC 5'-BamHI 
BalhD (*430A) R GTGCGGCCGCTGCCGGAAATGGATGTGG 3'-NotI 
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Table A.5 | Primers for unpublished cyclodehydratase mutants 
Primer Sequence 
BalhC D89A F CAATTCTTTATCCATAAATTTATATTTTTCTTGTAAAGCGTAATTTTTTATAATATTTTTCTCGTCTAACAATTT 
BalhC D89A R ATTGTTAGACGAGAAAAATATTATAAAAAATTACGCTTTACAAGAAAAATATAAATTTATGGATAAAGAATTG 
BalhC S109A F TGCAAAGATATGAAAGATTCATCGCAAATTTGACAGGTTCTTTATCC 
BalhC S109A R GGATAAAGAACCTGTCAAATTTGCGATGAATCTTTCATATCTTTGCA 
BalhC E136A F CCTTACACTTTCCTGTAATTCCGCATTTCCCATTAATACAATCTTC 
BalhC E136A R GAAGATTGTATTAATGGGAAATGCGGAATTACAGGAAAGTGTAAGG 
BalhC E137A F CTTTCCTTACACTTTCCTGTAATGCCTCATTTCCCATTAATACAATC 
BalhC E137A R GATTGTATTAATGGGAAATGAGGCATTACAGGAAAGTGTAAGGAAAG 
BalhC Q139A F CACAAGCTTTCCTTACACTTTCCGCTAATTCCTCATTTCCCATTAATACAAT 
BalhC Q139A R ATTGTATTAATGGGAAATGAGGAATTAGCGGAAAGTGTAAGGAAAGCTTGTG 
BalhC T211A F GTATAGGGCCAATATTCATTTCTAATGAAGCGGGTTGTTATAACTG 
BalhC T211A R CAGTTATAACAACCCGCTTCATTAGAAATGAATATTGGCCCTATAC 
BalhC R220A F AGATAAGAGTTTTCATAATTAGTAATTTTCGCACTTAAAAAGCAGTTATAACAACCCGTTTC 
BalhC R220A R GAAACGGGTTGTTATAACTGCTTTTTAAGTGCGAAAATTACTAATTATGAAAACTCTTATCT 
BalhC E226A F CATATATTTATAGCTAAGATAAGAGTTTGCATAATTAGTAATTTTCCTACTTAAAAAGCAGTTATAA 
BalhC E226A R TTATAACTGCTTTTTAAGTAGGAAAATTACTAATTATGCAAACTCTTATCTTAGCTATAAATATATG 
BalhC K221A F GGGTTGTTATAACTGCTTTTTAAGTAGGGCAATTACTAATTATGAAAACTCTTATCTTAG 
BalhC K221A R CTAAGATAAGAGTTTTCATAATTAGTAATTGCCCTACTTAAAAAGCAGTTATAACAACCC 
BalhC Y232A F ACTAATTATGAAAACTCTTATCTTAGCGCTAAATATATGAAGAAATATAATAGTGAATGG 
BalhC Y232A R CCATTCACTATTATATTTCTTCATATATTTAGCGCTAAGATAAGAGTTTTCATAATTAGT 
BalhC E241A F CCCAACATGCGTTTCATTCCATGCACTATTATATTTCTTCATATATTTATAG 
BalhC E241A R CTATAAATATATGAAGAAATATAATAGTGCATGGAATGAAACGCATGTTGGG 
BalhC E244A F CTGGAATAACCCCAACATGCGTTGCATTCCATTCACTATTATATTTC 
BalhC E244A R GAAATATAATAGTGAATGGAATGCAACGCATGTTGGGGTTATTCCAG 
BalhC E276A F CTTCTCTGATTGTATGCCTTGCGCAATAATTGGAAAAGAATTCACTT 
BalhC E276A R AAGTGAATTCTTTTCCAATTATTGCGCAAGGCATACAATCAGAGAAG 
BalhC E281A F TGTATGCCTTGCGAAATAATTGGAAAAGCATTCACTTATAATGTATTTAATTTAAGTT 
BalhC E281A R AACTTAAATTAAATACATTATAAGTGAATGCTTTTCCAATTATTTCGCAAGGCATACA 
BalhC K298A F TCTCTGATTGTATGCCTTGCGAAATAATTGGAGCAGAATTCACTTATAATGTATTTAATT 
BalhC K298A R AATTAAATACATTATAAGTGAATTCTGCTCCAATTATTTCGCAAGGCATACAATCAGAGA 
BalhD G58A F GAAATTATAGTGCTTTAGGATATAGCTATGATTCTGCTGAATCAGC 
BalhD G58A R CTATATCCTAAAGCACTATAATTTCCGCGGATTTTAATGCCCTC 
BalhD L59K F ATTATAGTGGTAAAGGATATAGCTATGATTCTGCTGAATCAGCAC 
BalhD L59K R TAGCTATATCCTTTACCACTATAATTTCCGCGGATTTTAATGCC 
BalhD G60A F ATAGTGGTTTAGCATATAGCTATGATTCTGCTGAATCAGCAC 
BalhD G60A R TCATAGCTATATGCTAAACCACTATAATTTCCGCGGATTTTAATGC 
BalhD Y81A F TTCTTGAGCGTGCTTGCTCATGTTATCTAAATACAGAAGCTTTAATC 
BalhD Y81A R TAACATGAGCAAGCACGCTCAAGAATTTCTCCAACTGCCGATATTAG 	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Table	  A.5	  Continued	  
Primer Sequence 
BalhD Q121A F ATTACGCAGCCTTTAAGAGAGCAATATGCAGAAACATATGGTATTAGCAAAG 
BalhD Q121A R CTTTGCTAATACCATATGTTTCTGCATATTGCTCTCTTAAAGGCTGCGTAAT 
BalhD S175A F CCCACATATAAGAGATTCAATTGCTACTGGTTTAGCAACAGG 
BalhD S175A R CCTGTTGCTAAACCAGTAGCAATTGAATCTCTTATATGTGGG 
BalhD E189A F TGCAAGCAATAGCAAACGCGGCACTAGAATGTATAG 
BalhD E189A R AGTGCCGCGTTTGCTATTGCTTGCAACCTTGTAG 
BalhD D199A F CACTAGAATGTATAGAAAGAGCCGCGATTATGATCACATGG 
BalhD D199A R CCATGTGATCATAATCGCGGCTCTTTCTATACATTCTAGTG 
BalhD W205A F TTATGATCACAGCGTTAAATGAATTATCGGTTCCATTAATAG 
BalhD W205A R AATTCATTTAACGCTGTGATCATAATCGCGTCTCTTTCTATAC 
BalhD K271A F AAATAGGAGCAGCAGCACATTACGATCCTCTTATAGCATTG 
BalhD K271A R TCGTAATGTGCTGCTGCTCCTATTTGTATATGAGGATATTTATTATAAAGATTCC 
BalhD D275A F AAGCACATTACGCTCCTCTTATAGCATTGAAGGGAGCTTTAATG 
BalhD D275A R GCTATAAGAGGAGCGTAATGTGCTTTTGCTCCTATTTGTATATGAGG 
BalhD K281R F TTATAGCATTGAGGGGAGCTTTAATGGAGACGTTGGCAAGTC 
BalhD K281R R ATTAAAGCTCCCCTCAATGCTATAAGAGGATCGTAATGTGCTTTTGC 
BalhD G282R F TAGCATTGAAGAGAGCTTTAATGGAGACGTTGGCAAGTC 
BalhD G282R R TCCATTAAAGCTCTCTTCAATGCTATAAGAGGATCGTAATGTGC 
BalhD P389G F CTTATATGTATATCGAGTGTTGATGGGAGAGTTGGCTTTTTTGGAAATAACT 
BalhD P389G R AGTTATTTCCAAAAAAGCCAACTCTCCCATCAACACTCGATATACATATAAG 
BalhD D370A F TCTATACATATGCTCTAACTACTGAAGATATAAGTTCTTTAGGC 
BalhD D370A R TCAGTAGTTAGAGCATATGTATAGAGGTTTAAATTCATGGTATTG 
BalhD D375A F TAACTACTGAAGCTATAAGTTCTTTAGGCTTATATGTATATCGAG 
BalhD D375A R AAAGAACTTATAGCTTCAGTAGTTAGATCATATGTATAGAGGTTTAAATTC 
BalhD R405A F TAAGTTGTAATGCGTTATTAGATGCTCCGAAAAACATGGG 
BalhD R405A R GCATCTAATAACGCATTACAACTTAGCATAGGTAAAGTTATTTC 	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APPENDIX B: ADDITIONAL BALH CYCLODEHYDRATASE MUTANTS 
 
 
B.1 Unpublished BalhC mutants. Mutations to BalhC were made in an attempt to locate 
residues responsible for YcaO potentiation. As structural information for a TOMM C protein was 
not available when the mutant library was constructed, the residues to be mutated were selected 
via bioinformatics. The effect of these mutations on the rate of cyclodehydration is displayed in 
table B.1.  
Table B.1 | Mutant BalhC activity. *, reaction carried out with 15 µM BalhA1 and 3 mM ATP. 
All kinetic experiments were performed on the plate reader.  	  
Mutation *Vo µM min-1 % WT Comment 
WT 6.6 ± 0.5 100 - 
D89A 0.11 ± 0.07 1 Potentially disrupted complex formation (see pg. 547) 
S109A 6.9 ± 0.6 104 - 
E136A 6.2 ± 0.2 94 - 
E137A 0.5 ± 0.2 8 Only 5 mg/L obtained. Structurally destabilized. 
Q139A 5.7 ± 0.6 91 - 
T211A 5.6 ± 0.4 84 - 
K221A 5.0 ± 0.3 76 - 
R220A 0.16 ± 0.06 3 No measureable heterocycle formation. Disrupted interaction with BalhD? 
E226A 4.6 ± 0.5 76 Small change in BalhA1 Km and kobs 
Y232A 3.6 ± 0.2 55 - 
E241A 5.4 ±0.5 85 - 
E244A 3.5 ± 0.3 56 BalhA1 Km increased 2-fold, kobs down 20% 
E276A 5.1 ±0.5 78 - 
E281A 1.1 ± 0.3 17 Only 3 mg/L obtained. Structurally destabilized. 
K298A 5.9 ± 0.4 94 - 	  
	  
	  	   193	  
B.2 | Unpublished BalhD mutants. Following the discovery that BalhD can install azoline 
heterocycles in the absence of BalhC, a mutant library was generated to locate the ATP-binding 
site and the catalytic residues in BalhD. All mutated residues were selected based on 
bioinformatics. Mutations that were not discussed in Chapters 4 and 5 are listed in tables B.2-
B.3.  
 
Table B.2 | Mutant BalhD activity. *, reaction carried out with 15 µM BalhA1 and 3 mM ATP. 	  
Mutation *Vo µM min-1 % WT Comment 
WT 6.2 ± 0.5 100   
G58A 2.55 ± 0.13 41 No background rate potentiation 
L59K 0.59 ± 0.05 9 - 
G60A 0.56 ± 0.05 9 No background rate potentiation 
Y81A 0.13 ± 0.16 2 No background rate potentiation; Protein expresses very well 
S175A 0.43 ± 0.07 7 - 
E189A - - Protein is structurally destabilized 
D199A - - Protein is structurally destabilized 
W205A - - Protein is structurally destabilized 
K271A 5.1 ± 0.4 83 - 
D275A 4.3 ± 0.2 69 - 
K281R 3 ± 0.2 48 - 
D370A 0.86 ± 0.04 14 - 
D375A 5.6 ± 0.8 91 - 
R385A 0.16 ± 0.03 3 - 
P389G 1.3 ± 0.1 22 - 
R405A 0.28 ± 0.01 4 - 
N424* 0.31 ± 0.14 5 No heterocycle formation 
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Table B.3 | Mutant BalhD BalhA1 and ATP Kinetics. *, reaction carried out with 3 mM ATP; 
**, reaction carried out with 80 µM BalhA1; -, kinetics not obtained; n.d., kinetics could not be 
determined. 	  
 
  BalhA1 Kinetics*     ATP Kinetics**   
Mutation kcat min-1 KM µM kcat/KM M-1 s-1 kcat min-1 KM µM kcat/KM M-1 s-1 
WT 12.9 ± 0.4 16 ± 2 13000 12.2 ± 0.3 240 ± 20 850 
G58A - - - - - - 
L59K - - - - - - 
G60A - - - - - - 
Y81A - - - - - - 
S175A 0.58 ± 0.03 18 ± 3 537 0.66 ±  0.04 840 ± 140 13 
E189A n.d. n.d. n.d. n.d. n.d. n.d. 
D199A n.d. n.d. n.d. n.d. n.d. n.d. 
W205A n.d. n.d. n.d. n.d. n.d. n.d. 
K271A - - - - - - 
D275A - - - - - - 
K281R 6.3 ± 0.3 15 ± 2 7000 7.5 ± 0.1 260 ± 10 480 
D370A - - - - - - 
D375A - - - - - - 
R385A 0.11 ± 0.01 17 ± 7 108 0.16 ± 0.01 1300 ± 200 2 
P389G - - - - - - 
R405A - - - - - - 
N424* n.d. n.d. n.d. n.d. n.d. n.d. 	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APPENDIX C: YCAO PROTEINS FOR CRYSTALLOGRAPHY SCREEN 
 
 
C.1 YcaO proteins screened at UIUC 
In an attempt to obtain an X-ray crystal structure of additional YcaO proteins, diverse proteins 
were cloned and expressed with an N-terminal fusion to MBP. Scab_1701, Scab_56671, and 
Scab_56661 were also expressed as an N-terminal His6 fusion. All proteins were overexpressed 
at 22 ˚C for 16 h. A solubility screen was performed by treating each protein with TEV protease 
for 16 h at 25 ˚C and visually inspecting the sample for precipitate. Jonathan Chekan and 
Vinayak Agarwal (S. Nair Lab; UIUC) carried out all crystallography screens.  
Table C.1 | YcaOs used for crystallography screens.  
	  
Locus Tag Organism Subclass 
Yield 
(mg/L) Comments 
Azl_d00180 Azospirillum sp. B510 TfuA Non-TOMM 60 Crystallization failed 
Azl_022710 Azospirillum sp. B510 TfuA Non-TOMM 12 
Precipitated during MBP 
cleavage 
Azl_a09740 Azospirillum sp. B510 TfuA Non-TOMM 8 Highly truncated 
BamD Bacillus amyloliquefaciens Plantazolicin 50 Crystallization failed 
BpumD Bacillus pumilus Plantazolicin 17 
Precipitated during MBP 
cleavage 
ClosD Clostridium botulinum Cytolysin 20 
Precipitated during MBP 
cleavage 
HMPREF9018_0535 Prevotella amnii CRIS 21A-A 
Uncharacterized 
TOMM 53 Crystallization failed 
ERDMAN_1534 
Mycobacterium tuberculosis str. 
Erdman TfuA Non-TOMM 9 
Precipitated during MBP 
cleavage 
McbD Escherichia Coli Microcin B17 25 
Precipitated during MBP 
cleavage 
SagD Streptococcus pyogenes Cytolysin 15 
Precipitated during MBP 
cleavage 
Scab_1701 Streptomyces scabies 87.22 
Uncharacterized 
TOMM 1 Highly truncated 
Scab_56671 Streptomyces scabies 87.22 Bottromycin 2 Highly truncated 
Scab_56661 Streptomyces scabies 87.22 Bottromycin 2 Highly truncated 
SO_0795 Shewanella oneidensis MR-1 Non-TOMM 70 Crystallization failed 	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C.2 YcaO proteins screened by Steve Almo (Albert Einstein College of Medicine) 
In collaboration with Steve Almo, an additional 38 TOMM and non-TOMM YcaO proteins were 
screened in an attempt to obtain additional structural information (table C.2). All proteins 
expressed as an N-terminal His6 fusion. The proteins were expressed on in small-scale cultures 
and solubility was determined via Western blot with an Anti-His6 antibody on the whole cell 
lysate. All proteins with a high level of solubility (2 or 3) were taken forward to large-scale 
production and subjected to a crystallography screen. Unfortunately, all proteins proved 
refractory to crystallization.  
Table C.2 | YcaOs screened by Steve Almo.  
	  
Accession Organism Type  AA count MW Solubility 
CAA09633.1 Streptomyces violaceoruber CD Fusion 774 82.92 Cloning Failed 
NP_250616.1 Pseudomonas aeruginosa Non-TOMM 638 70.57 Cloning Failed 
AAM03618.1 Methanosarcina acetivorans C2A methanogen 446 49.67 0 
NP_633482.1 Methanosarcina mazei Go1 methanogen 446 49.67 0 
AAN69820.1 Pseudomonas putida KT2440 Mcb 17 422 48.12 0 
BAC89240.1 Gloeobacter violaceus PCC 7421 TOMM 433 47.68 0 
CAE50519.1 Corynebacterium diphtheriae Non-TOMM 348 38.06 0 
AAS95701.1 Desulfovibrio vulgaris str. Hildenborough Non-TOMM 447 48.82 0 
YP_078247.1 Bacillus licheniformis DSM 13 Bcer CD 666 75.53 0 
YP_135672.1 Haloarcula marismortui ATCC 43049 Non-TOMM 717 78.49 0 
CAI49392.1 Natronomonas pharaonis DSM 2160 TOMM 585 60.93 Cloning Failed 
ABA48314.1 Burkholderia pseudomallei 1710b NHLP-Burk 866 93.12 Cloning Failed 
YP_388840.1 Desulfovibrio alaskensis G20 Non-TOMM 604 66.3 1 
ABC34570.1 Burkholderia thailandensis E264 TfuA-YcaO 905 99.04 0 
YP_441074.1 Burkholderia thailandensis E264 NHLP Burk 778 84.02 Cloning Failed 
NP_415425.4 Escherichia coli str. K-12 substr. MG1655 Non-TOMM 608 68.17 3 
YP_648520.1 Yersinia pestis Nepal516 Non-TOMM 610 68.23 3 
ABI90541.1 Burkholderia ambifaria AMMD NHLP Burk 767 83.45 0 
ABJ57813.1 Lactobacillus delbrueckii TOMM 355 40.15 0 
YP_949181.1 Arthrobacter aurescens TC1 TOMM 435 46.12 3 
ABN06765.1 Methanocorpusculum labreanum Z TfuA Non-TOMM 425 47.16 3 
ABN58160.1 Methanoculleus marisnigri JR1 Non-TOMM 419 46.52 2 
YP_001045574.1 Rhodobacter sphaeroides ATCC 17029 TOMM 460 49.66 Cloning Failed 
ABO24899.1 Shewanella loihica PV-4 Non-TOMM 750 84.27 3 
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   Table	  C.2	  Continued	  
Accession Organism Type  AA count MW Solubility 
ABP54882.1 Salinispora tropica CNB-440 TOMM 652 71.19 0 
ABQ73127.1 Mycobacterium tuberculosis H37Ra TfuA Non-TOMM 461 49.74 0 
YP_001363155.1 Kineococcus radiotolerans SRS30216 TOMM 546 59.18 Cloning Failed 
ABX43929.1 Clostridium phytofermentans ISDg TOMM 640 74.44 1 
ACB53447.1 Cyanothece sp. ATCC 51142 Cyanobactin 786 90.5 0 
ACK78345.1 Acidithiobacillus ferrooxidans ATCC 23270 TOMM 456 51.41 0 
ACL64263.1 Anaeromyxobacter dehalogenans 2CP-1 TOMM 401 40.77 0 
ACS40629.1 Methylobacterium extorquens AM1 TfuA Non-TOMM 561 61.06 1 
ACV48332.1 Halomicrobium mukohataei DSM 12286 TOMM 599 62.81 1 
ACZ11500.1 Sulfurospirillum deleyianum DSM 6946 Non-TOMM 562 64.33 3 
YP_003300351.1 Thermomonospora curvata DSM 43183 TOMM 779 86.06 Cloning Failed 
ACZ89043.1 Streptosporangium roseum DSM 43021 Non-TOMM 443 48.35 Cloning Failed 
ADI35913.1 Methanococcus voltae A3 TfuA Non-TOMM 465 52.45 3 
EGE61713.1 Rhizobium etli CNPAF512 TfuA Non-TOMM 443 47.7 Cloning Failed 	  	  
